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Abstract 
 Objective 
1. To conduct a post-marketing surveillance of different artesunate      
formulations used in Sudan.  
2. To assess the effect of transport and storage conditions, at different 
regions of Sudan, on the stability of artesunate tablets. 
3. To adopt an HPLC dissolution test method suitable for evaluating the 
artesunate drug release. 
Methodology 
        1.  Stability of artesunate tablets was evaluated. Three procedures were          
used for the evaluation: 
1.1. Four states in Northern, Eastern, Western, and Central of Sudan   
were chosen for sample collection in post-marketing study to 
represent all Sudanese market. The sampling procedure was 
designed in a way to determine whether the products were 
adversely affected by the transport and storage conditions at these 
states. 
1.2. Artesunate tablets were stored in different parts of the country 
(Khartoum, Elobied, Port Sudan and Atbara) which represent 
different climatic conditions in Sudan. Samples were taken for     
analysis at various time intervals. 
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1.3. Five generic brands of artesunate tablets were stored at room 
temperature and subjected to various compendia tests. 
2.  An HPLC dissolution method was adopted and applied for analysis of 
artesunate tablets. The method was compared with the official UV-
spectrophotometric method (Chinese pharmacopeia method 1996). 
    Results    
The results of post-marketing surveillance identified several     
significant problems in the stability of artesunate tablets in all states. 
There was a percentage failure of 12% in the first year and 4% in the 
second year for different generic brands of artesunate tablets in Sudanese 
market. There was a percentage failure of 100% in one generic brand of 
artesunate with regard to content and dissolution test. There was a failure 
of 76% in one generic brand due to dissolution test. Almost 98% failures 
were due to dissolution rate, followed by 7% failure due to dissolution and 
assay (content of the active substance), and 2%   failure due to physical 
appearance. The results showed a higher failure level in the public sector 
(14%) than the private supply system (2%) 
The results of the stability studies at room temperature indicated the 
presence of degredant resulting from the effect of high temperature and 
humidity. The degradant was one of the dihydoartemisinin namely α- 
dihydoartemisinin (α-DHA). However, the degradant, content of active 
substance and all other results of analysis of the product were within the 
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pharmacopeias specification limits (IP, 2005; Chinese pharmacopeia, 
1996). 
Analysis of different generic brands showed failure in dissolution 
test of all batches of one generic brand after three months storage at room 
temperature. One generic brand reached the lower limit (60%) of the 
dissolution test at the end of its shelf life (24months). 
The adopted HPLC dissolution test method of the artesunate tablets 
was validated .The results showed good linearity in the range of 40-120 
µg/ml of artesunate tablets with correlation coefficient of 0.999.The 
results of the developed HPLC method were compared with the official 
UV-spectrophotometric method (Chinese pharmacopeia method 1996). 
The results of the adopted method showed no significant difference from 
the official method. The calculated F-values between the adopted method 
and official method were found less than the tabulated ones which which 
confirm that the method is precise. The accuracy of the prescribed method 
was evaluated using t-tests. All the calculated t-values were found less 
than tabulated ones. Thus the adopted method is accurate.  The adopted 
method was repeatable and reproducible as shown by calculating the 
relative standard deviations (RSD) in two different laboratories. All the 
data were found within the acceptance criteria of 5% which confirm that 
the adopted method is precise. 
      Conclusion:  
The results of the present work revealed the presence of substandard 
antimalarial products circulating in Sudanese market. This appears to be 
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due to non-appropriate storage conditions and/or non-compliance with 
GMP guidelines by manufacturers in productions. The detection of poorly 
formulated artesunate tablets among different brands highlights the need 
for increasing drug surveillance and monitoring of the quality of 
antimalarial medicines currently in use so as to overcome treatment 
failure.  
The stability of artesunate tablets is affected by high temperature and 
humidity. Thus the product(s) should be appropriately blister-packed and 
stored in a cool dry place to assure maximal stability and product 
integrity. 
The adopted dissolution method for artesunate tablets is selective and 
reproducible and can be employed in poorly equipped laboratories like 
those found in most developing countries.  
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  ﺍﻷﻃﺮﻭﺣﻪ ﻣﺴﺘﺨﻠﺺ
  ﺍﻷﻫﺪﺍﻑ
  . ﺑﺎﻟﺴﻮﺩﺍﻥ  ﺔﺪﺍﻭﻟﺘﺍﻷﺭﺗﻴﺴﻮﻧﺎﺕ ﺍﳌ  ﺟﺮﺍﺀ ﻣﺮﺣﻠﺔ ﻣﺎ ﺑﻌﺪ ﺍﻟﺘﺴﻮﻳﻖ ﳌﺨﺘﻠﻒ ﻣﺮﻛﺒﺎﺕﺇ .1
    .ﺗﻘﻴﻴﻢ ﺗﺄﺛﲑ ﻇﺮﻭﻑ ﺍﻟﻨﻘﻞ ﻭﺍﻟﺘﺨﺰﻳﻦ  ﰲ ﺃﳓﺎﺀ ﳐﺘﻠﻔﺔ ﻣﻦ ﺍﻟﺴﻮﺩﺍﻥ ﰱ ﺛﺒﺎﺕ ﺃﻗﺮﺍﺹ ﺍﻷﺭﺗﻴﺴﻮﻧﺎﺕ .2
 .ﺍﳉﻮﺩﻩ ﺑﺈﺳﺘﺨﺪﺍﻡ ﺟﻬﺎﺯ ﺍﻟﻜﺮﻭﻣﺎﺗﻮﻏﺮﻓﻴﺎ ﺍﻟﺴﺎﺋﻞ ﻋﺎﱃ ﻷﻗﺮﺍﺹ ﺍﻷﺭﺗﻴﺴﻮﻧﺎﺕ ﺔﺧﺘﺒﺎﺭ ﺍﻟﺬﻭﺑﺎﻧﻴﺇﻃﺮﻳﻘﺔ  ﻋﺘﻤﺎﺩﺇ .3
    ﺍﻟﺒﺤﺚ ﻣﻨﻬﺠﻴﺔ
 :    ﻭﻗﺪ ﺍﺳﺘﺨﺪﻣﺖ ﺛﻼﺛﺔ ﺇﺟﺮﺍﺀﺍﺕ ﻟﻠﺘﻘﻴﻴﻢ. ﻷﺭﺗﻴﺴﻮﻧﺎﺕﺛﺒﺎﺕ ﺃﻗﺮﺍﺹ ﺍ  ﺗﻘﻴﻴﻢ .1
ﻥ، ﲤﺜﻞ ﺍﻟﺴﻮﻕ ﺍﻟﺴﻮﺩﺍﱏ، ﳉﻤﻊ ﺍﻟﻌﻴﻨﺎﺕ ﰲ  ﺧﺘﻴﺎﺭ ﺃﺭﺑﻌﺔ ﺃﻗﺎﻟﻴﻢ ﰲ ﴰﺎﻝ ﻭﺷﺮﻕ ﻭﻏﺮﺏ  ﻭﻭﺳﻂ ﺍﻟﺴﻮﺩﺍﺇ 1.1
ﲝﻴﺖ ﻳﺜﺒﺖ ﲢﺪﻳﺪ ﻣﺎ ﺇﺫﺍ ﻛﺎﻧﺖ ﻫﺬﻩ  ﺎﺇﺟﺮﺍﺀﺍﺕ ﺃﺧﺬ ﺍﻟﻌﻴﻨﺎﺕ ﰎ ﺗﺼﻤﻴﻤﻬ. ﻣﺮﺣﻠﺔ ﻣﺎ ﺑﻌﺪ ﺍﻟﺘﺴﻮﻳﻖ 
 .ﻭﺍﻟﺘﺨﺰﻳﻦﺍﻟﻨﻘﻞ ﺍﳌﻨﺘﺠﺎﺕ ﺗﺘﺄﺛﺮ ﺳﻠﺒﺎ ﰲ ﺣﺎﻟﺔ 
( ﺴﻮﺩﺍﻥ ﻭﻋﻄﱪﺓﺗﺍﳋﺮﻃﻮﻡ ، ﺍﻷﺑﻴﺾ ، ﺑﻮﺭ )ﰲ ﻣﻨﺎﻃﻖ ﳐﺘﻠﻔﺔ ﻣﻦ ﺍﻟﺒﻼﺩ  ﺃﻗﺮﺍﺹ ﺍﻷﺭﺗﻴﺴﻮﻧﺎﺕﲣﺰﻳﻦ  2.1
 .ﻟﺘﻤﺜﻞ ﳐﺘﻠﻒ ﺍﻟﻈﺮﻭﻑ ﺍﳌﻨﺎﺧﻴﺔ ﰲ ﺍﻟﺴﻮﺩﺍﻥ ، ﻭﰎ ﺃﺧﺬ ﻋﻴﻨﺎﺕ ﻟﺘﺤﻠﻴﻠﻬﺎ ﰲ ﻓﺘﺮﺍﺕ ﳐﺘﻠﻔﺔ
، ﻭﺃﺧﻀﻌﺖ  ﲡﺎﺭﻳﺔ ﻋﺎﻣﺔ ﻣﻦ ﺃﻗﺮﺍﺹ ﺍﻷﺭﺗﻴﺴﻮﻧﺎﺕ ﰲ ﺩﺭﺟﺔ ﺣﺮﺍﺭﺓ ﺍﻟﻐﺮﻓﺔ ﻣﺎﺭﻛﺎﺕﲬﺲ  ﲣﺰﻳﻦ 3.1
 . ﻻﺧﺘﺒﺎﺭﺍﺕ ﺩﺳﺘﻮﺭﻳﻪ ﳐﺘﻠﻔﺔ
ﺑﺈﺳﺘﺨﺪﺍﻡ ﺟﻬﺎﺯ ﺍﻟﻜﺮﻭﻣﺎﺗﻮﻏﺮﻓﻴﺎ  ﻟﺘﺤﻠﻴﻞ ﺣﺒﻮﺏ ﺍﻷﺭﺗﻴﺴﻮﻧﺎﺕ ﺓﻌﺘﻤﺪﺍﳌ ﻖ ﺃﺳﻠﻮﺏ ﺍﺧﺘﺒﺎﺭ ﺍﻟﺬﻭﺑﺎﻧﻴﻪﺒﻴﻄﺗ .2
ﺟﻬﺎﺯ ﺍﻷﺷﻌﺔ ﻓﻮﻕ ﻓﻴﻬﺎ  ﺴﺘﺨﺪﻡﻳﺍﻟﱴ ﻣﻊ ﺍﻟﻄﺮﻳﻘﻪ ﺍﻟﺪﺳﺘﻮﺭﻳﻪ  ﺍﻟﻨﺘﺎﺋﺞ ﻣﻘﺎﺭﻧﺔﻭﺍﳉﻮﺩﻩ،  ﺍﻟﺴﺎﺋﻞ ﻋﺎﱃ
  . (6991ﺍﻟﺼﻴﲎ ﻟﻌﺎﻡ  ﻃﺮﻳﻘﺔ ﺍﻟﺘﺤﻠﻴﻞ ﺑﺪﺳﺘﻮﺭ ﺍﻻﺩﻭﻳﺔ)ﺍﻟﺒﻨﻔﺴﺠﻴﺔ
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  ﺍﻟﻨﺘﺎﺋﺞ
ﻫﻨﺎﻟﻚ . ﻢﺮﺍﺹ ﺍﻷﺭﺗﻴﺴﻮﻧﺎﺕ ﰲ ﻛﻞ ﺍﻷﻗﺎﻟﻴﻗﺃ ﰱ ﺛﺒﺎﺕﻋﺪﺓ ﻣﺸﺎﻛﻞ  ﺃﻭﺿﺤﺖﺑﻌﺪ ﺍﻟﺘﺴﻮﻳﻖ  ﺔﻧﺘﺎﺋﺞ ﺍﳌﺘﺎﺑﻌ
 .ﺎﻧﻴﻪ  ﳌﺨﺘﻠﻒ ﻣﻨﺘﺠﺎﺕ ﺍﻷﺭﺗﻴﺴﻮﻧﺎﺕ ﰲ ﺍﻟﺴﻮﻕ ﺍﻟﺴﻮﺩﺍﻧﻴﺔﺍﻟﺜﰱ ﺍﻟﺴﻨﻪ  %4 ﻭﱃﺍﻷﻭ ﺔﰱ ﺍﻟﺴﻨ %21ﻧﺴﺒﺔ  ﻓﺸﻞ 
ﺍﺕ ﺍﻷﺭﺗﻴﺴﻮﻧﺎﺕ  ﰲ ﳏﺘﻮﻯ ﺍﳌﺎﺩﻩ ﺍﻟﻔﺎﻋﻠﻪ ، ﻭﺍﺧﺘﺒﺎﺭ ﺍﻟﺬﻭﺑﺎﻧﻴﻪ ﻷﺣﺪ ﻣﺴﺘﺤﻀﺮ% 001ﺎﻟﻚ ﻧﺴﺒﺔ ﻓﺸﻞ ﻨﻛﺎﻧﺖ ﻫ
ﻣﻦ  % 89ﺗﻘﺮﻳﺒﺎ . ﻧﺘﻴﺠﺔ ﻻﺧﺘﺒﺎﺭ ﺍﻟﺬﻭﺑﺎﻧﻴﻪ% 67ﺧﺮ ﺑﻨﺴﺒﺔ ﺍ ﻓﺸﻞ ﻣﺴﺘﺤﻀﺮ ﺑﻴﻨﻤﺎ ﻭﺍﳌﻈﻬﺮ ﺍﳋﺎﺭﺟﻰ ﻟﻸﻗﺮﺍﺹ
ﰱ  ﻧﺴﺒﺔ ﻓﺸﻞ %2ﻭ ﺍﻟﺬﻭﺑﺎﻧﻴﻪ ﻭﳏﺘﻮﻯ ﺍﳌﺎﺩﺓ ﺍﻟﻔﻌﺎﻟﺔ ﰱ ﻧﺴﺒﺔ ﻓﺸﻞ %7ﺧﺘﺒﺎﺭ ﺍﻟﺬﻭﺑﺎﻧﻴﻪ ، ﺗﻠﻴﻬﺎ ﺍﺍﻟﻔﺸﻞ ﻛﺎﻥ ﰱ 
  %. 2 ﺍﻟﻘﻄﺎﻉ ﺍﳋﺎﺹ ﻋﻨﻬﺎ ﰱ % 41ﺃﻇﻬﺮﺕ ﺍﻟﻨﺘﺎﺋﺞ ﺍﺭﺗﻔﺎﻉ ﻣﺴﺘﻮﻯ ﺍﻟﻔﺸﻞ ﰲ ﺍﻟﻘﻄﺎﻉ ﺍﻟﻌﺎﻡ  . ﺍﳌﻈﻬﺮ ﺍﳋﺎﺭﺟﻰ
 ﻭﺿﺤﺖﺮﺍﺹ ﺍﻷﺭﺗﻴﺴﻮﻧﺎﺕ ﰲ ﺩﺭﺟﺔ ﺣﺮﺍﺭﺓ ﺍﻟﻐﺮﻓﺔ ﺃﻗﺍﻟﻨﺘﻴﺠﺔ ﺍﻟﱵ ﰎ ﺍﳊﺼﻮﻝ ﻋﻠﻴﻬﺎ ﻣﻦ ﺩﺭﺍﺳﺎﺕ ﺍﻟﺜﺒﺎﺕ ﻷ 
 ﺣﻴﺚ ﻭﺟﺪ ﺘﺄﺛﲑ ﺩﺭﺟﺔ ﺍﳊﺮﺍﺭﺓ ﻭﺍﻟﺮﻃﻮﺑﺔﰲ ﲨﻴﻊ ﺃﳓﺎﺀ ﺍﻟﺒﻼﺩ ﻧﺘﻴﺠﺔ ﻟ ﺍﳌﻮﺟﻮﺩﺓ ﺮﺍﺹ ﺍﻷﺭﺗﻴﺴﻮﻧﺎﺕﻗﻷ ﻠﻞﻇﻬﻮﺭ ﲢ
ﺍﻟﺘﺤﺎﻟﻴﻞ  ﻭ ﺔﺍﳌﻮﺍﺩ ﺍﳌﺸﺎ ﲢﻠﻴﻞ ﻧﺘﺎﺋﺞ ﻋﻠﻰ ﺍﻟﺮﻏﻢ ﻣﻦ ﺫﻟﻚ ﻓﺈﻥ .ﻛﺄﺣﺪ ﺍﻟﻨﻮﺍﺗﺞﺃﺣﺪ ﻣﺮﻛﺒﺎﺕ ﺍﻟﺪﻳﻬﻴﺪﺭﻭﺍﺭﲤﻴﺴﻨﲔ 
ﺩﺳﺘﻮﺭ ﺍﻷﺩﻭﻳﺔ  ﻭ 5002ﺩﺳﺘﻮﺭ ﺍﻷﺩﻭﻳﺔ ﺍﻟﻌﺎﳌﻰ ﻟﻌﺎﻡ [ﺔﺿﻤﻦ ﺍﳌﻮﺍﺻﻔﺎﺕ ﺍﻟﺪﺳﺘﻮﺭﻳ ﻭﺟﺪﺕﺍﻷﺧﺮﻯ ﻟﻠﻤﻨﺘﺞ 
  . (6991ﺼﻴﲎ ﻟﻌﺎﻡ ﺍﻟ
ﺑﻌﺪ ﻣﺮﻭﺭ ﺛﻼﺛﻪ ﺃﺷﻬﺮ  ﻫﺎﻷﺣﺪ ﻧﻴﺔﺧﺘﺒﺎﺭ ﺍﻟﺬﻭﺑﺎﺃﻇﻬﺮﺕ ﻧﺴﺒﺔ ﻓﺸﻞ ﻹﻟﻠﻌﻘﺎﺭ  ﺔﺍﻟﺘﺠﺎﺭﻳﺔ ﺍﻟﻌﺎﻣ ﻴﻞ ﺍﳌﺎﺭﻛﺎﺕﲢﻠ 
  .ﺃﺧﺮﻯ ﰱ ﻣﺎﺭﻛﺔ ﻌﻤﺮ ﺍﳊﻘﻴﻘﻰﺍﻟﺩﱏ ﻣﺴﺘﻮﻯ ﻋﺘﺪ ﺎﻳﺔ ﺃﻭﺻﻞ  ﺑﻴﻨﻤﺎ.ﻋﻠﻰ ﲣﺰﻳﻨﻪ
ﻓﻴﺎ ﺑﺈﺳﺘﺨﺪﺍﻡ ﺟﻬﺎﺯ ﺍﻟﻜﺮﻭﻣﺎﺗﻮﻏﺮ ﺍﻷﺭﺗﻴﺴﻮﻧﺎﺕ ﻷﻗﺮﺍﺹ ﺍﳌﻌﺘﻤﺪﺓ ﺔﺧﺘﺒﺎﺭ ﺍﻟﺬﻭﺑﺎﻧﻴﺇﺔ ﰎ ﺍﻟﺘﺤﻘﻖ ﻣﻦ ﻃﺮﻳﻘ 
ﻣﻞ ﲟﻌﺎﻣﻞ /ﻣﻴﻜﺮﻭﺟﺮﺍﻡ 021-04ﻋﻄﺖ ﺍﻟﻨﺘﺎﺋﺞ ﻋﻼﻗﻪ ﺧﻄﻴﺔ ﻗﻮﻳﺔ ﰱ ﺍﳌﺪﻯ ﺃﺣﻴﺚ  ﺍﳉﻮﺩﻩ ﺍﻟﺴﺎﺋﻞ ﻋﺎﱃ
ﺟﻬﺎﺯ  ﺍﻟﱴ ﻳﺴﺘﺨﺪﻡ ﻓﻴﻬﺎ ﺔﺳﺘﻮﺭﻳﺪﺍﻟ ﺔﻟﻄﺮﻳﻘﻣﻊ ﺍ ﺍﳌﻌﺘﻤﺪﺓ ﺔﺧﺘﺒﺎﺭ ﺍﻟﺬﻭﺑﺎﻧﻴﺇ ﻧﺔ ﻧﺘﺎﺋﺞﺎﺭﻘﲤﺖ ﻣ . 999.0ﺍﺇﺭﺗﺒﺎﻁ
 ﺍﳌﻌﺘﻤﺪﺓ ﺔﻋﺪﻡ ﺍﺧﺘﻼﻑ ﺑﲔ ﺍﻟﻄﺮﻳﻘ ﺞﺋﺍﻟﻨﺘﺎ ﻭﺃﻇﻬﺮﺕ (  6991 ﻟﺪﺳﺘﻮﺭ ﺍﻟﺼﻴﲎ ﻟﻌﺎﻡﺍ) ﺍﻷﺷﻌﺔ ﻓﻮﻕ ﺍﻟﺒﻨﻔﺴﺠﻴﺔ
ﺑﲔ ﻧﺘﺎﺋﺞ ﺍﻟﻄﺮﻳﻘﺘﲔ ﻭﺟﺪﺕ  ﺃﻗﻞ ﻣﻦ ﺗﻠﻚ ﺍﻟﻘﻴﻢ ﺍﺪﻭﻟﺔ ﳑﺎ ﻳﺆﻛﺪ ﺩﻗﺔ  Fﲝﺴﺎﺏ ﻗﻴﻤﺔ ﻭ ﻭﺍﻟﻄﺮﻳﻘﺔ ﺍﻟﺪﺳﺘﻮﺭﻳﺔ
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ﳌﻌﺮﻓﺔ ﻣﺪﻯ ﺗﻮﺍﺗﺮ ﻧﺘﺎﺛﺞ ﺍﻟﺘﺤﻠﻴﻞ ﺑﺘﻠﻚ  ﲔﳐﺘﻠﻔﻠﲔ ﺟﺮﺍﺀ ﺍﻟﺘﺤﺎﻟﻴﻞ ﻋﺪﺓ ﻣﺮﺍﺕ ﰱ ﻣﻌﻤﺇﰎ ﻗﺪ ﻭ . ﺍﳌﻌﺘﻤﺪﺓﺍﻟﻄﺮﻳﻘﺔ 
 ًﺃﻳﻀﺎ ﺔﺃﺛﺒﺘﺖ ﺍﻟﺪﺭﺍﺳ . ﺍﻟﺘﺤﻠﻴﻞ ﺞﺋﻧﺘﺎ ﳑﺎ ﻳﻮﻛﺪ ﺗﻮﺍﺗﺮ ﺔﺍﻟﱴ ﻭﺟﺪﺕ ﺃﻗﻞ ﻣﻦ ﺍﺪﻭﻟ t ﻗﻴﻤﺔ ﺍﻟﻄﺮﻕ ﻭﺫﻟﻚ ﲝﺴﺎﺏ
ﺍﳌﻌﻴﺎﺭﻯ  ﳓﺮﺍﻑﺪ ﺩﺭﺟﺔ ﺍﻹﻳﻭﺗﻌﻄﻰ ﻧﻔﺲ ﺍﻟﻨﺘﺎﺋﺞ ﺑﺘﻜﺮﺍﺭﻫﺎ ﻭﺫﻟﻚ ﺑﺘﺤﺪ ﺔﻫﻰ ﺫﺍﺕ ﻣﺼﺪﺍﻗﻴ ﺍﳌﻌﺘﻤﺪﺓ ﺔﻘﻳﺃﻥ ﺍﻟﻄﺮ
  .ﺔﻟﻜﻞ ﺍﻟﺘﺸﻐﻴﻼﺕ ﺍﳌﺴﺘﺨﺪﻣ %5 ﱂ ﺗﺘﻌﺪﻯ ﺍﻟﱴﻭ ﺍﻟﻨﺴﱮ
   : ﺍﳋﻼﺻﺔ
ﻭﻗﺪ ﻳﻌﺰﻯ ﺫﻟﻚ  ﻣﺘﺪﺍﻭﻟﺔ ﺍﳉﻮﺩﻩ ﻟﻠﻤﻼﺭﻳﺎ ﻣﺘﺪﻧﻴﺔ ﺍﺕﻣﻀﺎﺩ ﺗﺘﻤﺜﻞ ﰱ ﻭﺟﻮﺩ ﺍﻟﺒﻴﺎﻧﺎﺕ ﺇﱃ ﻣﺸﻜﻠﺔ ﻛﺒﲑﺓ ﺗﺸﲑ      
ﻇﺮﻭﻑ ﺍﻟﺘﺨﺰﻳﻦ ﻏﲑ ﺍﳌﻨﺎﺳﺒﺔ ﻭﻋﺪﻡ ﺍﻻﻣﺘﺜﺎﻝ ﻟﻠﺘﻮﺟﻴﻬﺎﺕ ﺍﻟﺴﻠﻴﻤﻪ ﰱ ﺃﺳﻠﻮﺏ ﺍﻟﺘﺼﻨﻴﻊ ﺍﳉﻴﺪ ﻣﻦ ﻗﺒﻞ ﺍﻟﺸﺮﻛﺎﺕ   ﺇﱃ
   .ﺍﳌﺼﻨﻌﺔ
ﺭﺗﻴﺴﻮﻧﺎﺕ ﺑﲔ ﳐﺘﻠﻒ ﺍﳌﺎﺭﻛﺎﺕ ﻳﺴﻠﻂ ﺍﻟﻀﻮﺀ ﻷﻗﺮﺍﺹ ﺍﻷ ﻣﺘﺪﻧﻴﺔ ﺍﻟﺼﻨﻊ ﺘﺮﺍﻛﻴﺐﺍﻟ ﻭﺟﻮﺩ ﺑﻌﺾﻟﻜﺸﻒ ﻋﻦ ﺍ      
 ﻟﻠﺤﻴﻠﻮﻟﺔ ﺩﻭﻥ ﻓﺸﻞ ﻭﺫﻟﻚ ﻋﻠﻰ ﺍﳊﺎﺟﺔ ﻟﺰﻳﺎﺩﺓ ﻣﺮﺍﻗﺒﺔ ﻭﺭﺻﺪ ﺟﻮﺩﺓ ﺍﻷﺩﻭﻳﺔ ﺍﳌﻀﺎﺩﺓ ﻟﻠﻤﻼﺭﻳﺎ ﺍﻟﱵ ﺗﺴﺘﺨﺪﻡ ﺣﺎﻟﻴﺎ
   .ﺍﻟﻌﻼﺝ ﻓﺎﻋﻠﻴﺔ
ﺃﻗﺼﻰ ﻗﺪﺭ  ﺍﻷﺭﺗﻴﺴﻮﻧﺎﺕ ﻣﻌﺒﺄﺓ ﺑﺸﻜﻞ ﻣﻨﺎﺳﺐ ﻭﲣﺰﻥ ﰲ ﻣﻜﺎﻥ ﺑﺎﺭﺩ ﻟﻀﻤﺎﻥ ﻣﻨﺘﺠﺎﺕ ﻋﻘﺎﺭ ﻨﺒﻐﻲ ﺃﻥ ﺗﻜﻮﻥﻳ      
   .ﺍﳌﻨﺘﺠﺎﺕ ﺜﺒﺎﺕ ﻭﺳﻼﻣﺔﻣﻦ ﺍﻟ
ﳝﻜﻦ ﺍﺳﺘﺨﺪﺍﻣﻬﺎ ﰲ ﳐﺘﱪﺍﺕ ﻭ ﻗﺎﺑﻠﺔ ﻟﻠﺘﻄﺒﻴﻖ,ﺩﻗﻴﻘﺔ ﻗﺮﺍﺹ ﺍﻷﺭﺗﻴﺴﻮﻧﺎﺕﻷ ﺍﳌﻌﺘﻤﺪﺓ ﺔﺬﻭﺑﺎﻧﻴﺍﻟﻃﺮﻳﻘﺔ ﺇﺧﺘﺒﺎﺭ     
 .ﻣﺜﻞ ﺗﻠﻚ ﺍﳌﻮﺟﻮﺩﺓ ﰲ ﻣﻌﻈﻢ ﺍﻟﺒﻠﺪﺍﻥ ﺍﻟﻨﺎﻣﻴﺔ ﺎﹰﺑﺴﻴﻄ ﳎﻬﺰﺓ ﲡﻬﻴﺰﺍﹰ
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List of abbreviations 
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hr Hour 
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MS Mass spectrometry 
N Number of samples analyzed 
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NCL National Chemical Laboratory-Khartoum 
NMP National Malaria  Control Program -Sudan 
PPRO The Pharmacy and Poisons Act, and Regulations and 
0rder 
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Introduction 
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1.1. Post -marketing surveillance 
Post-marketing surveillance is the practice of monitoring a pharmace-
utical drug or device after it has been released to the market (EMEA, 2000). It 
confirms the safety of a drug after it is used in the general population by a 
large number of people who have a wide variety of medical conditions. Post- 
marketing surveillance plays an important role to discover undesirable effects 
that might be present. It provides additional information on the benefits and 
risks of a drug, resulting in possible drug safety hazards being identified which 
may influence the benefit/risk ratio of medicinal product (FDA, 2007). Public 
health research has neglected investigations of the quality of essential 
medicines, with few reliable data despite evidence suggesting that it is a major 
problem reducing the effectiveness of health care (Taylor et al, 2001; 
Caudron, et al, 2008). There are very few reliable published estimates of the 
prevalence of counterfeit, substandard or degraded medicines for any country 
(Newtonet al, 2006). Differentiation between counterfeit, substandard or 
degraded products is important as this information is vital to allow medicine 
regulatory authorities to determine appropriate counter-measures. Since the 
1990s, substandard drugs used for the treatment of potential-fatal tropical 
diseases, such as malaria, have been detected in increasing numbers. Malaria 
is a major health problem in many tropic countries, especially in Sub-Saharian 
Africa and Southeast Asia. Each year, there are approximately 515 million 
cases of malaria, killing between one and three million people, the majority of 
whom are young children in Sub-Saharian Africa (Amin et al,2005). Malaria 
is a major cause of morbidity and mortality in Sudan resulting in an estimated 
7.5 million cases and 35,000 deaths annually (Malik et al, 2004).In the late 
1990s, great efforts were directed to improve malaria cases management and 
this was included in the development of the Roll Back Malaria (RBM) 
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strategic plan in 2001( Malik and Saeed ,  2004). Case management requires 
the provision of prompt, effective and safe treatment to malaria cases (Jane, 
2005).Combin-ation therapies preferably using "novel" antimalarial drugs with 
different modes of action is the way forwarded for improving therapeutic 
efficacy and delaying development of resistance in antimalarial chemotherapy. 
Artemi-sinin based combinations have several distinct advantages in that they 
produce rapid clinical and parasitological cure. To our knowledge there is as 
yet no documented parasite resistance. They reduce gametocyte carriage rate, 
and are generally well tolerated (Jane, 2005). artemisinin- derivatives are now 
the recommended treatment in many countries where drug resistant malaria 
parasites exist and have become the target of an extremely sophisticated and 
prolific counterfeit drug trade.  Since the 1970s, chloroquine resistance has 
been documented and has since increased and spread all over Sudan 
(Stivanello et al, 2004). Using the results of research on resistance to 
chloroquine, Sudanese policy-makers updated their national malaria treatment 
guidelines in 2004 to artemisinin-based combination therapy (ACTs), both as 
first-line (AS+SP) and second-line (ART+LUM) (Malik et al, 2006). Policy 
makers at General Directorate of Pharmacy were highly concerned about the 
availability of artemisinin derivative–based combination therapy(ACTs) and 
their stability in hot weather, such as Sudan,  as no company at time of 
launching the new policy was qualified by WHO to provide co-blister of 
AS+SP,( Malik et al, 2006). These combination options need continued 
documentation of safety and efficacy as part of any potential implementation 
process, especially among very young children, pregnant women, and breast 
feeding mothers and their babies (Sivong et al, 2009). In many settings, 
antimalarial therapy is usually complicated not only because of drug resistance 
but also patient-related factors, such as poor adherence to therapy, drug side-
effects, such as vomiting, which lead to under-dosage, drug interactions and 
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individual variations (WHO, 2005). Therapeutic failure also occur due to 
pharmaceutical failure resulting from poor quality of products, instability of 
products, which leads to deterioration of their quality before they reach the 
patient, or the use of counterfeit products. Several WHO-sponsored studies 
have demonstrated significant instability of products during transport by sea, 
and also during road transfer to final destination (WHO,2005), the quality of 
antimalarials (chloroquineand sulphadoxine / pyrimethamine) in selected 
African countries (Gabon, Ghana, Kenya, Mali, Mozambique, Sudan, the 
United Republic of Tanzania and Zimbabwe) had been studied .The data 
indicated significant problems of substandard antimalarial products circulating 
within the drug distribution chains in the African region (Charles and 
Clive,2003).Based combination therapies are at an early stage in Africa and 
there is a need for extensive post-marketing surveillance(Sivong et al,2009). 
In Nigeria in vitro bioequivalence study of nine brands of artesunate tablets 
showed a significant variation in different brands (Esimonea et al, 2008; 
Odunfa et al, 2009). Drug market today places clinicians and pharmacists in a 
difficult situation regarding choice of a suitable brand and lead to spreading of 
counterfeit and substandard drugs in the market .In Sudan a report on the post- 
marketing surveillance of the various brands of anti malarial drugs-
(chloroquine tablets and injections, artemether injections, quinine injections 
and mefloquine tablets) showed a significant problem of substandard drugs 
circulating in the market, they include percentage failure ranging from 0% to 
100% (Afadl, et al,2006). The pharmaceutical products of poor quality might 
contribute to the emergence of resistance. When patients are treated with poor-
quality drugs, resulting in low bioavailability, this leads to drug sub-dose, 
which promotes the development of resistance. It is therefore important to 
consider product quality when dealing with the problem of antimalarial 
resistance. Treatment failure, ascribed to resistance, may also be due to low 
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quality of antimalarials posed a problem to malaria control, and therefore to 
public health. So there was a need to clarify the nature and magnitude of the 
problem of quality and consequently how it could be specifically addressed. 
This study on the quality and stability of the artesunate drug as a part of a 
comprehensive survey of quality and safety of all drugs circulating in 
Sudanese market aims to provide indication of the nature and magnitude of 
the problem. It is also meant to present data on the quality of oral artesunate 
in Sudan. 
1.2. Counterfeit/Substandard drugs  
Counterfeit medicine or fake, as defined by the WHO is one which is 
deliberately and fraudulently mislabeled with respect to identity and/or 
source.  Counterfeit can apply to both branded and generic products and 
counterfeit products may include products with the correct ingredients or 
with the wrong ingredients, without active ingredients, with insufficient 
active ingredient or with fake packaging.  While the substandard product is a 
legally branded or generic product, it is one that does not meet international 
standards for quality, purity, strength, or packaging. (WHO,1999). 
1.2.1.Counterfeit/substandard artemisinin derivative combination drugs 
Counterfeit/substandard anti-malarial drugs were found in both public 
and private sectors. Although artemisinine- derivatives are relatively 
inexpensive compared to other synthetic drugs, this asset has been devalued 
by the presence of substandard production. Counterfeits have been found in 
several Asian countries , up to 38% of artesunate based malaria medications 
are counterfeit, (WHO,2003). In 2004 most African countries have changed 
to artemisinine derivative–based combination therapy as first-line malaria 
treatment (Malik et al, 2006). Shortage in artemisinines drugs provided a 
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favorable situation for the spread of fake artemisinines that put the live of 
thousands of African children at risk. There is a thriving fake antimalarial 
drug industry in Africa (Basco, 2004). Fakes containing sub therapeutic 
amounts of artesunate could result in the emergence and spread of resistance 
to the artemisinins drugs, shortening the useful life of these vital medicines 
(Newton et al, 2006). Counterfeit oral artesunate has been a major public 
health problem in mainland Southeast Asia, impeding malaria control 
(Newton et al, 2006). However, since the discovery of counterfeit artesunate 
in the late 1990s in mainland Southeast Asia  there has been concern that 
much of the artesunate used by patients is counterfeit, containing no or 
inadequate active ingredient (Rozendaal, 2000;Newton et al, 2001;Newton et 
al, 2008).Public health research has neglected investigations of the quality of 
essential medicines, with few reliable data despite evidence suggesting that 
it is a major problem reducing the effectiveness of health care (Taylor et 
al,2001;Caudron et al,2008).There are very few reliable published estimates 
of the prevalence of counterfeit, substandard or degraded medicines for any 
country (Newton et al, 2006). Estimates of the prevalence of fake artesunate 
have all used 'convenience' sampling (Newton et al, 2001; Dondorp et al, 
2004), which is potentially flawed by bias (Newton et al, 2009). Biases may 
overestimate or underestimate the prevalence of poor quality drugs 
depending on whether the drug collectors, consciously or subconsciously, 
prefer to find or not find poor quality medicines. For quantitative estimates 
of the prevalence of counterfeit and substandard medicines and to allow 
comparisons through time, a standardized randomized sampling procedure, 
of sufficient sample size, is needed (Newton et al, 2009). 
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1.3. Stability of medicinal products 
A medicinal product is designed to possess certain desirable 
properties. When the product is administered by the specified route, the 
active constituent should achieve the required rate and extent of 
bioavailability. The product itself should be efficacious, safe, and acceptable 
to the patient; it should be convenient in use and stable. The stability of a 
product relates to its resistance to the various chemical, physical, and 
microbiological reactions that may change the original properties of the 
preparation during transport, storage, and use. Other criteria of stability are 
the effects of such changes on the fitness of the product for use as a 
medicine (Codex, 1994). Stability is often expressed in quantitative terms as 
the shelf-life. Shelf-life is the time during which the medicinal product is 
predicted to remain fit for its intended use under specified conditions of 
storage. The shelf-life of a medicinal product kept in its closed container 
under specified conditions is the time from manufacture or preparation until 
the original potency or content of active constituent has been reduced by 
10%. This time is known as the t10% (Codex, 1994). 
1.3.1. Reaction kinetics 
Reaction kinetics is the study of rate of chemical change and the way 
in which this rate is influenced by conditions of concentration of reactants, 
products, and other chemical species which may be present, and by factors 
such as solvent, pressure, and temperature. The most common types of 
reactions do not fit into any simple model of reaction kinetics .However 
most degradation process do fit to either zero- order or first -order kinetics 
equations (Codex, 1994). 
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  1.3.1.1. First order reaction 
The rate of a reaction (R) is proportional to the first power of the 
concentration of a reactant and may be expressed mathematically as 
follows:-  
When log c is plotted against t it will gave straight line; and the values 
of K , t10, t1 was expressed as follows: 
K = ‐slop x 2.303 
t10 = 0.105/K 
t50= 0.693/K 
1.3.1.2. Second order reaction 
The rate of a reaction is proportional to concentration of each of two 
reactants or the second power of the concentration of one reactant and may 
be expressed mathematically as follow: 
‐ dcA/dt =‐dcB/dt = K.cA cB 
t50 =1/K a 
1.3.1.3. Zero order reaction 
The rate is independent of concentration of reactants. In such cases the 
rate is expressed as follows: 
‐ dc/dt =K 
 And t10, t50 are expressed as follows: 
t10 = 0.1a/K 
t50 = 0.5a/ K 
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 Where a is the initial concentration of a reactant. (Codex, 1994). 
 1.3.2. Factors affecting product stability 
The stability of drug substances and dosage forms can be affected by 
different environmental factors such as exposure to adverse temperature, 
light, humidity, oxygen, and carbon dioxide. The major factors that influence 
drug stability include particle size, pH, solvent system composition, 
compatibility of anions and actions, ionic strength, primary container, 
specific chemical additives, and molecular binding and diffusion of drugs 
and excipients. There are many other reactions that cause loss of drug 
content such as, hydrolysis, epimerization, decarboxylation, oxidation, 
photochemical decomposition  (Codex ,1994). 
1.3.3. Testing frequency 
For long-term studies, frequency of testing should be sufficient to 
establish the stability of the finished pharmaceutical product. The frequency 
of  testing at the long-term storage conditions  should normally be every 
three months over the first year, every six months over the second year and 
annually thereafter throughout the proposed shelf-life. At the accelerated 
storage condition, a minimum of three time points, including  the initial and 
final time points , from a six-month study is recommended (WHO, 2007; 
WHO,2009). 
1.3.4. Climatic zones  
Five climatic zones can be distinguished for the purpose of worldwide 
stability testing, .These are:-                                                                              
• Zone I: temperate climate. 
• Zone II: subtropical and Mediterranean climate. 
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• Zone III: hot and dry climate. 
• Zone IVA: hot and humid climate. 
•  Zone IVB: humid climate. 
The  WHO  specified  for  long-term  stability  study at   21 ± 2°C / 
45% RH for Zone I, 25 °C ± 2 °C/60% RH ± 5% RH for Zone II, 30± 2 °C / 
35%  RH for Zone I11,30 °C ± 2 °C/65% RH ± 5% RH for Zone IVA and 
30 °C ± 2 °C/75% RH ± 5% RH for Zone IVB. The temperature for long –
Term stability study is calculated from the mean kinetic temperature (WHO, 
2007; WHO, 2009), which is the temperature at which the total amount of 
degradation over a particular period is equal to the sum of the individual 
degradations that would occur at various temperatures. It is calculated from 
temperature in a storage facility (USP2007). 
Artemisinin compounds are sensitive to moisture. The shelf-life of 
most products is around two years and this depends on high standards of 
blister-packaging and good storage (WHO, 2003). Attention must therefore 
be paid to their manufacturing and storage conditions. Furthermore, there is 
limited experience with these products by drug regulatory authorities and 
health care professionals. It is therefore necessary to adhere to stringent raw 
material standards, drug-manufacturing practices, norms and standards 
(Good Manufacturing Practices, GMP). The product(s) should be appropri-
ately blister-packed to assure maximal stability and product integrity (WHO, 
2003). The pharmacopeia monographs of artesunate tablet recom-mended 
storage condition for artesunate(IP,2005;Chinese pharmacypeia-,2005;Indian 
pharma-copeia,2009).  
New artemisinin combination therapies pose difficulties of implem -
entation in developing and tropical settings because they have a short shelf-
11 
 
life relative to the medicines they replace (Roger et al, 2009). This limits the 
reliability and cost of treatment, and the acceptability of this treatment to 
health care workers. A multi-pronged investigation was made into the 
chemical and physical stability of fixed dose combination therapies stored 
under heterogeneous, uncontrolled African conditions, to probe if a shelf-life 
extension might be possible(Roger et al, 2009).Seventy samples of expired 
ART+LUM  were collected from private pharmacies and malaria researchers 
in seven African countries, and  subjected to thin-layer chromatography 
(TLC), disintegration testing, and near infrared Raman spectrometry for 
ascertainment of active ingredients, tablet integrity, and chemical 
degradation of the tablet formulation including both active ingredients and 
excipients. The data indicated that ART+LUM is chemically and physically 
stable well beyond its stated shelf-life in uncontrolled tropical conditions 
(Roger et al, 2009). The stability tests of the reconstituted suspensions for 
artesunate, dihydroartemisinin and artemether, showed bad results for 
artesunate, even when the pH was adapted. In contrast, dihydroartemisinin 
showed only 10% degradation within 10 days and artemether was stable at 
least 21 days. (Gabriëls and Plaizier, 2004). 
Sudan as a large country with total area of about 3.5 million Km2, 
possesses  different climatic conditions ranging from hot and dry in the 
North, to hot and humid in the East, and tropic  in  the South. WHO 
classified Sudan under Zone IVA (WHO, 2009). Sudan imports drugs from 
various countries .The majority of these drugs are transported by sea, 
through the sea port at Port Sudan .However the climatic condition at the 
harbor in Port Sudan is very drastic especially during autumn when relative 
humidity is up to 65% and the maximum temperature is over 45°C. These 
drastic conditions may affect the stability of drugs and cause physical or 
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chemical changes of the drugs in Sudan. Different antimalarial and other 
drugs had been studied during transport and storage condition in Sudan. The 
results showed in-stability of the drugs upon transportation and storage at 
room temperature. Results of the stability study of different drugs in Sudan, 
showed a significant decrease in the content of the active ingredient in some 
pharmaceutical products including lignocaine injection, adrenaline injection, 
suxamethonium chloride injection, ergometrine maleate injection, ampicillin 
capsules, tetracycline capsules and procaine penicillin injection (Abu-Reid et 
al, 1990). A report on the storage and transport of ART+LUM tablets in 
Sudan showed un-stability of ART tablets upon transportation by the normal 
transport condition and storage at room temperature (Gamil et al, 2008). 
Literature review showed that there is no study of the stability of 
artesunate in Sudan. 
1.4. Artemesinin and its derivatives 
Artemesinin is a Chinese herb (Qinghaosu) that has been used in the 
treatment of fevers for over 1,000 years, thus predating the use of Quinine in 
the western world (Woodrow. et al, 2005). It is derived from the plant 
Artemisia annua, with the first documentation as a successful therapeutic 
agent in the treatment of malaria is in 340 AD. The active compound was 
isolated first in 1971 and named artemsinin. It is a sesquiterpene lactone 
with a chemically rare peroxide bridge linkage. It is this that is thought to be 
responsible for the majority of its anti-malarial action. At present it is strictly 
controlled under WHO guidelines as it has proven to be effective against all 
forms of multi-drug resistant P. falciparum.  It is only given in combination 
with other anti-malarials (Mankil, 1994).Various semi synthetic derivatives 
of artemisinin[artenimol (dihydroarte misinin), artesunate, artemether and 
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artemotil(arteether)] are in use for the treatment of patients with either 
uncomplicated or severe malaria, including multidrug-resistant falciparum 
malaria. (Klayman, 1985). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure No. (1): Structures of artemisinin and its derivatives.  
1.4.1. Chemistry and general properties of artemesinin and its 
derivatives 
The chemical structure of artemisinin is quite different from all 
previously known antimalarials.The compound is an unusually stable 
sesquiterpene   lactone bearing a peroxy group . The presence of the 
peroxide bridge is essential for artemisinins antimalarial activity as a 
reduced form of the compound, deoxyartemisinin, lacks the antimalarial 
activity. (Woerdenbag et al, 1994). 
O
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R1,R2 = O                                                 Artemisinin 
R1= H, R2 = OH                                       Dihydroartemisinin 
R1= H, R2 = OCH3                                        Artemether 
R1= H, R2 = OCH2CH3                             Arteether 
R1= H, R2 = OCH2C6H5CO2H                  Artelinic Acid 
R1= H, R2 = OCOCH2CH2CO2H              Artesunic Acid (artesunate) 
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1.4.2. Mechanism of action of artemesinin and its derivatives 
The specific mechanism of action of artemisinins is not well unde-
rstood, and there is ongoing research directed at elucidating it. One of these 
postulation attributed that artemisinin contains a structural feature called a 
peroxide bridge, which is believed to form highly reactive free radicals. The 
theory has been that these artemisinin-derived free radicals chemically 
modify and inhibit a variety of parasite molecules, resulting in parasite 
death. A rich source of intracellular Fe2+ is haem—an essential component 
of haem-oglobin—and it has long been suspected thatFe2+-haem is 
responsible for activating artemisinins inside the parasite (Robert,2003). 
Other sources attributed the mechanisms of action of artemisinin to 
interference with parasite transport proteins, disruption of parasite 
mitochondrial function, modulation of host immune function and inhibition 
of angiogenesis (Golenser et al, 2006). 
1.4.3. Antimalarial efficacy of artemesinin and its derivatives 
Artemisinin and its derivatives have proved effective against strains 
resistant to conventional antimalarials such as chloroquine   and mefloquine.  
(Alin, et al, 1992; Price et al, 1998; Winstanley et al, 2000). There is no 
clinically relevant artemisinin-resistant human malaria, although there are 
developments of the rodent malaria parasite strains resistant to the drug 
(Chawira, et al 1986; Li, et al, 1989). The genetic basis of the artemisinin 
and its derivatives has a rapid antimalarial effect, decreasing the number of 
parasite faster than any other known drug (White, et al, 1994). Also lower 
gametocyte carriage rates have been observed after treatment with 
artemisinin and its derivatives (Price et al, 1996). The fast decline in the 
number of parasites is beneficial in combination therapies (White et al, 
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1999). Another advantage of the rapid clearance of the parasite is the earlier 
return of the patients to the normal life. However, since the clinical 
symptoms of malaria disappear within a day or two after treatment initiation, 
compliance could become a problem. The rapid decline in the number of 
parasites has not proved to be of clinical benefit compared to quinine in 
severe malaria cases (Cao et al, 1997), although there seems to be a lower 
frequency of side effects in patients treated with the artemisinin compounds 
(Tran et al, 1996). 
1.4.4. Clinical safety and Toxicity of artemesinin and its derivatives 
Artemisinin and its derivatives are well tolerated in clinical practice. 
(Dayan et al, 1998; Van et al, 2000; White and Olliao, 1998). The neur-
otoxicity seen in animals after high doses of these compounds has not been 
reported in humans. (Ambroise,1999). The artemisinin compounds are 
considered to be well-tolerated, with few or none side effects in clinical use 
(van Agtmael et al.1999). 
1.5. Artesunatum – Artesunate 
 C19H28O8       (Figure 1) 
1.5.1. Chemical name  
(3R,5aS,6R,8aS,9R,10S,12R,12aR)-Decahydro-3,6,9-trimethyl-3,12-epoxy-
12H-pyrano[4,3-j]-1,2-benzodioxepin-10-ol, hydrogen succinate.(IP, 1995). 
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1.5.2. Physical properties  
Afine, white crystalline powder, very slightly soluble in water; very 
so-luble in dichloromethane R; freely soluble in ethanol (~750 g/l) TS and 
acetone R. (IP, 1995). 
1.5.3. Pharmacokinetics of artesunate 
The artesunate is characterized by a short half-life and rapid action. 
artesunate is rapidly converted to artenimol (DHA) at rates that vary with the 
route of administration(Navaratnam et al, 2000). Following intravenous 
injection, artesunate has a peak plasma drug concentration (Cmax) of 13.7 
mg/L, an elimination half-life (t½) of 2.2 min, a clearance of 3.0 L/hr/kg, and 
a volume of distribution of 0.16 L/kg. Dihydroartemisinin has a Cmax of 2.2 
mg/L, a tmax of 8 min, a t½ of 37 min, an apparent clearance of 1.1 L/hr/kg, 
and an apparent volume of distribution of 0.9 L/kg. Following oral 
artesunate, the mean relative bioavailability of DHA is 85%, the Cmax is 3.0 
mM (0.85 mg/L), the tmax is 75 min., and t½ was 40 min. (Benakis et al, 
1998). 
1.5.4. Synthesis of artesunate 
There are several methods of the synthesis of artesunate . Artesunate 
is synthesized by the extraction of artemisinine with dichloromethane and 
purified on the basis of variations in polarity and in the hydrophile/lipophile 
balance of solvents. Transformation into artesunate was a two-step process 
involving reduction to dihydroartemisininee using diisobutylaluminium 
hydride followed by esterification using succinic anhydride. (Chekem and 
Wierucki S, 2007).Another method of synthesis is by the chemical 
modification of artesunate to the key compound dihydroartemisinin by 
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reduction with sodium borohydride in methanolic suspension. The hemi 
succinate (artesunate) was obtained by estrification of dihydro artemisinine 
with succinic anhydride under basic condition.(Presser and S.Buzzi. 2009). 
Also  artesunate is synthesized by transformation into artesunate by two-step 
process involving reduction to dihydroartemisininee using methanolic 
solution of sodium borohydride and acetic acid glacial in presence of 
heptane followed by esterification using  methylene chloride and succinic 
anhydride in presence of heptane Figure(2) (János,2004). 
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ARTESUNATE SYNTHESIS – Step1 
 
 
ARTESUNATE SYNTHESIS – Step2 
Figure No. (2): Synthesis of artesunate(Reproduced from Ref. János,2004) 
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1.5.5. Resistance 
A potential for resistance development by Plasmodium species to 
artesunate was examined in vitro and in vivo.  In a preliminary study, the 
erythrocytic forms of the FCR3 strain of P. falciparum were passaged by 
exposure to increasing concentrations of artesunate (starting with 4 ng/ml) 
for 48 hours each, followed by growth in drug-free medium for 18 days 
(equivalent to 9 life cycles). The artesunate IC50 value increased by 3-fold 
after 6 to 7 passages over a period of 130 days.  Such an effect was 
reversible when the parasites were grown in drug free medium for 5 
weeks.Studies in vivo show that serial passage of the N strain of P. berghei 
in mice treated with escalating doses of artesunate for 4 days each, increased 
the 90% effective dose (ED90) by about 29-fold after 21 passages (85 days). 
The effect was reversible after discontinuation of therapy. However, the 
clinical significance of these observations is unknown. In patients with 
severe or moderate malaria, treatment with a single dose of rectal artesunate 
decreased the parasite count by > 90% in 24 hours. In patients treated with 
multiple doses of artesunate (oral, rectal or IV) the parasite clearance time 
was 16 to 56 hours. However, recrudescence was reported on Days 10 to 28 
after discontinuation of therapy.  In the absence of genotyping and 
phenotyping it is unclear whether the recrudescence is due to resistance.  
Also, the presence of dormant parasites cannot be ruled out (White.2004). 
1.5.6. Drug combination 
A combination of artesunate with mefloquine or quinine is synergistic 
against P. falciparum. However, a combination of artesunate with pyri-
methamine is antagonistic. The combination of artesunate with chloroquine 
varied from additive to antagonistic against the different P. falciparum 
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strains tested. The oxidant drugs (miconazole and doxorubicin) also show a 
synergistic effect in combination with artesunate.  A combination of artemi-
sinin with mefloquine is synergistic whereas that with pyrimethamine is 
antagonistic in vitro and in vivo. Combinations of artemisinin with other 
antimalarials (sulfadiazine, sulfadoxine, sulfadoxine-pyrimethamine, cyclo-
guanil, and dapsone) were also shown to be antagonistic in vivo (WHO, 
2001). 
1.5.7. Stability of artesunate 
Amulti-prolonged investigation was made into the chemical and 
physical stability of artesunate and fixed dose combination (AS+AP). 
Artesunate was found to be stable in 0.9% w/v sodium chloride at 9°C, 23° 
C and 36.5° C for 130h, 10.6h and 1.6 h, respectively. Exposure to light did 
not affect the degradation rate; (Batty et al, 1996). Muco-adhesive gel 
formulation of artesunate storage in tropical climates in the dry component 
of the gel, showed stablility in the dry blend for 6 months at 45 °C and 60% 
RH. (Karen et al, 2008). Instability of artesunate was established in three 
pharmaceutical solvents ethanol, propylene glycol and polyethylene glycol 
400 (PEG 400). None of these solvents prevented artesunate from 
degradation longer than 3 months (Gaudin et al, 2007).The stability tests of 
the reconstituted suspensions showed bad results for artesunate, even when 
the pH was adapted. In contrast, dihydroartemisinin showed only 10% 
degradation within 10 days and artemether was stable for at least 21 days 
(Gabriëls and Plaizier, 2004). Artesunate drug substance, for a rectal capsule 
formulation, when heated at 100 °C for 39 h gives β-artesunate, artesunate 
dimers, 9,10-anhydrodihy-droartemisinin (glycal), a DHA β-formate ester, 
and smaller amounts of other products that arise via intermediate formation 
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of dihydroartemisinin (DHA) and subsequent thermal degradation.( Richard 
et al,2007). WHO reported the effect of the humidity on artesunate tablets 
and recomended blister-packed for artesunate tablets (WHO, 2003). Also the 
pharmacopeias recommended different storage conditions for artesunate 
tablet:  
Artesunate tablets should be kept in a well-closed container (Chinese 
pharmacopeia, 1996), 
Artesunate tablets should be kept in a well-closed container, protect from 
light(IP,2005). 
Artesunate tablets should be kept in a well-closed container (IP2009). 
Store protected from moisture (Indian pharmacopeia.2009). 
Packaging in tightly closed, light-resistant container at temperature not 
exceeding 30° (USP, 2009). 
1.5.8. Assay of artesunate 
Several analytical methods are now available for determination of 
artesunate in pharmaceutical dosage form and in biological fluid. A simple 
spectrophotometric method for the determination of artesunate is described; 
the method is based on the reaction of H2O2 generated by the cleavage of 
endoperoxide linkage of artesunate and its reaction with potassium iodide to 
liberate iodine. The liberated iodine bleaches the red colored Safranin O to 
colorless species and is measured at 521 nm while it oxidizes color-
lessVariamine blue to violet colored species and is measured at 556 nm 
(Thekke and Badiadka, 2009). A reversed phase liquid chromatographic 
method was developed for the simultaneous determination of artesunate and 
amodiaquine in combined pharmaceutical dosage form , chromatographic 
separation of the two drugs was performed on a BDS Hypersil C18, 
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100 mm × 4.6 mm, 3 µm particle size column as stationary phase with a 
mobile phase comprising phosphate buffer (pH 3.0) and acetonitrile in the 
proportion of 50:40 (v/v), at a flow rate of 0.8 mL min−1 and UV detection 
at wavelength 210 nm for artesunate and 300 nm for amodiaquine using 
photodiode array detection.(Manishaet al,2008).HPTLC method has been 
developed for the estimation of artesunate in bulk and pharmaceutical 
formulations. The study employs silica gel F254 as stationary phase on 
aluminium foil and mobile phase comprising toluene: ethyl acetate: acetic 
acid (2:8:0.2). Vanillin (1%) in sulphuric acid (5%) in ethanolic solution 
gave prominent well-resolved pink colour spot for artesunate, which was 
stable for more than a day. The densitometric analysis was carried out in the 
absorbance mode at 520 nm.( Agarwal, et al,2007). Also High-performance 
liquid chromatography has been developed for artesunate tablet , using a 
stainless steel column (10 cm × 4.6 mm) packed with particles of silica gel, 
the surface of which has been modified with chemically bonded  
octadecylsilyl groups (3 µm) and a mixture of 44volumes of acetonitrile and 
56 volumes of buffer pH 3.0 as the mobile phase. The system operates with a 
flow rate of 1.0 ml per min. (Ema, 2009). Artesunate was analysed by liquid 
chromatography with atmospheric pressure chemical ionisation (APCI) mass 
spectrometric (MS) detection on a Hypersil Gold column (100 mm x 4.6 
mm) using a mobile phase containing methanol-ammonium acetate 10 mM 
pH 5.3 (70:30, v/v) at a flow rate of 1 mL/min.(Lindegårdh, 2007). A high-
performance liquid chromatographic method with reductive electrochemical 
detection is described for the simultaneous quantification of artesunate and 
dihydroartemisinin (DHA) in plasma. The procedure involved the extraction 
of artesunate, DHA and the internal standard (artemisinin) with a mixture of 
dichloromethane and tert.-methyl butyl ether (8:2, v/v). Chromatographic 
separation consisted of the mobile phase (acetonitrile–water containing 0.1 
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M acetic acid, pH 4.8; 45:55, v/v) running through the column (Nova-Pak 
C18, 150 cm×3.9 mm I.D., 5µm particle size) (Bangchang et al, 1998). In 
support of the development of specifications, major impurities are identified 
using high resolution HPLC–MS, isolation via preparative HPLC followed 
by NMR. The identified impurities differ from those previously claimed 
(Rodger et al, 2009). Also sensitive method has been developed for the 
determination of artesunate and its active metabolite dihydroartemisinin 
(DHA) in human plasma using artemisinin as an internal standard. Solid 
phase extraction using Oasis HLB extraction cartridges was used for sample 
preparation and analysis was performed on a Shimadzu LCMS-2010 in 
single ion monitoring positive mode using atmospheric pressure chemical 
ionization as an interface. Positive ions were measured using extracted ion 
chromatogram mode. The extracted ion for artesunate, α- and β-DHA was 
m/z 221 and for artemisinin was m/z 283. Chromatography was carried out 
using a Synergi Max-RP, 4 µ, 75 mm x 4.6 mm column using glacial acetic 
acid 0.1%, acetonitrile and methanol mixture (38:46.5:15.5) as a mobile 
phase delivered at a flow rate of 0.5 mL/min. (Himanshu et al, 2005). Also 
other method was developed to analyze human plasma samples for the 
contents of artesunate and dihydroartemisinin. The plasma samples are 
extracted with ethyl acetate, concentrated, and redissolved in 
water/acetonitrile. Analysis was performed with liquid chromatography-
mass spectrometry using a binary gradient program with aquaeous formic 
acid and acetonitrile formic acid on   a XTerra MS C18-column. (Van et al, 
2008). Liquid chromatography-mass spectrometry (LC-MS) analytical 
method used for the co-quantification of artesunate and its active metabolite, 
dihydroartemisinin in human plasma using  artemisinin  as an internal 
standard. The liquid-liquid extraction of samples was carried out using 
dichloromethane and tert.-methyl butyl ether (at a ratio of 8:2v/v) and then 
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evaporated to dryness by a stream of nitrogen gas at room temperature. 
Chromatographic separation and mass analysis were performed on 
chromatography/mass spectrometer detector trap system, using electrospray 
ionization as an interface. The stationary phase was an Elipse XDB-C18 
column. The mobile phase contained acetonitrile and 0.003 M glacial acetic 
acid at ratio of 62:38(v/v) delivered ataflow rate of 0.5ml/min.(Lindegardh et 
al,2009)                    
Pharmacopeial monographs published different methods of analysis of 
artesunate in bulk and in dosage formulations. Chinese pharmacopeia (1996) 
published titration methods by dissolving an accurately weighed quantity of 
powder containing about 0.5g of artesunate in 50 ml of neutralized ethanol 
and phenolphthalein/ethanol TS as indicator. IP2005 published an HPLC 
method using stainless steel column (12.5cm×3mm) (5µ) C18, a mixture of 
equal volumes of acetonitrile and buffer (potassium dihydrogen phosphate 
pH 3.0) as mobile phase, flow rate 0.6 ml per minute, and UV-detector set at 
216 nm. Also IP published a draft in 2009 changed the previous HPLC 
method of the assay to anther HPLC method using stainless steel column (10 
cm × 4.6 mm) (3 µm) C18 at 30°, mobile phase of a mixture of 44volumes 
of acetonitrile and 56 volumes of potassium dihydrogen phosphate (pH 3.0), 
flow rate 1ml per min, and UV-detector  set at 216 nm .The IP(2009) method 
is the same as that published by Ema (2009). USP(2009)  published a draft 
for the assay of artesunate tablets  using a mixture of acetonitrile and buffer  
pH3 as mobile phase, column 25 cm x 4.6 mm packed with octadecylsilane 
bonded to porous silica 5 µm, at temperature 30°,and UV-detector set at 216 
nm. Indian pharmacopeia (2009) published an assay method of artesunate 
tablets using HPLC method a mixture of 30 volumes of a solution of pH 5.5 
(containing 3.85 g of ammonium acetate and 1 ml of triethylamine in 1000 
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ml of water) and 70 volumes of methanol as mobile phase, stainless steel 
column 15 cm x 4.6 mm packed with octadecylsilane bonded to porous silica 
(3.5 µm) at 15°C, flow rate 0.6 ml per min., and UV-detector set at 216 nm. 
There are different Pharmacopeial methods for the dissolution test of 
the artesunate tablets. Unfortunately, these official methods have their 
demerits which greatly impair their functionality specialy in developing 
countries like Sudan .It is either a problem of non- availability of equipment 
needed for the assay procedure (IP2009;Indian pharmacopeia 2009),or non 
sensitivity of the method (Chinese pharmacopeia 1996;USP,2009). IP (2009) 
published a draft of the dissolution test for solid oral dosage form using 
buffer pH 6.8 as dissolution medium, paddles, and 75rpm for 45 minutes. 
After that the  samples are filtered through in-line filter and analyzed  by 
high-performance liquid chromatography, using a stainless steel column C18 
(25cm × 4.6 mm) (5µm) at 30°C, a mixture of equal volumes of acetonitrile 
and buffer pH 3.0 as mobile phase, flow rate 1.5 ml per minute, and UV-
detection  at λmax210 nm. Indian pharmacopeia (2009) published a method 
for the dissolution test using apparatus No. 1, phosphate buffer pH 5.0 as 
dissolution medium, and the system rotation at 50 rpm for 30 minutes.  The 
chromatographic system consists of stainless steel column C18 (15cm x 
4.6mm) (3.5 µm)   at 15°C, a mixture of 30 volumes of a solution of pH 5.5 
(containing 3.85 g of ammonium acetate and 1 ml of triethylamine in 1000 
ml of water) and 70 volumes of methanol as a mobile phase. The flow rate is 
0.6 ml per minute, and the samples are analyzed by UV-detector at 216 nm. 
Chinese pharmacopeia (1996) and USP (2009) published the same method 
of the dissolution test, using apparatus 1, distilled water as a dissolution 
medium, and rotation speed at 100 rpm for 30min.The samples are analyzed 
using UV-Spectrophotometer at λmax289nm. 
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1.6. Quality assurance of pharmaceutical products 
Quality assurance of pharmaceutical products is assurance of the 
quality, safety and efficacy of pharmaceutical product. It is a continuing 
concern of WHO. Despite efforts made around the world to ensure supply of 
high-quality and effective drugs, substandard, spurious and counterfeit 
products still compromise health care delivery in many countries (WHO, 
2003). To respond to the global need for adequate quality assurance of 
pharmaceuticals, WHO has over the years made numerous recommendations 
to establish standards and guidelines to promote the effective functioning of 
national regulation and control systems and the implementation of 
internationally agreed standards by trained personnel (WHO, 2004). This is 
an initiative through which WHO, in collaboration with other UN agencies, 
will pre-qualify manufacturers of artemisinine  compounds and ACTs on the 
basis of compliance with internationally recommended standards of 
manufacturing and quality (WHO,2003).Dr Ying1998 (Shanghai Institute of 
Materia Medica of the Chinese Academy of Sciences) asserts “If local drug 
regulators in developing countries are not equipped with easily portable, 
operable and low-cost analysis equipment, it is still very difficult for them to 
effectively and efficiently prevent fake drugs against malaria.  
1.6.1. Quality of pharmaceutical products 
The suitability of drugs for their intended use is determined by their 
efficiency weighed against safety, according to label claim, or as promoted 
or publicized and their conformity to specifications regarding identity, purity 
and other characteristics (WHO, 2009). It is a concept that covers all 
measures taken, including the setting of specifications, sampling, testing and 
analytical clearance, to ensure that the raw materials, intermediates, 
27 
 
packaging materials and finished pharmaceutical products conform with 
established specifications for identity, strength, purity and other 
characteristics. Poor manufacturing practices, poor storage of a product as 
well as the use of incorrect excipients will lead to poor dissolution profiles 
and thus result in compromised bioavailability. Dissolution testing for 
pharmaceutical products in tablet and capsule form is required by the US 
Food and Drug Administration (FDA) and increasingly used outside the 
USA to report on the quality of drug (Obinna et al, 2009).  
1.7 Method development and validation processes 
The steps of methods development and method validation depend 
upon the type of method being developed. However, the following steps are 
common to most types of projects: 
• Method development plan definition. 
• Background information gathering. 
• Laboratory method development. 
• Generation of test procedure. 
• Methods validation protocol definition. 
• Laboratory methods validation. 
• Validated test method generation. 
• Validation report. 
A well-developed method should be easy to validate. A method 
should be developed with the goal to rapid test preclinical samples, 
formulation prototypes, and commercial samples. As the methods 
development and validation processes advance, the information gathered is 
captured in the design and subsequent improvement of the method. The 
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validation protocol should be written only following a thorough 
understanding of the method’s capabilities and intended use. The validation 
protocol will list the acceptance criteria that the method can meet. Any 
failure to meet the criteria will require that a formal investigation be 
conducted. The required validation parameters depend upon the type of 
analytical method. Pharmaceutical analytical methods are categorized into 
five general types (ICH, 2000): 
• Identification tests. 
• Potency assays. 
• Impurity tests: quantitative. 
• Impurity tests: limit tests. 
• Specific tests. 
Validation requirements depend upon the type of test method, 
including: 
• Specificity: ability to measure desired analyte in a complex mixture. 
• Accuracy: agreement between measured and real value. 
• Linearity: proportionality of measured value to concentration. 
• Precision: agreement between a series of measurements. 
• Range: concentration interval where method is precise, accurate, and           
linear. 
• Detection limit: lowest amount of analyte that can be detected 
• Quantitation limit: lowest amount of analyte that can be measured 
• Robustness: reproducibility under normal and variable laboratory           
conditions.   
Only specificity is needed for an identification test. However, the full 
range of specificity, accuracy, linearity, range, limit of detection (LOD),limit 
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of quantitation (LOQ),precision, and robustness testing is needed for more-
complex methods such as quantitative impurity methods(USP,2007; 
FDA,2000). 
1.7.1. Developing a new dissolution method 
Dissolution data based on a discriminating and well thought 
dissolution test is of tremendous value in the selection of the proper 
formulation .The dissolution test can also serve as routine control 
mechanism to assure the uniformity of regular production batches 
(Remington, 2005). Development of the new method needs the proper 
choice of the apparatus. There are three types of the apparatus described in 
the compendia, the basket, the paddle and the flow-through cell. Apparatus 
differ with regard to the shape and geometry of dissolution vessel, the type 
and intensity of agitation, the position of the dosage form, the dispersion of 
particles, the volume of the dissolution medium, the ability to change the 
solvent at a certain rate to maintain sink conditions, and the reproducibility 
of the system (Remington, 2005).The paddle is now the apparatus of choice 
for many preparations. The flow –through cell may be more appropriate for 
preparations of poorly soluble active ingredient (BP,2005).The  medium  of 
900  ml of distilled water with an agitation speed of 100rpm for the rotating 
basket and 50 rpm for the paddle method are generally used ,the system set  
at 37ºC. A check to determine if dearation of water is necessary has to be 
conducted. If such parameters prove to be in adequate, slightly lower and 
higher stirring rate may be tried. If not successful, the composition of the 
dissolution medium could be changed. Dilute hydrochloric acid or buffer 
systems of different pH could be used. The tests can be conducted for 
various durations from 15 minutes to 24 hours with appropriate sampling. 
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The results of the dissolution analysis are reported as cumulated percent 
drug dissolved at specified time intervals (Remington, 2005). 
1.8. Drug dissolution testing 
Drug dissolution testing is a quantitative analytical technique for 
assessing drug release from pharmaceutical products, in particular solid oral 
dosage forms such as tablets and capsules (Remigton, 2005). The drug 
dissolution is critical for drug absorption into the systemic circulation 
(bloodstream) or human body in general. The availability of drug in the body 
is known as bioavailability and is defined as, the rate and extent of 
absorption of a drug into the systemic circulation. The rate and extent of 
drug absorption are generally represented by maximum observed 
concentration (Cmax) of a drug in blood and area under the drug 
concentration versus time curve (AUC), respectively (Remigton, 2005).The 
drug dissolution results are compared these in vivo parameters. Describing 
and comparing these in vitro and in vivo relationships of drug release are 
referred to as in vitro-in vivo correlations (IVIVC) and are conceptually 
valid and widely accepted (Remigton ,2005). 
Dissolution is the process by which a solid solute of only fair 
solubility characteristics enters into solution (Remington 2005).The rate of 
dissolution of solid substances is determined by a very thin layer saturated 
solution that forms instantaneously around the solid particles. The 
mathematical relationship that correlates the dissolution rate to the solubility 
gradient of the solid (Remington 2005) is as follows: 
 
Where, dc/dt = dissolution rate of the drug 
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                  K = the proportionality constant  
                 = the saturation concentration (maximum solubility) 
                = concentration at time t  
         – = concentration gradient  
The proportionality constant K is also called the dissolution constant 
and the equation has been shown to obey first order kinetics. Eq 1 was 
modified to incorporate the surface area, S, as a separate variable 
(Remington 2005).  
 
The called film model theory (Remigton, 2005) proposed that under 
the influence of no reactive or chemical forces, a solid particle immersed in a 
liquid, undergoes two consecutive steps; first is the solution of the solid at 
the interface, forming a thin stagnant layer or film, h, around the particle; 
and second, is the diffusion from this layer at the boundary to the bulk of the 
fluid. The first step (solution) is almost instantaneous, the second (diffusion) 
is much slower and therefore, is the rate limiting step, Eq 2 was expanded to 
include the diffusion coefficient, D, the thickness of the stagnant diffusion 
layer, h, and the volume of the dissolution medium, v, producing 
Eq3(Remington,2005).    
 
1.8.1. Sink condition                                                                                                  
    The term sink condition originated from a fact that the drug 
concentration on both sides of the epithelial layer of the intestinal wall 
approaches equilibrium in a short time, and that the gastrointestinal tract acts 
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as a natural sink; i.e., the drug is instantaneously absorbed the moment it 
dissolves (Remington 2005). Therefore, under in vivo conditions, there is no 
concentration buildup and hence the retarding effect of the concentration 
gradient on the dissolution rate, as predicted by Eq 1, does not occur. In 
order to simulate the in vivo sink condition, in vitro dissolution testing is 
usually conducted using either a large volume of dissolution medium or a 
mechanism by which the dissolution medium is constantly replenished with 
fresh solvent at specified rate so that the concentration of the solute never 
reaches more than 10–15% of its maximum solubility. If such a parameter is 
maintained, the dissolution testing is said to be conducted under sink 
condition, as seen from the following mathematical treatment. Assuming Cs 
>> Ct, Eq 3 becomes,   
 
     As Cs and D are constants for   each specific chemical substance therefore 
they could be incorporated in K2 and Eq 4 becomes,  
 
           If the volume of the dissolution medium, the surface area and the 
thickness of the stagnant diffusion layer (h) are kept constant during the 
duration of the dissolution test, then  
  
Eq. 6 predicts a constant dissolution rate under sink condition and 
represents a zero order kinetic process, i.e. the concentration of the drug 
increases linearly with time. Eq 6 is also believed to approximate the in vivo 
condition where the dissolution rate of sparingly soluble drugs plays a 
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fundamental role in determining their bioavailability. In Eq 2, the surface 
area was considered constant for the duration of the dissolution test. 
Although this could be achieved, by using a non disintegrating disk of the 
chemical substance, a technique usually employed for the determination of 
the intrinsic dissolution rate, the same could not be maintained for a 
dissolving crystal or regular solid dosage form where complete 
disintegration is a priority. To develop a dissolution equation that is based on 
a changing surface area ,Eq 2 was modified to represent the rate of 
appearance of the solute in the solution by multiplying each side of the 
equation by v (volume), letting     
       
 
Where W is the weight of solute in solution. 
Also by assuming that S =  , where k is a constant containing 
the shape factor and the density of the particle, and w is the weight of un 
dissolved particles at time t,  
 
After multiple mathematical treatments involving the application of 
Fick’s first law and integration under the condition that W is equal to W , 
the weight of the particle at time zero ; Eq (9) result , 
  
Eq (9) is called the Hixson and Crowell’s Cubic Root Law for 
dissolution (Remington 2005).  
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 1.8.2. Factors affecting the rate of dissolution  
          There are three factors that affect the rate of dissolution (Remington 
2005).  
1.8.2 .1. Factors relating to the physicochemical properties of the drug   
The physicochemical properties of the drug substance play a prime 
role in controlling it's dissolution from the dosage form 
(Remington,2005).The aqueous solubility of the drug is the major factor 
which determines it’s dissolution rate. Other factors that affect the 
dissolution rate include particle size, crystalline state, such as polymorphism 
and state of hydration, solvation, complexation, as well as surfactant and 
other reactive additive. Other physicochemical propertiess such as density, 
viscosity, and wettability contribute to the general dissolution problems of 
flocculation, flotation and agglomeration. Adsorption characteristics of the 
drug have also been found to have a significant effect on the dissolution of 
certain drugs. (Remington 2005). 
1.8. 2.2. Factors relating to the solid dosage form  
These include: 
1.8.2.2.1. Effect of formulation factors                   
The dissolution rate of a pure drug can be altered significantly when 
mixed with various adjuncts during the manufacturing process of solid 
dosage forms. These adjuncts are added to satisfy certain pharmaceutical 
functions such as diluents (fillers), dyes, binders, granulation agents, 
disintegrants, and lubricants (Remignton, 2005). Identical tablet and capsule 
products manufactured by different pharmaceutical factories were found to 
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exhibit significant difference in dissolution rates for their active ingredients 
(Remington, 2005). 
1.8.2.2.2. Effect of the processing factors  
The many processing factors used in tablet manufacturing greatly 
influence the dissolution rates of the active ingredients. The method of 
granulation, the size, density, moisture content and age of the granules, as 
well as the compression force utilized in the tabletting process, all contribute 
to the dissolution rate characteristics of the final product (Remington, 2005). 
1.8.2.2.3. Effect of compression force on dissolution rate  
There is great influence of the compression force employed in the 
tabletting process on the apparent density, porosity, hardness disintegration 
time, and average primary particle size of compressed tablets (Remington, 
2005). There is always a competing relationship between the enhancing 
effect due the increase in surface area through the crushing effect and the 
inhibiting effect due to the increase in particle bonding that causes an 
increase in density and hardness and, consequently, a decrease in solvent 
penetrability. The high compression also may inhibit the wettability of the 
tablet due to the formation of a firmer and more effective sealing layer by 
the lubricant under the high pressure and temperature that usually 
accompanies a strong compressive force (Remington, 2005). 
1.8.2.3. Factors relating to test parameters   
These include, intensity of agitation, temperature, selection of the 
dissolution medium, surface tension and viscosity of the dissolution medium 
(Remington, 2005). 
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1.9. Quality testing technique 
   Recent progress in methods development is largely a result of 
improvements in analytical instrumentation. This is especially true for 
chromatographs and detectors. Isocratic and gradient reverse-phase HPLC 
have evolved as the primary techniques for the analysis of nonvolatile active 
pharmaceutical ingredients (APIs) and impurities. The HPLC detector of 
choice for many types of methods developments the photodiode array (PDA) 
detector because it can be used for both quantitative and qualitative analysis. 
The use of a PDA detector to determine peak purity of the active ingredient 
in stressed samples greatly facilitates the development of stability-indicating 
assays. The emphasis on identification of trace impurities and degradants has 
led to the increased use of techniques such as liquid chroma -tography–mass 
spectrometry (LC–MS) and liquid chromatography–nuclear magnetic 
resonance spectroscopy (LC–NMR). This trend will continue with the need 
to better define degradation pathways. The ultraviolet (UV) absorbance 
detector remains the most common HPLC detector for potency and impurity 
determination. Once specificity has been demonstrated, the PDA detector is 
replaced with a variable wavelength detector and the HPLC effluent is 
monitored at fixed wavelengths. Stability-indicating methods often are 
required to measure analytes within a wide concentration range. For 
example, process impurities and/or degradation products may be present at 
levels of 0.1%, and the main active ingredient typically is present at the 
nominal concentration (100%).This amount is well within the linear range of 
a fixed wavelength detector but not within that for LC–MS detectors. Recent 
FDA and ICH guidance about chiral drug products and impurities has posed 
new challenges for methods development scientists (ICH, 2000). Recent 
advances in the use of chiral HPLC columns have greatly facilitated progress 
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in this area. The advances are primarily a result of the introduction of chiral 
stationary phases (CSPs) prepared by reacting amylose or cellulose 
derivatives with silica. The new CSPs allow trace levels of enantiomeric 
impurities to be measured. Gas chromatography remains the method of 
choice for the analysis of volatile compounds. Gas chromatography with 
mass spectrometry detection (GC–MS) is increasingly being used to identify 
impurities and determine active ingredient peak purity in stressed samples. 
Advances in the use of non destructive infrared (IR) and near-infrared 
spectroscopy (near IR) and NMR techniques are particularly promising for 
methods development scientists. (Jay et al, 2003). 
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2.1. Aim 
The main purpose of this study is:- 
To assess the quality of artesunate tablets in Sudan, it is a part of a 
comprehensive study to test the quality of antimalarial drugs in Sudanese 
market (post- marketing surveillance).  
2.2. Objectives 
1. To conduct a post-marketing surveillance of different artesunate 
formulations used in Sudan.  
2. To assess the effect of the transport and storage conditions, at different 
parts of Sudan, on the stability of artesunate   tablets. 
3. To adopt an HPLC dissolution test method suitable for evaluating the 
artesunate drug release and to validate the results obtained in the field 
by U.V spectrophotometric method of Chinese Pharmacopeia 1996. 
2.3. Research questions 
1. Do a storage conditions throughout Sudan affect stability of artesunate 
tablets? 
2. Do transport conditions throughout Sudan affect stability of artesunate 
tablets? 
3. Do all   artesunate   tablets   present in Sudanese market conform to the 
standards of quality? 
4. Does the adopted dissolution method has advantages over the official 
Chinese Pharmacopeia 1996?  
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3.1. Instrumentation 
• A double–beam UV-VIS spectrophotometer, Shimadzu, Japan, model 
700 was used in the quantitative analysis of dissolution test. The 
absorption spectra of test and reference solution were recorded in 1-
cm quartz cells at λmax 289.  
• Dissolution tester, Shimadzu, Japan, model 1700 was used in the 
dissolution test, using 1 liter vessel at100rpm and at37° for 30min. 
• High performance liquid chromatography used was Shimadzu, Japan, 
connected to a UV/VIS detector SPD-10AVP with soft ware .The 
separations were performed at room temperature. the samples were 
introduced through  basket I injector with 20µl sample loop.  
• High performance liquid chromatography used was Varian Proster, 
Australia, connected to a UV/VIS detector 325and, with soft ware 
.The separations were performed at room temperature. The samples 
were introduced through basket injector with 20µl sample loop.  
3.2. Columns used  
• Waters-Nova pak®C18- 3µ -150mm×3.5mm was used for the 
stability studies.                    
• En.ert Sil ODS-3µ-10cm×4.6mm was used for detection of the 
artesunate impurities and development of the new dissolution method. 
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3.3. Reagents and standards 
All reagents used were of analytical grade (sodium hydroxide, 
potassium dihydrogen phosphate, phosphoric acid, acetone, Na lauryl 
sulphate and acetonitrile) from BDH, Pool, England. 
  Distilled water from NDQCL used for dissolution test. 
Cellulose filter 0.45µ PTFE membrane filter (Pall corporation ,Ann             
Arbor.MI,USA) used for filtration of mobile phase and samples filteration. 
 Artesunate working standard, Dafra Pharma ,Belgium. Batch No- 
ARSU-AS-106258; expiry date April/2006, and potency 99.8%. 
Artesunate working standard, Shangahai-Sudan  Pharmaceutical, CO. 
Ltd,  Sudan. Batch No.20060703; manufacture date July/2006, expiry date 
June/2009, and potency 100.85%. 
Dihydroartemisinine working standard, Shangahai Pharmaceutical, CO. 
Ltd, Sudan. Batch No.100202; manufacture date February/2004-, expiry 
date February /2009. 
Artemisinine working standard, Shangahai Pharmaceutical,CO. ,Ltd, 
Sudan.. Batch No.100184; manufacture date February/2004-, expiry date 
February /2009. 
3.4. Samples selected to be analyzed 
 Different batches of the artesunate tablets (AS+SP) from different 
brands circulating in the Sudanese market were collected in the post –
marketing surveillance, include the following:- 
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• Artesumine tablets (100mg and 50mg artesunate): Guilin 
Pharmaceutical co., Ltd, China.  
• Artecosp tablet (100mg and 50mg artesunate): Guilin Pharmaceutical 
co., Ltd, China. 
• Ariplus tablets (100mg and 50mg artesunate): Dafra Pharma 
,Belgium. 
• Artemal tablets (100mg and 50mg artesunate): Lachif  Pharm, Italy. 
• Combisunate tablets (100mg artesunate): Ajanta Pharma limited, 
India. 
• ASP tablets (100mg and 50mg artesunate): working standard, 
Shangahai Pharmaceutical, CO.,Ltd, Sudan..  
Batches of artesunate tablet analyzed for stability study included:- 
• Artesumine adult tablets, labeled to contain 100mg artesunate per 
tablet:- 
Batch No .040801(manufactured date 8.2004 and expiry date 8.2007). 
Batch No .041201(manufactured date 12.2004 and expiry date 12.2007). 
Batch No .LS060301 (manufactured date 2.2006 and expiry date 2.2009). 
Batch No .LS060401 (manufactured date 4.2006 and expiry date 4.2009). 
Batch No .LS060602 (manufactured date 6.2006 and expiry date 6.2009). 
• Artesumine children tablets labeled to contain 50mg artesunate per 
tablet:- 
Batch No.040801 (manufactured date 8.2004 and expiry date 8.2007). 
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Batch.No.040901 (manufactured date 9.2004 and expiry date 9.2007). 
Batch No. LS061201 (manufactured date 8.2006 and expiry date 8.2009). 
Batch No. LS060401 (manufactured date 4.2006 and expiry date 4.2009). 
Batch No. LS060601 (manufactured date 6.2006 and expiry date 6.2009). 
• Artecosp adult tablets labeled to contain 100mg artesunate per tablet:- 
Batch No.051106 (manufactured date 11.2005 and expiry date 11.2007). 
Batch No.05021 (manufactured date 10.2005 and expiry date 10.2007). 
• Artecosp children tablets labeled to contain 50mg artesunate per. 
tablet:- 
Batch No.051018 (manufactured date 10.2005 and expiry date 10.2007). 
Batch No.051020 (manufactured date 11.2005 and expiry date 11.2007). 
• Ariplus adult tablets labeled to contain 100mg artesunate per tablet:- 
Batch No.04Jo6 (manufactured date 8.2004 and expiry date 8.2006). 
Batch No.04J11 (manufactured date 11.2004 and expiry date 11.2006). 
• Ariplus children tablets labeled to contain 50mg artesunate per tablet:- 
Batch No.04J22 (manufactured date 9.2004 and expiry date 9.2006). 
Batch No.04ko4 (manufactured date 9.2004 and expiry date 9.2006). 
• Artemal adult tablets labeled to contain 100mg artesunate per tablet:- 
Batch No.F0278 (manufactured date 4.2005 and expiry date 4.2008). 
Batch No.F0622 (manufactured date 7.2005 and expiry date 7.2008). 
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• Artemal children tablets labeled to contain 50mg artesunate per 
tablet:- 
Batch No.E1025 (manufactured date 10.2005 and expiry date 10.2008). 
Batch No.E1041 (manufactured date 12.2005 and expiry date 12.2008). 
Batch No.08051 (manufactured date 6.2008 and expiry date 6.2011). 
• ASP adult labeled to contain 100mg artesunate per tablet:- 
Batch No.060624 (manufactured date 6.2006 and expiry date 6.2008). 
Batch No.060523 (manufactured date 6.2006 and expiry date 6.2008). 
• ASP children tablets labeled to contain 50mg artesunate per tablet:- 
Batch No.060806 (manufactured date 6.2006 and expiry date 8.2008). 
Batch No.060610 (manufactured date 6.2006 and expiry date 8.2008). 
Batch No.091002 (manufactured date 1.2009 and expiry date 10.2012). 
3.5. Study design and sampling                                                                           
      Three procedures were used for the evaluation of Stability of artesunate 
tablets: 
• For post-marketing surveillance, several batches of artesunate tablets 
were collected from Northern, Eastern, Western and Central of Sudan 
are presenting all Sudanese market. Samples were collected randomly. 
Facilities which were monitored included community and hospital 
pharmacies, drug stores, public pharmacy and pharmacies run by 
mission and other non-governmental organizations (NGOs).The 
Collection of the samples was from four regions in Sudan (Khartoum, 
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Elobied , Elgadarif and Atbara) .The region from which the samples 
were collected were recommended by The National Malaria Control 
Program (NMP) in Sudan. Official inspectors (pharmacists from 
NMP) were coordinating the collection from several states and were 
responsible for sample coding and transport to the NDQCL Khartoum 
for analysis. Informations that were obtained with each sample 
included the name of the drug (trade and generic), strength, dosage 
form, batch number, date of manufacture, date of expiry, description 
of packaging material, any remarks on storage, location of samples, 
collection point, and date of sample collection. The study was carried  
out for three years every 6 moths defined as( round 1,2,3,4,5,6). Due 
to some problems in collection of the samples round four in Elgadarif 
was not included. 
• Three batches of Artesumine tablets for adults (100mg artesumine)and 
three batches of Artesumine tablets for children (50mg artesumine) 
were collected by NMP inspector  from the  company store  before 
dispensing, The collected samples were  stored on shelves at room 
temperature  in different regions of Sudan (Elobied ,Port Sudan, 
Atbara, and Khartoum) to represent West ,East, North,  Center of 
Sudan. These also represent different climatic conditions in Sudan. 
According to the literature review, that artesunate tablets were found 
to be affected by moisture and temperature (WHO, 2003; Chinese 
Pharmacopeia,  2005 and IP, 2005), Elobied, Port Sudan, and 
Khartoum were chosen, because they are   humid and hot zones. 
Atbara is less humid than these areas but very hot. The importation of 
most drugs in Sudan is through sea port area. Un-loading process and 
waiting usually take considerable time, and as Port Sudan is the main 
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Sudanese port area, it was a target for the study. The South of Sudan, 
though very humid through the year (tropic conditions) was 
unfortunately not included. The samples collected were tested at zero 
time, after 3, and then after 6, 9,12, 18, 24, and 36 months (WHO, 
2007) for the content of the active ingredient, dissolution test, 
degradation product and physical appearance.  
• Five brands of artesunate tablets from Central Medical Supply (CMS) 
stores and private companies were collected by NMP inspector. 
These artesunate tablets represent all brands registered in Sudan at the 
time of the study .Four batches (two batches of artesunate tablets for 
adult and two batches of artesunate tablets for children) were 
analyzed. These samples represent the imported brands (Artesumin 
tablets, Artemal tablets, Ariplus and Artecosp tablets) and local 
brands (ASP). The collected samples were stored directly after being 
cleared from the companies and CMS stores. They were stored in the 
National Drug Quality Control Laboratory NDQCL on shelves at 
room temperature and tested at zero time, and then after 3, 6, 9, 12, 
18, 24 and 36 months to detect the quality of different brands at the 
same storage conditions. The samples were tested for the content of 
the active ingredient, dissolution, degradation product and physical 
appearance.  
3.6. Method of analysis of artesunate tablets 
Determination of potency, degradation products, detection of change in 
physical appearance and dissolution test were performed according to the IP 
(2005) and Chinese Pharmacopoeia (1996) to assess the quality of the 
products. The Chinese Pharmacopoeia was used for dissolution test as the 
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test has not been developed in the IP at the beginning of this study. The 
Chinese Pharmacopoeia method is a validated method, thus it has been used 
in this study to evaluate the results of different formulations .It is the method 
used by the NDQCL for evaluation of post-marketing surveillance of 
artesunate tablets. 
3.6.1. Analysis of the active ingredient 
3.6.1.1. Sample preparation  
Twenty tablets were accurately weighed and powdered. A mass 
containing about 0.05gm of artesunate was accurately weighed and 
transferred to 25ml volumetric flask. Acetonitrile was added to dissolve and 
to adjust the volume .The solution was filtered through 0.45µfilter, and was 
analyzed using HPLC method (IP, 2005). 
3.6.1.2. Standard preparation 
About 0.05gm of pure powder of artesunate was accurately weighed and 
transferred to 25ml volumetric flask, dissolved in acetonitrile and adjusted to 
volume with the same solvent. 
3.6.1.3. Phosphate buffer pH3 
    This was prepared by weighing 1.36g of potassium dihydrogen 
phosphate, transferred to 1000ml volumetric flask, dissolved in distilled 
water and adjusted to volume with the same solvent. The solution was 
adjusted to pH 3.0 with phosphoric acid. 
3.6.1.4. Determination of artesunate content 
        The samples and the standard were analzed using HPLC method using 
mobile phase consist of mixture of phosphate buffer (pH3.0) and acetonitrile 
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in the ratio (1:1). The mobile phase was filtered. The separation was carried 
out using a C18 column with a flow rate 1.0ml/min., at wavelength 216nm 
(IP, 2005).The injection volume was 20µl.  
The % content of the active ingredient=AUP of the samples/AUP of the 
standard x potency of the standard 
Where   
AUP = Area under the peak.  
3.6.2. Test for related substances 
1ml of sample preparation used in the assay method was transferred to 
100ml volumetric flask, and diluted to 100ml with acetonitrile. This solution 
was injected with the sample prepared for assay preparation using the same 
HPLC parameters (IP, 2005).  
3.6.3. Dissolution test method 
Six tablets of artesunate were introduced into the dissolution vessels 
contain 900ml of distilled water. The system was set at 37C° using paddles 
with the rotational speed 100 rpm. A quantity of the dissolution medium in 
the different vessels were withdrawn after 30 minutes, and filtered with 
membrane filter having porosity of 0.45µ. 20ml of the filtered solution of 
each vessel was accurately measured using a volumetric pipette and 
transferred to six 25ml volumetric flask. 2.5ml of sodium hydroxide solution 
(1 mol/L) was added and the volume completed with distilled water 
(Chinese Pharmacopeia, 1996). 
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3.6.3.1. Preparation of the standard   
0.01gm   of pure powder of artesunate was weighed and transferred to 
250ml volumetric flask. 200 ml of distilled water, and 25 ml of sodium 
hydroxide solution (1 mol/L) were added, then the volume was completed   
with distilled water. The dissolution samples and the standard preparation 
were warmed simultaneously in a water bath at 50 ± 1°C for 45 minutes, and 
cooled rapidly to room temperature. Absorbance of each solution was 
measured using distilled water as blank at λmax 289(Chinese Pharmacopeia, 
1996). 
The % content of the active ingredient =Abs. of the samples/Abs. of the 
standard x potency of the standard 
Where  
Abs. = Absorbance  
3.7. Adoption of the dissolution test method 
The dissolution method was only official in the Chinese pharmaco-
peia(1996) at the beginning of this study till the end of 2009, using 
spectrophotometric method. Other pharmacopeias published drafts in 2009 
some of them used HPLC method (IP draft, 2009) and Indian pharmacopeia 
draft, (2009) and others published the same Chinese pharmacopeia method 
USP draft (2009).The dissolution test method was adopted for the following 
reasons: 
1- The spectrophotometric method is not stability indicating method. 
2- Many steps are used after sample filtrations till the assay time. 
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3- The method needs to be carried out without delay during filtration of       
the samples, and at the detection time after cooling. 
4- The heating step of the sample dissolution needs carful adjustment of 
temperature and time. 
5- The official method of analysis of the main degredants of artesunate 
namely artemisinin and dihydroartemisinin is same as the method 
used to detect artesunate by UV-spectrophotpmeter (IP, 2005). The 
degredants are detected at λmax 292nm ,which is close to the artesunate 
λmax 289nm.These two wave lengths for detection of  arte-sunate and 
the degredants(artemisinin and dihydroartemisinin)are very close, and 
may interfere and give false results, 
6- From the data of the stability carried out for artesunate tablets in this 
work the main problem was found to be in tablets the dissolution. 
Thus it was therefore deemed important to develop sensitive method 
for testing dissolution. 
3.7.1. Dissolution test conditions 
The selection of dissolution medium is based on the solubility data and 
the solution state stability of the drug as a function of the pH 
value(USP,2007).Artesunate is very slightly soluble in water(IP,2005) and 
insoluble in acid(Indian pharmacopeia, 2009). Artesunate is absorbed in the 
stomach (Navaratnam et al 2000). Typical medium for dissolution may 
include, Water, dilute HCL, buffers in the physiologic pH range of 1.2 to 7.5 
(USP2007) .As rtesunate is insoluble in water and acid, thus phosphate 
buffer pH 7.0 was used. But artesunate is slightly soluble in this buffer. A 
percentage of surfactant can be used to enhance drug solubility in case of 
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poorly soluble drugs (USP2007).Different concentrations of sodium lauryl 
sulphate(0.1,0.2,0.3%) were therefore added to phosphate buffer pH7.0 
medium to improve aertesunate solubility. The results obtained were 
compared with the official Chinese pharmacopeia (1996), the close results 
were obtained with phosphate buffer in 0.2% sodium lauryl sulphate and at 
dissolution time 45min.  
Validation of the method was carried out according to the validation 
protocol of the USP2007 and WHO 2007. Validation parameter such as 
selectivity, linearity, accuracy and precision (reproducibility), as well as 
chromatographic parameters like peak asymmetry were assessed. Four 
batches of artesunate tablets (three batches 100mg and one batch 50mg 
artesunate) and three different formulations of artesunate tablets(Artemal 
,ASP, and Artesumine tablets) were used. The results obtained were 
compared with the Chinese Pharmacopeia (1996) method results. 
3.7.2. Dissolution test of artesunate tablets by the adopted method  
Six tablets of artesunate were introduced into the dissolution vessels 
containing 900ml of dissolution medium. The system was set at 37C° using 
paddles, with speed of 100 rpm. A quantity of the dissolution medium in the 
different vessels was withdrawn after 45 minutes, and filtered with 
membrane filter having porosity of 0.45µ .The samples were analyzed for 
artesunate content by HPLC method. The amount of the artesunate dissolved 
after 45 minutes is expressed as a percentage of the label claim. 
3.7.2.1. Dissolution medium 
This was prepared by weighing 6.805g of monobasic potassium 
phosphate, 1.164g of NaOH and 2gm of Na lauryl sulphate , then transferred  
them to  1000ml volumetric flask and  800ml distilled water was added to 
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dissolve. The mixture was sonicated for 30min.to complete the dissolution, 
then distilled water was added to complete the volume. The solution was 
adjusted to pH 7.0 with phosphoric acid. 
3.7.2.2. Standard preparation 
In case of   artesunate tablets for children, 0.055 gm of artesunate 
working standard was accurately weighed and dissolved in 250 ml of the 
dissolution medium and sonicated for 15 minutes then 25ml of this solution 
was diluted with 100ml of the dissolution medium. 
In case of artesunate tablets for adults, 0.1 gm of artesunate working 
standard was accurately weighed and dissolved in 250 ml of the dissolution 
medium and sonicated for 15 minutes then 25ml of this solution was diluted 
with 100ml of the dissolution medium. 
3.7.2.3. Determination of the samples 
The analysis of samples and the standard were carried out using 
mixture of 44volumes acetonitrile and 56 volumes phosphate buffer pH 3.0 
as a mobile phase. The mobile phase was filtered and degassed before use 
.The separation was carried out using, C18 column with a flow rate 
1.3ml/min., at wavelength 216nm (IP, 2005). The column temperature was 
maintained at ambient temperature. The injected volume was 20µl. Six 
samples were analyzed. The percentage content of the artesunate for each 
sample was calculated. 
          The % content of the active ingredient =AUP of the sample/AUP of 
the standard x potency the standard 
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3.7.3. Method validation:‐ 
3.7.3.1. Chromatographic parameter: 
   3.7.3.1.1 Peak asymmetry 
The peak tailing was assessed by the following equation: 
Asymmetry factor (AF) =b/a 
Where: 
a = the leading half of the peak measured at 10% of the peak height.  
b =the trailing half of the peak measured at 10% of the peak height. 
Asymmetry range is 0.95-1.15 (David, 1999). 
3.7.3.2. Validation parameters 
3.7.3.2. 1. Specificity 
To detect the interference of the degredants with the active ingredient, 
two solutions were prepared. One contained the expected degredants 
artemisinin and dihydroartemisinin pure powder in the dissolution medium. 
The other solution contained artesunate pure powder and the expected 
degredant artemisinin and dihydroartemisinin. The two solutions were 
analyzed using the adopted HPLC method. 
To detect the interference of excipients with the active ingredient, 
three different formulations were analyzed using the adopted HPLC method 
and compared with those obtained by the UV- spectrophotometric method 
(Chinese pharmacopeia method, 1996). 
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3.7.3.2. 2. Linearity: 
Series of artesunate (pure powder) solutions were prepared in the 
dissolution medium to give concentration of (40, 50, 60, 70, 80, 
90,100,110,120 µg /ml).The solutions were subjected to dissolution test 
conditions and analyzed by the adopted HPLC method. 
3.7.3.2. 3.Accuracy 
Tablets (n=6) of each batch were subjected to dissolution test 
conditions and analyzed by the adopted HPLC method. The results were 
compared with UV-spectrophotometric method (Chinese Pharmacopeia 
method 1996) and calculated as the difference between the mean and the 
acceptance true value at 95% confidence level. 
Calculation of standard error of the mean:- 
                  (Miller and Miller,2005).   Where: 
S.e.m= standard error of the mean 
Calculation of the t-value:- 
 
Where 
n = number of samples 
xI =values obtained for each measurement 
x ̄ =mean of the measurements 
Where (i) goes from 1 to n 
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Where 
x1̄ = mean of first sample of n1 observations 
x2̄= mean of second sample of n2 observations 
3.7.3.2. 4.Precision (Reproducibility):‐  
The dissolution test was carried out in two laboratories (NDQCL and 
the National Chemical Laboratory (NCL) Khartoum). The results were 
compared with UV-spectrophotometric method (Chinese Pharmacopeia 
method 1996) and calculated as the difference between the variance and the 
acceptance true value at 95%confidence level.  
 
   Where 
SD = standard deviation 
n = number of samples 
xI =values obtained for each measurement 
x =mean of the measurements 
 
Where 
%RSD = relative standard deviation 
Calculation of the F-value:- 
               (Miller and Miller,2005). 
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4.1. Results of post-marketing surveillance of different brands 
of artesunate tablets (AS+SP. 
Several batches of artesunate tablets (AS+SP) from different generic 
brands circulating in Sudanese markets were collected from Northern, 
Easter, Western and Central of Sudan. Facilities which were monitored 
included community and hospital pharmacies, drug stores, public pharmacy 
and pharmacies run by mission and other non-governmental organizations 
(NGOs).The Collection of the samples was from four regions in Sudan 
(Khartoum, Elobied , Elgadarif and Atbara) . The study was carried  out for 
three years every 6 moths defined as( round 1,2,3,4,5,6). Two rounds had 
been done per year. Due to some problems in collection of the samples 
round four in Egadarif was not included. The collected samples were 
analyzed for their active content, degradation products, dissolution test, 
disintegration test and physical appearance according to IP2005 and Chinese 
pharmacopeia 2005. The results obtained are shown in tables (1-8, which is a 
part of tables31-53). 
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   Figure No. (3): Combined percentage failure of the artesunate tablets 
                               tests in three years post- marketing surveillance 
Figure (3) shows the combined results for these regions during the 
three years of the post-marketing surveillance, the results are expressed as a 
percentage of the samples failing the pharmacopoeia standards out of the 
total number analyzed. Failed samples were found in all regions in the first 
and the second year of the surveillance. The failure in the first year was 12% 
and in the second year was 4% and with no failure detected in the third year. 
The failures of the samples were in the dissolution rate, sample content and 
physical appearance. However there was no failure in the test of related 
substance for all samples analyzed. The data presented in present work 
indicate that there was a significant problem of substandard artesunate 
products circulating in the Sudanese markets, detected in the first and the 
second year of the study .This problem was not detected in the third year. 
This may be due to the action taken by the regulatory authority which 
removed and canceled the registration of the failed products from the market 
(DGP, 2007; PPRO, 2008). This action was taken as a result of a report from 
the present study. The results obtained from the post-marketing surveillance 
for artesunate tablets  added specific data of substandard antimalarial drug  
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circulating in Sudanese markets to other published data of  the substandard  
anti malarial drugs that carried out  in Sudan by Afadl, et al,2006.Also the 
result obtained added general data of the substandard  anti malarial drug  
circulating in African countries markets  to other published data of  the 
substandard  anti malarial drugs that carried out  in different African 
countries by Charles And Clive ,2003. 
 
        Figure No. (4): Types of failure of the artesunate tablets in three 
years post-marketing surveillance 
Figure (4) shows the types of failure occurred to the artesunate tablets 
during the post marketing surveillance, expressed as percentage failure. 
Almost 98% failures were due to dissolution rate, followed by 7% failure 
due to dissolution and assay (content of the active substance), and 2%   
failure in the physical appearance. The data presented indicated that there is 
a significant problem of substandard artesunate. The most significant results 
were the failure in the dissolution rate. The presence of substandard 
artesunate products indicates a very serious problem which warrants further 
investigation and intervention. Nevertheless, this high rate of failure due to 
dissolution test indicates a very serious problem of the bioavailability of this 
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drug. As failure in dissolution rate of tested samples stand for more than 
90% of failures, this indicates that, transport and storage conditions 
throughout Sudan may affect the quality of tested products .however as 
problem of substandard product found in Khartoum was at a level almost 
similar to other states (Figure 5). It’s very difficult to suggest that transport 
conditions have significant contribution to the problem of substandard.  
 
        Figure No. (5): Percentage failures of artesunate tablets in different         
                                regions during the post- marketing surveillance    
              
         FigureNo. (6): Percentage failures of artesunate tablets according  
                               to generic brands 
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Figure (6) shows the results of percentage failure of the artesunate 
tablet according to their generic brands. The highest percentage failure was 
observed in Combisunate tablet, (100%) due to failure in the content, 
dissolution test and physical appearance followed by the Ariplus tablets 
(76%) due to dissolution test. ASP tablet (5%) failure in dissolution test, 
there was no failure in other generic brands (Artesumine, Artemal ,Artecosp 
tablets) . This confirms that the difference in the drug formulation may affect 
dissolution rate.  However the rate of dissolution affected by several factors 
such as, the factors that relating to the solid Dosage Form (formulation 
factors, Processing factors and Compression Force), and that relating to the 
physicochemical properties of the drug (Effect of particle Size, Effect of the 
crystalline state of the Drug) (Remington, 2005). 
 
   Figure No. (7): Percentage failure of artesunste tablets according to 
                              The Supplier      
Figure (7) showed the results according to supplier (public or private), 
was expressed as percentage failure. The results showed a higher failure 
level in the public sector (14%) than the private supply system (2%). Failure 
level in the public was significant. As every government allocates substantial 
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portion of its total health budget to drugs (WHO, 1997), the current findings 
should raise an alarm to the authorities, It is important that the government 
should assure the quality of imported drugs. 
4.2. Results of stability study of Artesumine tablets for adults 
and children stored at room temperature in different states of 
Sudan. 
Three batches of Artesumine tablets for adult (100mg artesunate) and 
Three batches for children (50mg artesunate) were stored on shelves at room 
temperature in different regions of Sudan (Elobied ,Port Sudan, Atbara, and 
Khartoum) to represent West ,East, North,  Center of Sudan. These also 
represent different climatic conditions in Sudan. The samples were tested at 
zero time, after 3, 6, 12, 18, 24 and 36 months (WHO, 2004).The samples 
were tested for the content of the active ingredient, dissolution, degradation 
product and physical appearance according to IP,2005 and Chinese 
pharmacopeia 1996.  
Tables (9-16) show the combined results of results of stability study of 
Artesumine tablets (adults and children) stored at room temperature in 
different states of Sudan.The results showed that the percentage contents, 
dissolution rate and related substances of artesunate tablets were within the 
International Pharmacopeia limits. The results indicated that artesunate 
tablets are reasonably stable.The results also showed the presence of some 
degradation products. The detection of the degradation products varies 
according to the area where the artesunate tablets were stored. They were 
detected after 3 months in Khartoum and Port Sudan, 9 months in Elobeid 
and 24 months in Atbara. It is reported that artesunate tablets are affected by 
humidity (WHO, 2003). This difference in the detection time of the 
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degradation products may be due to the higher humidity and temperature in 
Khartoum and Port Sudan compared to Elobeid (tables 50-53 show the mean 
temperature and relative humidity in the areas of the study). Atbara is the 
least humid area and this may explain the late detection of the degredant. 
The results indicated that the stability of artesunate tablets is affected by 
temperature and humidity, but the effect of humidity is more than the 
temperature (WHO, 2003). The south of Sudan has a tropical climate (high 
humidity). Unfortunately not included in this study.  
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4.2.1. Kinetic studies on Artesumine tablets   
The stability data of artesumine tablets for children Table (9) Batch. No. 
LS061601  and  artesumine  tablets  for  adults Batch. No.  LS060602  in  each 
state were analyzed to predict the effect of temperature on the rate of the 
reaction, order of Reaction, shelf life and half life. 
 
Figure No. (8): Zero order reaction kinetics of Artesumine tablets 
                            for adultsstore in Khartoum: 
 
Figure No. (9): Zero order reaction kinetics of Artesumine tablets 
                           for adults store in Atbara: 
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Figure No. (10): Zero order reaction kinetics of Artesumine tablets 
                               for adults store in Port Sudan:     
                                    
 
Figure No. (11): Zero order reaction kinetics of Artesumine tablets 
                              for adults store in Elobied: 
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Figure No. (12): Zero order reaction kinetics of Artesumine tablets 
                             for children store in Khartoum: 
 
 
Figure No. (13): Zero order reaction kinetics of Artesumine tablets 
                               for children store in Atbara: 
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Figure No. (14): Zero order reaction kinetics of Artesumine tablets 
                               for childrenstore in Port Sudan: 
 
 
Figure No. (15): Zero order reaction kinetics of Artesumine tablets 
                               for children store in Elobied: 
       Figures (8‐15) show that the results of reaction kinetics do not fit  into 
any  simple  model  of  reaction  kinetics  .Many  pharmaceutical  processes, 
including certain degradation reactions ,do not fit into any simple model of 
reaction kinetics(Codex,1994). The best result for reaction kinetics of  
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Artesumine tablets for adults was obtained in Figure (11) and for children 
was obtained in Figure (14). The stability revealed zero order reaction 
kinetics.  
        In Figure (11) the calculated rate of reaction, t10 and t50 were: 
K= -slop 
t10 = 0.1a/K 
t50 = 0.5a/K 
K =-0.107 
t10 =0.1x101.4/ 0.107= 94.7 months 
t50 =0.5 x101.4/0.107 = 473.8months 
In Figure (14) the calculated rate of reaction, t10 and t50 were: 
K =-0.155 
t10 =0.1x102.0/ 0.155= 65.8 months 
t50 =0.5 x102.0/0.155 = 329.0months 
Although it is often convenient to express shelf-life solely in terms of the 
chemical stability of the active constituent, it is essential that the other 
desirable properties of the product are retained during storage. Physical may 
on storage lead to a decrease in dissolution rate and bioavailability and thus 
decrease in efficacy (Codex, 1994).The results obtained showed that the 
stability of artesunate was affected by the decrease in dissolution test .It is 
difficult to predict it’s shelf life exactly by doing a real time test at ambient 
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temperature. Furthermore the variation in the temperature during the years 
throughout the study makes the prediction of the shelf life difficult because 
the study of the reaction kinetics needs constant temperature (Codex, 1994).  
The real time tests at ambient conditions are the only true indication of shelf 
life (Codex, 1994). 
4.3. Results of comparison of different brands of artesunate 
tablets (AS+SP) stored at room temperature in NDQCL 
Five brands of (AS+SP) tablets for adult(100mg artesunate)and for 
children(50mg artesunate) from Central Medical Supply (CMS) stores and 
private companies were stored in the National Drug Quality Control 
Laboratory NDQCL on shelves at room temperature and tested at zero time, 
after 3, 6, 12, 18, 24 and 36 months(WHO,2007). The study was developed 
to detect the quality of these brands at the same storage condition. The 
samples were tested for the content of the active ingredient, dissolution, 
degradation product and physical appearance 0f artesunate tablets according 
to IP,2005 and Chinese pharmacopeia,1996.  
Tables (17-26) show the combined results of different generic brands of 
artesunate tablets stored in NDQCL at room temperature. The results 
showed failure in the dissolution test for all Ariplus tablets. ASP tablets, 
which are locally made, reached the lower limit of the pharmacopoeia 
standards for dissolution test at the end of the shelf life (24months). When 
the results in tables (17-26) were compared with the results in Tables (1-8) 
for post- marketing surveillance, the comparison indicated that the same 
batches of Ariplus tablets that failed the dissolution test in the NDQCL 
failed the dissolution test in all states. This means that the failure may be due 
to the storage conditions rather than the transportation. The results in tables 
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(17-26) showed no failure in the percentage content for all generic brands. 
Although there is one degradation product detected in all generic brands 
after three months, the test of related substances remained within the 
Pharmacopeia limit<0.1% (less than the detectable limit of the IP 
pharmacopeia 2005). The Artesumine and Artecosp tablets from Guilin 
Company showed the best results of dissolution rate and percentage content. 
This is clearly due to the high quality of Artecosp and Artesumine tablets 
which are the only products prequalified by WHO (WHO, 2007).  The 
difference in the dissolution rate between different brands may be due to the 
difference in the drug formulation that affects the rate of the dissolution of 
the tablets (Remington 2005). Also the difference of the dissolution rate 
indicates problem of bioavailability of this drug .Hence the bioequivalence 
study is needed in the registration of the artesunate tablets. This study 
indicates that not all   artesunate   tablets   present in Sudanese market 
conform to the standards of quality. 
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4.4. Results of detection of of artesunate degredant by HPLC 
method 
Different batches of Artesumine tablets (artesunate 50mg and 100mg) 
stored in different regions of Sudan, and different generic brands of 
artesunate (AS+SP) stored  in (NDQCL) at room temperature were analyzed 
directly after clearance from the supplier(at zero time. Figure (16) shows the 
HPLC chromatogram of Artesumine tablet for adult at zero time. 
 
 
 
 
 
 
 
 
 
                                                                                         
 
 
 
 
Figure No. (16): HPLC chromatogram of Artesumine tablets at zer 
 time 
An HPLC chromatogram of artesunate at zero times in figure (16) 
shows acetonitrile peak at 0.9min.and peak of the artesunate at retention 
time of 4.1min.   
The results of different batches of Artesumine tablets (50mg and 
100mg artesunate) in the post-marketing surveillance, and that stored at 
room temperature for three months showed degradation product of 
artesunate (Figure 17).  
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Figure No. (17): HPLC chromatogram of Artesumine degradant  
In figure (17) three peaks were detected at different retention times, 
acetonitrile peak at 0.9min., degradant peak at 1.6 min. and the main 
artesunate peak at 4.3 min. To know the type of the degradant of the 
artesunate tablets in this study, a new published method for assay and 
detection of impurities of Artesunate tablets (Ema, 2009 method) was used. 
IP (2009) also published a draft method which is the same as Ema(2009) 
method for assay and detection of impurities of Artesunate tablets. IP(2009) 
draft reported four peaks of artesunate and it’s  impurities, these are, α-
dihydro-artemisinin(α -DHA) at retention time  5.0 min., β-DHA  at 
retention time 8.0 min., artemisinin at retention time 11.5min and the main 
peak of artesunate at retention time 9 min. This new method was employed 
because it gave good resolution of peaks for the expected degradants of the 
artesunate namely dihydroartemisinin(DHA). The old assay method of the 
artesunate tablets (IP,2005) did not give good resolution of peaks for the 
expected degradants DHA as shown in the HPLC chromatogram of DHA 
Figure (18).  
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Figure No. (18): HPLC chromatogram of dihdroartemisinin powder 
                                using IP(2005) method 
The HPLC chromatogram of dihdroartemisinin pure powder in figure 
(18) shows main peak of DHA at retention time 4.3min. which is the same 
as the retention time  of  the main peak of artesunate in Figure(17) when 
used the old method(IP2005).For this reason  the published method IP(2009) 
was used instead of IP(2005) method for detection of  the artesunate 
degradants. 
 
           
Figure No. (19): HPLC chromatogram of Artesumine tablets using 
                           (IP,2009) method 
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   An HPLC chromatogram of Artesumine tablets (100mg artesunate) 
using IP (2009) method, Figure (19), shows  two peaks( degradant peak at 
retention time of 5.4min., and the main peak of artesunate at retention time 
of 10.1 min). 
 
 
 
Figure No. (20): HPLC Chromatogram of dihydroartemisinin pure 
                            powder using (IP, 2009) method 
An HPLC Chromatogram of dihydroartemisinin pure powder using 
IP(2009) method in figure (20) shows three peaks(peak at 5.3min., main 
peak of dihydroartemisinin at 8.5mn and peak at 12.7min). The results 
obtained in Figure (19) showed degradant of artesunate at retention time 
(5.4mn) and Figure (20) showed degradant of dihydroartemisinin (DHA) at 
the same retention time of 5.4min. 
Comparing the retention times of the artesunate degradant ( Figure 19) 
with the retention time of the impurities peaks that reported by the IP(2009) 
the results indicated that the degradant obtained is α-DHA which appears at 
retention time 5.0 min. in the IP(2009).  
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For further confirmation of the type of degradant of the Artesumine 
tablets, three solutions were prepared.  Solution (1) was from Artesumine 
tablets consisting of a quantity equivalent to 0.05g/ml artesunate in 
acetonitril. Solution (2) consists of 0.1g/ml 0f dihydroatemisinin pure 
powder in acetonitrile. Solution (3) consists of a mixture of Artesumine 
tablets (equivalent to 0.05g/ml artessunate) and 0.1g/ml dihydroatemisinin 
pure powder, in acetonitrile. Each solution was subjected to analysis by 
HPLC. The chromatograms of solution (1),(2), and (3) are shown in Figures 
(21), (22) and (23) respectively. 
                                 
                                   
Figure No. (21): HPLC Chromatogram of artesunate degradant  
The HPLC chromatogram of the artesunate degredant in figure (21) 
shows a peak at retention time 3.5 min. 
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                  Figure No. (22): HPLC Chromatogram of dihydroartemisinin      
                                              degradant 
The HPLC chromatogram of dihydroartemisinin degredant in Figure 
(22) shows a peak at retention time 3.8min. 
               
   Figure No. (23): HPLC chromatogram of the combined solutions of  
 artesunate 100mg tablets and DHA powder             
The HPLC chromatogram of the combined solutions of Artesumine 
tablets and dihydroartemisinin pure powder (Figure 23) shows one peak at 
retention time of 3.9min. with increased area under the peak of the  
degredant. The results obtained confirmed that the artesunate degredant is 
one of the dihydroartemisin degredants namely (α-DHA). 
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4.5. Results of the adopted dissolution test method. 
New method of dissolution test was adopted. Validation of the method 
was carried out according to the validation protocol of the USP(2007) and 
WHO guidelines (2007). Validation parameters. Four batches of artesunate 
tablets (three batches 100mg and one batch 50mg artesunate) were used.  
.Samples were analyzed in two laboratories (NDQCL and NCL Khartoum). 
Six tablets of artesunate were introduced into the dissolution vessels 
contains 900ml of dissolution media. The system set at 37C° using apparatus 
2(paddle), the rotational speed of the paddle was 100 rpm. A quantity of the 
dissolution media in the different vessels were withdrawn after 45 minutes, 
and filtered with membrane filter having porosity of 0.45µ and without any 
further dilution, the samples were analyzed for artesunate content by HPLC 
method,using mixture of 44 volume acetonitrile and 56 volume phosphate 
buffer pH3.0.The separation was carried out using C18 columnwith flow rate 
1.3 ml/min,at wave length 216 nm. The Results were compared with the 
dissolution method of the Chinese Pharmacopeia (1996). 
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 Figure No. (24): HPLC chromatogram of Artesumine tablets (for  
                            adults) using the proposed dissolution test method   
 
 
 
 
 Figure No. (25): HPLC chromatogram of Artesumine tablets (for 
                     children) using the proposed dissolution test method     
Figures (24&25) show HPLC chromatograms of the dissolution test of   
the Artesumine tablets for adults and children respectively using proposed 
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method.The chromatograms in Figure (24) showed a peak of artesunate with 
peak asymmetry (b/a) 0.3/0.3 = 1. And Figure (25) showed a peak of 
artesunate with peak asymmetry (b/a)   0.3/0.4 = 0.75. 
4.5.1. Validation of the adopteded dissolution method. 
4.5.1.1. Specificity 
Specificity was examined by analyzing a solution of the expected 
degradants (Figure26), and  a solution of a mixture of  the expected degra-                    
dants (artemisinin and dihydroartemisinin) and artesunate pure powder 
(Figure27).The chromatograms show peaks at retention time at 4.2 min. for 
dihydroartemisinin , at 7.0 min. for artesunate and at 9.3 min.for artemisinin. 
No interference was observed. 
Different dosage forms (Artemal, ASP, and Artesumine tablets) were 
analyzed using the UV- spectrophotometric method (Reference method)and 
HPLC method(Proposed method) to investigate the interference of the 
exciepients with the active ingredient of artesunate .The results are 
compared as presented in tables(27-29).The results obtained by the Proposed 
method showed that there was no exciepients interference in the 
formulations analyzed.  
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Figure 26: Aypical HPLC chromatorram of artesunate degredants( 
artemisinin (B) and dihydroartemisinin (A)). 
 
 
 
Figure 27: Typical HPLC chromatorram of artesunate (B) and it’s 
degredants( artemisinin (C) and dihydroartemisinin (A)). 
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Table No.(27): Results of specificity of the adopted dissolution test 
method(Artemal tablets for children) Batch No. 08051. 
 
sample Reference method %released 
Proposed method  
%released 
 
1 89.04 91.94 
2 87.15 89.09 
3 96.66 92.96 
4 94.08 93.52 
5 94.55 89.28 
6  81.91 95.80 
Mean: 90.7 92.09 
N 6 6 
% RSD: 5.86 2.57 
ST.Error Mean 2.17 0.96 
Calculated t-value=0.605 
Tabulated t-value=2.23(at 95%cofidence level) 
 
Table No. (28): Results of specificity of the adopted dissolution test 
method(ASP tablets for children) Batch No. 091002. 
sample Reference method %released 
Proposed method  
%released 
 
1 
83.04  81.07 
2 86.36  84.3 
3 85.04  79.61 
4 83.72  81.07 
5 81.88  78.13 
6  79.51  82.00 
Mean: 83.25 81.03 
N 6 6 
% RSD: 2.89 2.59 
ST.Error Mean 0.98 0.86 
Calculated t-value=0.094 
Tabulated t-value=2.23( at 95%cofidence level) 
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Table No. (29): Results of specificity of the adopted dissolution test 
method (Artesumine tablets for children) Batch No. LS060601.  
sample Reference method %released 
Proposed method  
%released 
 
1 
90.1  91.85 
2 88.3  90.64 
3 86.87  89.78 
4 90.61  89.22 
5 88.89  91.3 
6  89.11  92.36 
Mean: 88.98 90.85 
N 6 6 
% RSD: 1.49 1.33 
ST.Error Mean 0.54 0.49 
Calculated t-value=2.54 
Tabulated t-value=2.23( at 95%cofidence level) 
 
4.5.1.2. Linearity 
       The linearity of the adopted method for dissolution test of artesunate 
tablets response was evaluated from 40-120µg/ml range. Concentration (40-
120µg/ml) versus area under the peak, Figure (26) showed correlation 
coefficient of 0.999. 
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Table (30): Calibration data of artesunate using the adopted HPLC          
method for dissolution test 
Concentration in µg/ml Peak area of atresunate  pure 
powder 
40  84569 
50  105712 
60  125854 
70  147999 
80  175149 
90  190382 
100  211424 
110  232567 
120  253709 
 
 
  
 Figure (28): Calibration curve of artesunate using the adopted HPLC  
                         method for dissolution test. 
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4.5.1.3. Accuracy 
The accuracy of the adopted HPLC method (method 2) was evaluated, 
tables (31-34). Four batches were subjected to dissolution test conditions 
and analyzed by method 2. The results were compared with those obtained 
by the UV-spectrophotometric method (Chinese Pharmacopeia ,1996) 
(method 1), and calculated as the difference between the mean and the 
acceptance true value at 95% confidence level ,with degree of freedom equal 
10[n-1(12-2=10)] .It was found that the standard error of the mean for all 
batches was less than the standard error of the means obtained by the UV-
spectrophotometric method(Miller and Miller,2005).The results obtained by 
the adopted HPLC method showed no significant difference from  those 
obtained by the official U.V method. The calculated t-values for samples by 
the HPLC method in different laboratories were 0.14, 2.17, 0.12, and 0.84, 
which were less than the tabulated ones 2.23. This indicates that the adopted 
method is accurate (Miller and Miller, 2005). 
Table No. (31): Determination of accuracy of the adopted dissolution 
test method (Artesumine tablets for adults batch.no.LS060301) 
sample Refrence method %released 
Proposed method  
%released 
1 89.79 91.94 
2 87.15 89.09 
3 96.66 92.96 
4 94.08 93.52 
5 94.55 89.28 
6  91.91 95.80 
Mean: 92.36 92.09 
N 6 6 
Sd 3.26 2.58 
% RSD: 3.76 2.80 
ST.Error Mean 1.41 1.05 
Calculated t-value=0.14 
Tabulated t-value=2.23(at 95%cofidence level) 
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Table No. (32): Determination of accuracy of the adopted dissolution 
test method (Artesumine tablets for adults batch.no.LS060602)                              
sample Refrence method %released 
Proposed method  
%released 
1 101.7 89.54 
2 92.0 86.61 
3 89.0 89.4 
4 91.1 87.9 
5 90.0 89.03 
6  91.0 86.46 
Mean: 92.46 88.16 
N 6 6 
Sd 4.65 1.38 
% RSD: 5.02 1.56 
ST.Error Mean 1.89 0.56 
Calculated t-value=2.17 
Tabulated t-value=2.23(at 95%cofidence level) 
 
Table No. (33): Determination of accuracy of the adopted dissolution 
test method (Artesumine tablets for adults batch.no.LS060401) 
sample Refrence method %released 
Proposed method  
%released 
1 92.66 92.52 
2 94.12 94.34 
3 97.5 94.39 
4 91.21 92.96 
5 95.72 93.76 
6  93.69 96.17 
Mean: 94.15 94.02 
N 6 6 
Sd 2.22 1.21 
% RSD: 2.36 1.37 
ST.Error Mean 0.91 0.52 
Calculated t-value=0.12 
Tabulated t-value=2.23( at 95%cofidence level) 
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Table No. (34): Determination of accuracy of the adopted dissolution 
test method (Artesumine tablets for children batch.no.LS060401) 
sample Refrence method %released 
Proposed method  
%released 
1 83.12 85.79 
2 84.36 84.19 
3 81.37 83.69 
4 85.85 82.99 
5 81.11 81.19 
6  81.11 84.26 
Mean: 82.82 83.68 
N 6 6 
Sd 1.98 1.53 
% RSD: 2.39 1.83 
ST.Error Mean 0.81  0.62 
Calculated t-value=0.84 
Tabulated t-value=2.23(at 95%cofidence level) 
 
4.5.1.4. Precision (reproducibility) 
The precision of the method was determined by measuring the 
reproducibility in two laboratories, tables (35-38) .The percentage relative 
standard deviations are within the acceptance criteria of 5% (USP, 2007). 
The calculated F-values for samples by the adopted method were 1.88, 3.7, 
1.63, which were less than the tabulated ones 5.05. This confirms that the 
adopted method is reproducible. 
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TableNo.(35)Determination of reproducibility of the adopted dissolution 
test method (Artesumine tablets for adults batch.no.LS060602)                 
sample Laboratory(1) %released 
Laboratory(2) 
%released 
1 97.40 89.54 
2 91.45 86.61 
3 91.24 89.4 
4 90.56 87.9 
5 87.76 89.03 
6  88.08 86.46 
Mean: 91.08 88.15 
N 6 6 
Sd 3.47 1.38 
% RSD: 3.34 1.57 
Calculated F-value=3.7 
Tabulated F-value=5.05(at 95%cofidence level) 
 
TableNo.(36):Determination of reproducibility of the adopted dissolu-
tion test method (Artesumine tablets for adults batch.no.LS060401) 
sample Laboratory(1) %released 
Laboratory(2) 
%released 
1 97.0 92.52 
2 96.1 94.34 
3 96.29 94.39 
4 96.0 92.96 
5 98.02 93.76 
6  98.07 96.17 
Mean: 96.9 94.02 
N 6 6 
Sd 0.94 1.28 
% RSD: 0.97 1.37 
Calculated F-value=1.88 
Tabulated F-value=5.05(at 95%cofidence level) 
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TableNo.(37):Determination of reproducibility of theadopted dissolu-
tion test method (Artesumine tablets for children batch.no.LS060401) 
sample Laboratory(1) %released 
Laboratory(2) 
%released 
1 85.16 85.79 
2 85.79 84.19 
3 84.85 83.69 
4 83.91 82.99 
5 83.83 81.19 
6  82.42 84.26 
Mean: 84.32 83.68 
N 6 6 
Sd 1.19 1.53 
% RSD: 1.42 1.82 
Calculated F-value=1.63 
Tabulated F-value=5.05(at 95%cofidence level) 
 
4.5.2. The advantages of the adopted dissolution test method on other              
Pharmacopeial methods: 
1. In the adopted dissolution method, samples are analyzed by HPLC 
method which is more selective than UV-spectrophotometric method 
(Chinese Pharmacopeia, 1996). Also the assay of the samples is 
performed directly after filtration. While in the Chinese pharmacopeia 
method (1996) several steps are needed to detect the samples after 
filtration. 
2. The adopted method is off-line filtration techniques for filtration of 
dissolved samples. While the IP 2009 method needs in-line filtration 
techniques which is not affordable by most developing countries. 
Moreover the samples under test need to be detected without delay, 
which means that the results affect by time. This is not the case in the 
adopted method. Also IP method needs injection volume of 100 µl to 
detect the samples, while the adopted method needs 20µl to give 
response for 50mg and 100mg artesunate. Because, artesunate  is 
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practically insoluble at all pH and sparingly soluble in water (Indian 
pharmacopeia,2009), thus in the adopted method 0.2% Na lauryl 
sulphate  was  added to dissolution medium to increase the solubility of 
the artesunate . In case of IP method only buffer 6.8 is used. 
3. The adopted method is not expensive compared to the Indian 
Pharmacopeia method 2009 (HPLC method) for analysis of samples 
which needs special device to adjust the column temperature at 
15°C.While in the adopted HPLC method the analysis  carried out at 
room temperature (30°C) . Moreover, in the Indian Pharmacopeia 
method 50µ is needed to detect the samples by HPLC, because the 
dissolution medium used is phosphate buffer pH5.0.     
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Chapter 5 
Conclusion & 
Recommendations 
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5.1. Conclusion  
• Substandard products exist within the drug distribution chains in Sudan. 
In view of the potential danger that substandard antimalarials could 
already be pose and in the fight against malaria, an intervention plan 
should be developed immediately. This could involve setting up quality 
surveillance systems within drug regulatory authorities in Sudan. There is 
a need for more carefully planned studies in order to define quality 
problems further. 
• Although the humidity and temperature in all states of Sudan affected  the 
artesunate molecule causing a degradation product which is one of the 
dihydroartemisinin degredant namely (α-DHA), the results showed 
reasonable stability of artesunate .There are areas of high humidity in 
south of Sudan (tropic  condition)  not involved in this study, because of 
the situation. Thus there is a need for further study in these areas.  
• Analysis of different generic brands of artesunate tablets showed that 
there is a significant problem of the drug formulation .Failure in 
dissolution test of one generic brand after three months storage at room 
temperature and other generic brand reach the lower limit of the 
dissolution test is a problem of low quality drugs registered in Sudan. The 
study indicates that not all artesunate   generic brands   present in 
Sudanese market conform to the standards of quality. Further 
investigation will be important especially for local manufacturers since it 
is easier to act and correct problem that involve domestic manufacturers.  
There is need for the regulatory authorities in Sudan to improve the 
quality of the of antimalarials drugs in Sudan and support manufacturers 
to improve GMP compliance. 
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• The development of cost-effective analytical protocol for artemisinin and 
its derivatives has become very important in the face of increasing supply 
and demand for this antimalarial agent. The adopted dissolution method 
for artesunate tablets can be employed in poorly equipped laboratories. 
The proposed method is selectiveive, precise and accurate.  
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5.2. Recommendations 
• Appropriate storage conditions for artesunate tablet (AS+SP) must be 
ensured to maintain product stability and integrity. 
• The product(s) should be appropriately blister-packed and stored in a cool 
place to assure maximal stability and product integrity. 
• Artesunate tablets (AS+SP) should be procured from pharmaceutical 
companies with an assured competence to manufacture the product(s) 
according to GMP standards, and to concentrate on the prequalified 
manufacturers. 
• Ministry of Health must ensure rational deployment of (AS+SP) with 
regimen adherence for optimal treatment and to prolong the useful 
therapeutic life of these drugs by comprehensive monitoring and 
evaluation of product use, through the post-marketing surveillance. 
• Bioequivalence studies must be a principal issue for registration of drugs 
in Sudan. 
• The adopted dissolution test method for artesunate tablet can be used in a 
routine test as it is selective, precise and accurate.  
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Table No. (1): Results of analysis of post -marketing surveillance of artesunate tablets (AS+SP) for adults in Khartoum  
 
IP requirement: 90-110 of amount stated on label (n=3);bn =6; all brands had satisfactory  physical appearance and passed related substances test (IP requirement: <1.0%) . 
dn=6 IP requirement for dissolution test >60% 
 
 
    
Dosage 
form Product 
Round 1 Round 2 Round 3 Round 4 Round 5 Round 6 
Drug rel  
% 
30 minb. 
aContent% 
(w/w) 
Drug rel  
% 
30 minb. 
aContent% 
(w/w) 
Drug rel  
% 
30 minb. 
aContent% 
(w/w) 
Drug rel  
% 
30 minb. 
aContent% 
(w/w) 
Drug rel  
% 
30 minb. 
aContent% 
(w/w) 
Drug rel  
% 
30 minb. 
aContent
% 
(w/w) 
Artesunate 
for Adult 
Artesumie 
98.59 ±1.2 103.97±0.4 96.00±1.1 99.68±0.33 94.02±2.1 102.19±0.4 85.68±1.1 103.47±0.3 89.8±3.3 100.8±0.4 91.6±1.3 101.5±0.4 
95.45±0.99 99.62±0.43 96.51±1.2 98.42±0.4 82.51±4.1 99.36±0.34 90.84±2.1 109.68±0.4 93.2±3.2 99.13±0.8   
95.96 ±2.1 97.93 ±0.5 97.75±2.3 101.00±0.6   83.93±3.1 101.14±0.8     
  98.32±0.9 100.3±0.5         
Ariplus 
66.09±0.98 96.23±0.33 61.49±2.4 98.43±0.3         
59.54±3.1 99.71±0.67 64.89±1.1 100.95±0.9         
62.39 ±2.3 100.5±0.77 69.92±1.1 96.82±0.66         
67.47± 2.2 97.37±0.45 60.88±2.5 98.44±0.4         
  52.84±1.3 97.2±0.8         
  55.71±4.1 98.5±0.4         
Artemal 
  80.38±3.1 98.89±0.7 91.43±2.4 96.30±0.5 91.03±3.2 101.12±0.3 76.6±2.1 95.1±0.4 84.05±08 96.08±0.5 
  84.41±2.1 96.18±0.5 83..84±07 97.97±0.6 79.40±2.1 95.65±0.5   80.44±07 96.83±0.7 
  86.21±3.1 95.7±0.44         
Combisuate
    59.32±1.2 94.27±0.5       
    54.71±2.3 89.40±0.6       
    52.90±2.5 87.46±0.7       
ASP 
      79.74±4.1 96.22±0.5 82.0±2.7 97.22±0.4 80.8±3.1 98.93±0.3 
      80.00±1.9 98.99±0.3 74.1 ±3.2 94.44±0.7 81.7±0.9 100.3±0.8 
      65.45±2.5 98.08±0.5 73.4±1.3 95.09±0.5 81.2±3.8 95.00±0.5 
      61.64±2.2 94.00±0.7   80.8±1.9 96.60±0.3 
60 
 
 
 
 
 
 
Table No. (2): Results of analysis of post -marketing surveillance of artesunate tablets (AS+SP) for children in Khartoum  
 
IP requirement: 90-110 of amount stated on label (n=3);bn =6; all brands had satisfactory  physical appearance and passed related substances test (IP requirement: <1.0%)  
dn=6 IP requirement for dissolution test >60% 
 
 
 
 
 
 
Dosage 
form Product 
Round 1 Round 2 Round 3 Round 4 Round 5 Round 6 
Drug rel  
% 
30 minb. 
aContent% 
(w/w) 
Drug rel  
% 
30 minb. 
aContent% 
(w/w) 
Drug rel  
% 
30 minb. 
aContent
% 
(w/w) 
Drug rel  
% 
30 minb. 
aContent
% 
(w/w) 
Drug rel  
% 
30 minb. 
aContent% 
(w/w) 
Drug rel  
% 
30 minb. 
aContent% 
(w/w) 
Artesunate 
for 
children 
Artesumie 
95.17 ±2.3 100.62±0.7   95.13±2.3 105.63±0.6 91.77±2.3 104.61±04 88.70 ± 0.9 102.21±0.5 92.37±2.2 98.10±0.3 
94.71 ±1.1 99.96±0.43   96.18±0.9 98.85±0.8 91.76±3.3 101.6±0.6 93.45 ± 1.1 96.98±0.4 92.57±1.4 94.69±0.5 
      92.02±1.8 105.26±04 94.22 ±4.1 101.57±0.3   
Ariplus 
47.96 ±3.5 107.11±0.5 45.68±2.5 98.2±0.43         
50.29 ±2.2 100.89±0.7 43.79±2.3 100.09±0.4         
50.59± 1.4 100.33±0.6 81.02±1.4 93.16±.06         
80.87±4.1 97.00±0.34 45.08±0.9 98.17±0.5         
Artemal 
  89.90±1.5 95.01±0.50 90.91±1.9 97.33±0.5 94.61±1.1 109.5±0.8 82.08±2.1 97.44±0.6 84.13±2.1 100.12±0.6 
  89.97±2.2 96.00±0.6 90.43±2.7 96.68±0.4       
  90.83±0.9 94.64±0.44 92.91±0.9 98.73±0.3       
ASP 
    91.03±3.1 94.92±0.4       
      66.82±2.3 97.65±0.3 68.25 ±2.2 93.69±0.3 92.12±1.0 101.23±0.5 
      79.08±1.5 99.46±9.5 87.32 ±1.9 98.3±0.5 83.91±1.1 100.55±0.3 
        84.07 ±1.7 96.26±0.3 84.41±2.4 94.81±0.4 
        67.58 ±1.5 93.78±0.6 82.86±2.4 97.46±0.7 
          69.87±4.1 94.29±0.6 
          67.75±2.3 96.96±0.4 
61 
 
 
 
 
 
 
Table No. (3): Results of analysis  of post -marketing surveillance of artesunate tablets (AS+SP) for adults in Elgadarif 
 
IP requirement: 90-110 of amount stated on label (n=3);bn =6; all brands had satisfactory  physical appearance and passed related substances test (IP requirement: <1.0%)  
dn=6 IP requirement for dissolution test >60% 
. .----=This round not done 
 
Dosage 
form Product 
Round 1 Round 2 Round 3 Round 4 Round 5 Round 6 
Drug rel  
% 
30 minb. 
aContent% 
(w/w) 
Drug rel  
% 
30 minb. 
aContent% 
(w/w) 
Drug rel  
% 
30 minb. 
aContent% 
(w/w) 
Drug rel  
% 
30 minb.
aConten
t% 
(w/w) 
Drug rel  % 
30 minb. 
aContent% 
(w/w) 
Drug rel  
% 
30 minb. 
aContent% 
(w/w) 
Artesunate 
for Adult 
 
Artesumine 
 
95.55±1.5 103.41±0.33 96.66±2.1 98.54±0.33 94.27±1.8 108.06±0.7 ----- ----- 81.63 ±2.1 98.64±0.9 90.83±0.9 100.60±0.4 
98.81±2.3 100.77±0.43 94.18±1.3 100.74±0.5 96.23±1.7 101.47±0.4 ----- ----- 86.67± 0.9 99.96±0.3 93.15±3.2 99.44±0.8 
      ----- ----- 87.08 ±0.8 99.06±0.30.   
Ariplus 
53.18±1.9 99.98±0.46 71.14±1.1 95.81±.0.45   ----- -----     
56.78±3.1 101.12±0.66 59.69±1.4 99.74±0.6   ----- -----     
56.09±3.3 98.84±0.44 62.56±2.1 95.49±0.4   ----- -----     
54.64±2.3 98.02±0.46 53.71±0.8 91.49±0.6   ----- -----     
57.01±1.5 98.82±0.71     ----- -----     
Artemal 
  94.25±1.7 96.48±0.4   ----- ----- 69.6± 0.9 97.3±0.5 65.98±1.1 93.60±0.6 
  89.27±0.8 101.78±0.5   ----- ----- 69.01± 4.2 98.5±0.8   
  95.47±2.1 98.25±0.7   ----- -----     
Artescope 
    92.19±0.9 100.87±0.4 ----- ----- 88.70±2.1 99.64±0.4 101.24±2.0 103.56±0.4 
    90.27±0.9 105.21±0.8 ----- ----- 85.52±1.3 97.84±0.3 92.03±3.7 99.32±0.3 
    90.84±2.2 99.69±0.4 ----- ----- 83.68±2.5 98.00±0.6   
    89.78±3.2 100.04±0.3 ----- ----- 84.60±2.2 98.68±0.4   
Combisunate
    49.48±1.5 94.11±0.9 ----- -----     
    53.70±1.4 90.55±0.8 ----- -----     
    53.53±2.1 89.92±0.4 ----- -----     
    55.23±1.1 91.40±0.6 ----- -----     
ASP       ----- ----- 69.35± 1.2 98.05±0.6 67.27±0.9 93.60±0.5       ----- ----- 68.62 ±2.2 96.27±0.7 76.00±1.1 94.56±0.4 
62 
 
 
 
 
 
 
 
 
Table No. (4): Results of analysis  of post -marketing surveillance of artesunate tablets (AS+SP) for children in Elgadarif 
IP requirement: 90-110 of amount stated on label (n=3);bn =6; all brands had satisfactory  physical appearance and passed related substances test (IP requirement: <1.0%) 
 dn=6 IP requirement for dissolution test >60% 
 .----=This round not done 
 
 
Dosage 
form Product 
Round 1 Round 2 Round 3 Round 4 Round 5 Round 6 
Drug rel  
% 
30 minb. 
aContent% 
(w/w) 
Drug rel  
% 
30 minb. 
aContent% 
(w/w) 
Drug rel  
% 
30 minb. 
aContent% 
(w/w) 
Drug rel  
% 
30 minb.
aContent%
(w/w) 
Drug rel  
% 
30 minb. 
aContent% 
(w/w) 
Drug rel  
% 
30 minb. 
aContent% 
(w/w) 
Artesunate 
for children 
Artesumine 
96.90± 1.2 98.92±0.54 96.65±2.1 107.32±0.6 91.46±1.1 104.21±0.4 ----- ----- 95.5± 1.1 97.0±0.5 100.1±3.3 102.46±0.9 
97.07±0.99 103.17±0.77 95.40±3.1 99.60±0.43 100.63±3.1 98.41±0.7 ----- ----- 100.66± 0.7 101.40.±0.6   
  101.5±3.2 103.74±0.8 90.48±1.5 102.62±0.4 ----- ----- 99.7± 0.6 100.8±0.3   
  95.63±1.1 103.13±0.4   ----- -----     
  94.15±1.4 100.96±0.4   ----- -----     
  95.40±0.9 104.43±0.8   ----- -----     
  99.98±0.8 103.57±0.6   ----- -----     
Ariplus 
41.66±0.99 100.02±0.5 45.53±1.5 93.04±0.8   ----- -----     
41.0±0.98 101.61±0.6     ----- -----     
48.75±3.1 101.3±80.34     ----- -----     
42.02±0.89 99.89±0.4     ----- -----     
39.91±2.4 100.25±0.6     ----- -----     
Artemal   93.06±1.1 101.53±0.3 85.16±2.1 101.18±0.3 ----- ----- 75.32 ±1.1 93.99±-0.3 83.59 ±2.1 97.42 ±0.3   93.81±0.7 100.67±0.7 94.57±2.2 104.66±0.4 ----- -----     
Artescope 
    100.03±1.4 103.12±0.6 ----- ----- 97.61± 3.2 99.5±0.7 97.92±1.6 100.21±0.4 
    94.90±1.3 99.67±0.4 ----- ----- 94.71±3.1 101.56±0.3 95.25±1.2 101.34±0.5 
    99.00±2.3 100.00±0.7 ----- ----- 94.25± 4.1 98.56±0.4 94.5±1.3 98.87±0.3 
    97.25±2.1 105.20±0.7 ----- ----- 93.44 ±3.5 101.18±0.3   
      ----- ----- 99.35± 1.1 100.5±0.6   
ASP       ----- -----   81.54±3.2 99.72±0.6 
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Table No. (5): Results of analysis  of post -marketing surveillance of artesunate tablets (AS+SP) for adults in Atbara 
 
IP requirement: 90-110 of amount stated on label (n=3); bn =6; all brands had satisfactory  physical appearance and passed related substances test (IP requirement: <1.0%)  
dn=6 IP requirement for dissolution test >60% 
.   
 
  
Dosage 
form Product 
Round 1 Round 2 Round 3 Round 4 Round 5 Round 6 
Drug rel  
% 
30 minb. 
aContent% 
(w/w) 
Drug rel  
% 
30 minb. 
aContent% 
(w/w) 
Drug rel  
% 
30 minb. 
aContent% 
(w/w) 
Drug rel  
% 
30 minb. 
aContent
% 
(w/w) 
Drug rel  
% 
30 minb. 
aContent% 
(w/w) 
Drug rel  
% 
30 minb. 
aContent% 
(w/w) 
Artesunate 
for Adult 
Artesumine 
97.50±1.2 95.51 ±0.3 75.56±1.1 99.20 ±0.6 89.59±2.3 101.89±0.6 73.65±4.1 96.19±0.3 91.34 ±0.9 102.62±0.7 93.61±2.0 101.55±0.4 
96.90±0.90 95.51± 0.6   98.38±3.2 102.38±0.4 90.0 ±2.3 99.01±0.4     
93.10 ±1.6 92.42± 0.4           
Ariplus 
56.47± 2.2 97.23±0.44 42.33±2.4 97.80±0.33         
62.08 ±1.8 93.11±0.36 48.06±3.1 96.81±0.8         
  47.13±4.1 102.27±0.6         
  52.33±2.2 98.21±0.5         
  54.73±0.9 99.72±0.4         
ASP 
      75.99±2.2 97.18±0.3 70.33 ±4.1 98.39±0.6 67.12±3.3 103.06±0.3 
      70.49±4.1 101.6±0.4 74.62 ±1.1 97.74±0.4 69.60±2.2 99.33±0.7 
      68.27±3.3 95.27±0.3 73.87 ±3.1 97.19±0.4 78.65±2.3 95.33±0.6 
      68.11±1.3 96.74±0.5     
Artema 
  77.57±2.5 98.58±0.5 94.38±1.1 101.6±0.5 82.83±2.3 95.6±0.6     
  96.50±2.3 98.23±0.4 93.61±3.2 98.98±0,3 81.17±2.2 98.36±0.3     
      77.88±1.5 101.4±0.6     
Combisunate 
    53.14±0.9 86.19±0.3       
    47.82±1.8 92.21±0.6       
    49.52±0.9 93.21±0.7       
    51.29±2.2 93.21±0.4       
Artecosp 
        92.40 ±2.1 100.10±0.7 91.9±30.9 97.07±0.4 
        94.82± 2.2 99.78±0.5 94.92±0.8 103.02±-.6 
        91.27 ±1.6 101.61±0.4 89.62±3.2 98.34±0.4 
          91.72±4.1 103.22±0.5 
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Table No. (6): Results of analysis  of post -marketing surveillance of artesunate tablets(AS+SP)  for children in Atbara 
 
IP requirement: 90-110 of amount stated on label (n=3);bn =6; all brands had satisfactory  physical appearance and passed related substances test (IP requirement: <1.0%)  
dn=6 IP requirement for dissolution test >60% 
  
 
 
 
 
Dosage 
form Product 
Round 1 Round 2 Round 3 Round 4 Round 5 Round 6 
Drug rel  
% 
30 minb. 
aContent% 
(w/w) 
Drug rel  
% 
30 minb. 
aContent% 
(w/w) 
Drug rel  
% 
30 minb. 
aContent% 
(w/w) 
Drug rel  
% 
30 minb. 
aContent% 
(w/w) 
Drug rel  
% 
30 minb. 
aContent% 
(w/w) 
Drug rel  
% 
30 minb. 
aContent% 
(w/w) 
Artesunate 
for 
children 
Artesumine 
98.2±3.1 99.48 ±0.8 100±1.4 102.32±0.4 94.61±4.1 94.84±0.6 80.43±3.4 97.77±0.8 96.27 ±1.9 99.59±0.5 99.38±1.9 101.43±0.5 
    95.75±2.4 100.89±0.8       
    103.61±3.3 104.24±0.3       
Ariplus 
50.11±1.9 98.58±0.33 94.59±0.8 100.79±0.23         
45.35±0.88 91.49 ±0.4 44.82±1.3 97.27±0.6         
47.76±0.97 100.09±0.7 41.72±2.1 97.76±0.6         
  45.73±1.5 101.19±0.7         
Artemal 
  93.00±1.9 96.75±0.33 100.18±2.2 107.04±0.7 90.85±1.9 95.06±0.5 91.08 ±2.8 98.38±0.5 81.58±2.7 93.96±0.3 
    96.19±3.1 102.59±0.6 93.93±4.2 100.34±0.7   92.80±1.8 94.34±0.6 
    91.01±1.4 103.08±0.5 90.95±2.2 95.16±0.4     
ASP 
      70.87±1.1 99.83±0.6 82.87 ±2.2 96.63±0.5 76.60±3.1 96.70±0.5 
      77.98±1.3 96.69±0.4 82.89± 2.3 94.01±0.3 78.92±4.1 95.40±0.3 
      62.81±2.1 99.96±0.5 75.83± 2.2 94.83±0.3 85.20±3.5 97.31±0.9 
      73.04±0.9 96..36±0.8     
Artecosp 
        80.08 ±1.8 91.50±0.8 95.56±0.9 100.74±0.7 
        101.45±3.2 102.57±0.3 99.0±2.2 99.29±o.3 
        93.24 ±3.1 104.02±0.5 98.48±3.0 100.96±0.3 
          103.06±2.2 104.19±0.4 
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Table No. (7): Results of analysis  of post -marketing surveillance of artesunate tablets (AS+SP) for adults in 
Elobied  
Dosage 
form Product 
Round 1 Round 2 Round 3 Round 4 Round 5 Round 6 
Drug rel  
% 
30 minb. 
aContent% 
(w/w) 
Drug rel  
% 
30 minb. 
aContent% 
(w/w) 
Drug rel  
% 
30 minb. 
aContent% 
(w/w) 
Drug rel  
% 
30 minb. 
aContent% 
(w/w) 
Drug rel  % 
30 minb. 
aContent% 
(w/w) 
Drug rel  
% 
30 minb. 
aContent% 
(w/w) 
Artesunate 
for Adult 
Artesumine 
96.79±3.2 100.63±0.44 96.07±1.3 96.42±0.5 82.43±3.1 98.00±0.7 84.75±1.1 102.0±0.7 93.31±1.8 98.16±0.3 87.49±1.5 100.22±0.4 
  96.58±2.2 97.95±0.7 89.97±4.1 102.14±0.3 94.99±2.1 98.61±0.3 88.58±2.2 98.40±0.8 95.22±4.2 98.02±0.3 
  98.71±2.3 99.33±0.8         
Ariplus 57.04±1.9 98.33±0.5 52.79±1.1 96.16±0.8         58.21±1.9 99.17±0.6           
artemal 
  92.77±0.9 95.62±0.6 96.45±0.9 101.32±0.4   81.78±4.1 99.43±0.2   
  83.61±2.2 93.82±0.3         
  84.29±3.2 90.68±0.7         
Artecosp 
    90.74±1.0 99.60±0.3 86.66±1.4 100.13±0.3 94.82±0.3 100.29±2.1 98.8±2.2 99.97±0.4 
    92.04±2.1 102.14±0.4 90.3±1.2 97.83±0.6 91.24±2.1 97.59±0.9 96.72±1.9 99.97±0.6 
    94.11±2.2 100.50±0.6 99.05±1.1 100.33±0.4 95.09±1.5 96.65±0.5   
    101.33±1.3 107.80±0.7 90.0±0.9 97.78±0.7 91.59±1.6 96.29±0.6   
    93.77±1.4 100.50±0.7       
ASP       59.77±3.2 96.34±0.7 79.56±0-9 96.53±0.6 73.73±2.1 97.97±0.8       59.61±4.1 94.13±0.4 75.47±1.7 93.23±0.7 76.64±3.2 98.70±0.3 
IP requirement: 90-110 of amount stated on label (n=3);bn =6; all brands had satisfactory  physical appearance and passed related substances test (IP requirement: <1.0%)  
dn=6 IP requirement for  dissolution test >60%. .  
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Table No. (8): Results of analysis  of post -marketing surveillance of artesunate tablets (AS+SP) for children in 
Elobied  
 
IP requirement: 90-110 of amount stated on label (n=3);bn =6; all brands had satisfactory  physical appearance and passed related substances test (IP requirement: <1.0%) 
 dn=6. IP requirement for f dissolution test >60%.  
 
Dosage 
form Product 
Round 1 Round 2 Round 3 Round 4 Round 5 Round 6 
Drug rel  
% 
30 minb. 
aContent% 
(w/w) 
Drug rel  
% 
30 minb. 
aContent% 
(w/w) 
Drug rel  
% 
30 minb. 
aContent% 
(w/w) 
Drug rel  
% 
30 minb. 
aContent% 
(w/w) 
Drug rel  % 
30 minb. 
aContent% 
(w/w) 
Drug rel  
% 
30 minb. 
aContent% 
(w/w) 
Artesunate 
for 
children 
Ariplus 
46.03±0.99 97.72±0.35 46.32±3.1 95.72±0.4         
40.03±1.4 100.0±0.77           
49.29±4.1 100.50±0.67           
Artesumine 
  93.55±1.4 95..55±0.33 87.61±1.1 101.10±0.8 86.56±2.2 100.27±0.3 100.15±4.1 105.81±0.9 91.37±4.0 100.20±0.4 
  96.51±1.5 98.53±0.5 97.11±2.2 104.18±0.6 95.45±2.1 100.58±0.4 96.79±1.1 98.16±0.2 91.34±3.0 98.5±0.9 
  98.31±3.1 98.35±0.7   90.87±2.2 100.3±0.6 96.13±2.2 99.08±0.4 95.59±3.2 102.22±0.7 
  96.72±2.1 97.73±  0.4         
Artemal 
  89.1±1.70 94.98±0.8 91.682.2 97.03±0.3 96.91±3.1 98.20±0.4 86.92±3.1 92.9±0.3 82.59±1.1 98.27±0.5 
  88.39±1.9 94.71±0.6   86.1±3.3 96.49±0.5 81.14±1.1 101.92±0.4   
      88.6±3.4 97.03±0.7     
Artecosp 
    100.8±0.3 101.70±0.3 95.05±2.4 97.42±0.4 90.13±2.3 97.06±0.3 92.0±2.2 96.94±0.6 
    95.42± 2.3 102.20±0.4 98.7±2.2 99.62±0.3 96.11±1.5 95.96±0.6 93.73±3.7 95.35±0.5 
    96.80±1.6 105.23±0.9 94.72±1.7 98.69±0.5 95.79±2.2 96.72±0.2 96.68±0.9 98.27±0.8 
    94.54±3.1 104.1±0.5 98.71±1.9 99.89±0.3 91.66±3.3 98.62±0.2   
    101.51±1.1 105.21±0.6       
ASP         75.01±2.8 97.9±0.8 84.73±3.3 93.63±0.6         86.25±1.1 93.23±0.3 75.75±2.2 95.01±0.9 
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Table No. (9): Results of analysis of the stability study of Artesumine tablets for children at room 
temperature in Khartoum 
Time 
(month) 
aContent%(w/w) 
Drug rel  %  
30 mnb. 
Degradation 
products 
Batch No. 
LS061201 
Batch No. 
LS060401 
Batch No. 
LS060601 
Batch No. 
LS061201 
Batch No. 
LS060401 
Batch No. 
LS060601 
Batch No. 
LS061201 
Batch No. 
LS060401 
Batch No. 
LS060601 
Zero 102.0±0.44 100.9±0.70 106.3±0.77 98.3±2.83 89.0±1.12 104.0±1.8 Not detected 
3 months 101.4±0.16 99.0±0.71 105.0±0.50 98.0±1.01 88.3±1.40 104.0±1.3 detected 
6 months 100.7±0.06 98.9±0.46 104.1±0.82 97.9±1.07 87.7±1.20 102.9±2.0 detected 
9 months 99.0±0.01 98.0±0.32 103.3±0.40 96.9±1.22 87.5±1.77 103.1±3.8 detected 
12 months 98.92±0.34 98.1±1.64 102.1±0.60 95,1±1.56 96.9±1.50 102.7±3.9 detected 
18 months 98.0±0.77 97.8±0.33 101,7±0.33 94.3±0.90 96.5±3.0 101.6±1.0 detected 
24 months 97.92±0.65 97.0±0.88 100.4±0.90 94.1±1.70 96.3±0.98 100.9±0.9 detected 
36 months 96.70±1.60 96.2±0.28 100.00±1.11 93.00±3.2 85.1±1.66 100.0±3.7 detected 
          IP requirement:90-110 of amount stated on label(n=3);bn =6; all brands had satisfactory  physical appearance and passed related substances test (IP requirement: <1.0%) 
         IP requirement for dissolution test >60% 
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Table No. (10): Results of analysis of the stability study of Artesumine tablets for adults at room 
temperature in Khartoum 
Time (month) 
aContent%(w/w) 
Drug rel  % 
30 mnb. 
Degradation 
products 
Batch No. 
LS060602 
Batch No. 
LS060301 
Batch No. 
LS060401 
Batch No. 
LS060602 
Batch No. 
LS060301 
Batch No. 
LS060401 
Batch No. 
LS060602 
Batch No. 
LS060301 
Batch No. 
LS060401 
Zero 102.07±0.77 101.9±0.3 104.9±0.33 97.42±0.8 95.6±1.2 98.5±2.0 Not detected 
3 months 100.3±0.6 100.0±0.8 103.8±0.4 96.9±1.5 95.0±1.4 98.1±4.1 detected 
6 months 100-0±0.3 100.0±0.4 103.0±0.5 94.4±0.6 96.4±2.8 96.4±3.9 detected 
9 months 99.8±0.5 99,8±0.66 102.1±0.6 95.02±4.9 95.1±4.7 97.0±1.0 detected 
12 months 98.5±0.8 98.3±0.8 101.0±0.6 93.7±2.9 94.8±1.9 96.1±0.9 detected 
18 months 97.8±0.6 97.1±0.9 100.3±0.3 93.2±4.1 93.2±0.88 95.2±1.3 detected 
24 months 97.8±0.9 96.3±0.4 98.1±0.77 92.4±1.2 91.2±1.4 94.90±4.1 detected 
36 months 96.89±0.33 96.7±0.35 97.5±0.3 92.0±1.1 90.2±1.9 94.00±5.2 detected 
     IP requirement:90-110 of amount stated on label(n=3);bn =6; all brands had satisfactory  physical appearance and passed related substances test (IP requirement: <1.0%) 
     IP requirement for dissolution test >60% 
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Table No. (11): Results of analysis of the stability study of Artesumine tablets for children at room 
temperature in Port Sudan 
Time 
(month) 
aContent%(w/w) 
Drug rel  % 
30 mnb. 
Degradation 
products 
Batch No. 
LS061201 
Batch No. 
LS060401 
Batch No. 
LS060601 
Batch No. 
LS061201 
Batch No. 
LS060401 
Batch No. 
LS060601 
BatchNo.0 
LS061201 
Batch No 
LS060401 
Batch No. 
LS060601 
Zero 102.0±0.33 100.9 ±0.4 106.3±0.3 98.3±3.2 89.0±2.1 104.1±4.1 Not detected 
3 months 101.05±0.8 100.4±0.6 105.0±1.1 97.8±3.2 89.0±1.5 103.6±2.2 detected 
6 months 101.0±0.7 100.1±1.0 103.9±0.1 97.2±3.7 87.1±1.1 102.9±0.9 detected 
9 months 100.3±0.5 99.2±0.3 102.2±0.4 96.0±1.1 86.9±3.1 101.0±2.1 detected 
12 months 99.0±0.4 98.7±0,3 101.0±0,12 95.8±1.9 86.3±0.8 100.3±2.0 detected 
18 months 98.5±0.33 97.2±1.0 100.4±0.2 95.2±4.2 85.2±2.0 100.0±2.6 detected 
24 months 98.14±0.7 96.30±0.4 99.01±0.06 94.4±3.1 84.9±1.3 100.0±1.1 detected 
36 months 96.22±.0.55 95.80±0.9 97.20±0.04 93.5±0.8 84.20±1.8 99.3±2.1 detected 
IP requirement:90-110 of amount stated on label(n=3);bn =6; all brands had satisfactory  physical appearance and passed related substances test (IP requirement: <1.0%) 
 IP requirement for dissolution test >60% 
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Table No. (12): Results of analysis of the stability study of Artesmine tablets for adults at room 
temperature in Port Sudan  
Time (month) 
aContent%(w/w) 
Drug rel  % 
30 mnb. 
Degradation 
products 
Batch No. 
LS060602 
Batch No. 
LS060301 
Batch No. 
LS060401 
Batch No. 
LS060602 
Batch No. 
LS060301 
Batch No. 
LS060401 
Batch No. 
LS060602 
Batch No. 
LS060301 
Batch No. 
LS060401 
Zero 102.07±0.47 101.9±0.34 104.9±0.4 97.42±0.30 95.60±4.20 98.5±1.9 Not detected 
3 months 100±0.66 101,0±0.77 103.2±0.66 96-80±0.34 95.30±1.80 98.2±1.3 detected 
6 months 100.01±0.34 101.4±0.44 102.9±0.50 95.1±3.80 95.00±4.20 97.0±2.0 detected 
9 months 99.4±0.62 100. 9±0.9 101.0±0.40 94.0±5.0. 94.20±1.90 96.6±3.8 detected 
12 months 97.6±0.34 99.8±0.3 100.0±0.44 90.32±101 93.30±0.80 96.0±3.9 detected 
18 months 98.31±0.44 98.3±0.50 99.3±0.35 88.9±1.9 92.10±2.30 95.1±1.0 detected 
24 months 96.4±0.53 97.7±1.00 98.0±0.70 91.88±3.6 90.90±0.60 94.0±1.4 detected 
36 months 95.66±0.50 96.0±0.44 96.8±0.60 90.90±3.1 90.90±1.90 93.8±2.2 detected 
IP requirement:90-110 of amount stated on label(n=3); bn =6; all brands had satisfactory  physical appearance and passed related substances test (IP requirement <1.0%) 
     IP requirement for dissolution test >60% 
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Table No. (13): Results of analysis of the stability study of Artesumine tablets for children at room 
temperature in Atbara                            
Time (month) 
aContent%(w/w) 
Drug rel  %  
30 mnb. 
Degradation 
products 
Batch No. 
 LS061201 
Batch No. 
LS060401 
Batch No. 
LS060601 
Batch No. 
 LS061201 
Batch No. 
LS060401 
Batch No. 
LS060601 
Batch No. 
 LS061201 
Batch No. 
LS060401 
Batch No. 
LS060601 
Zero 102.0±0.33 100.9 ±0.8 106.3±0.6 98.3±2.11 89.0±0.98 104.1±3.90 Not Detected 
3 months 101.9±0.7 100.8±0.3 106.2±0.3 98.1±0.90 88.9.0±1.5 104.6±1.20 Not Detected 
6 months 101.0±0.5 100.11±0.9 106.5.0±0.9 97.9±3.1 87. ±3.00 104.1±0.50 Not Detected 
9 months 100.3±0.06 100.0±0.6 105.4±1.33 96.2±1.1 86.9±1.0 103.80±3.10 Not Detected 
12 months 100.0±0.3 99.70±0.7 104.9±0.9 95.8±0.99 86.0±1.80 103.10±1.40 Not Detected 
18 months 99.6±0.09 99.0±0.25 103.0±1.01 94.1±2.20 85.6±0.99 102.90±1.80 Not Detected 
24 months 99.0±0.77 98.20±0.4 102.2±0.6 92.1±3.10 84.9±2.2 102.30±4.20 Detected 
36 months 99.0±0.4 98.0±0.29 101,0±0.2 89±1.10 84.0±0.96 99.00±3.20 Detected 
     IP requirement:90-110 of amount stated on label(n=3); bn =6; all brands had satisfactory  physical appearance and passed related substances test (IP requirement: <1.0%) 
     IP requirement for dissolution test >60% 
 
78 
 
 
Table No. (14): Results of analysis of the stability study of Artesumine tablets for adults at room 
temperature in Atbara                                            
Time 
(month) 
aContent%(w/w) 
Drug rel  % 
30 mnb. 
Degradation 
products 
Batch No. 
LS060602 
Batch No. 
LS060301 
Batch No. 
LS060401 
Batch No. 
LS060602 
Batch No. 
LS060301 
Batch No. 
LS060401 
Batch No. 
LS060602 
Batch No. 
LS060301 
Batch No. 
LS060401 
Zero 102.07±0.2 101.9±0.2 104.9±1.0 97.42±3.3 95.6±3.2 98.5±0.9 Not Detected 
3 months 100.9±0.1 101.1±0.8 104.0±0.3 97.0±4.4 95.2±1.1 97.9±2.1 Not Detected 
6 months 101.10±0.4 101.0±0.12 103.8±0.5 96.3±1.9 94.0±0.9 96.4±2.8 Not Detected 
9 months 100.0±0.4 100.9±0.55 102.7±0.67 95.0±0.9 92.9±1.9 95.2±2.0 Not Detected 
12 months 99.6±0.5 100.1±0-21 101.9±0.3 88.6±3.7 91.2±3.1 94.8±4.1 Not Detected 
18 months 98.0±0.3 99.3±0.4 101.0±0.9 91.9±1.1 90.1±3.1 93.0±0.9 Not Detected 
24 months 98.2±0.2 98.2±0.61 100.2±1.0 92.2±2.1 88.0±2.0 91. 9±1.2 Detected 
36 months 97.02±0.5 97.4±0.2 99.0±1.4 90.0±4.0 86.0±1.2 88.7±1.2 Detected 
    IP requirement:90-110 of amount stated on label(n=3);bn =6; all brands had satisfactory  physical appearance and passed related substances test (IP requirement:<1.0%) 
     IP requirement for dissolution test >60% 
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Table No. (15): Results of analysis of the stability study of Artesumine tablets for children at room 
temperature in Elobied                                           
Time (month) 
aContent%(w/w) 
 
Drug rel  % 
30 mnb. 
Degradation 
products 
Batch 
No.0 
LS061201 
Batch No 
LS060401 
Batch No. 
LS060601 
Batch 
No.0 
LS061201 
Batch No 
LS060401 
Batch No. 
LS060601 
Batch 
No.0 
LS061201 
Batch No 
LS060401 
Batch No. 
LS060601 
Zero 102.0±0.33 101.9±0.4 106.3±0.2 98.3±3.4 89.0±3.01 104.1±2.1 Not Detected 
3 months 101.0±0.6 101.5±0.5 106.1±1.0 97.3±2.2 88.0±0.9 104.1±2.2 Not Detected 
6 months 100.8±1.1 101.0±0.2 105.8±0.3 96.9±0.9 87.1±1.5 1o4.1±1.8 Not Detected 
9 months 100.0±0.7 100.0±0.8 104.1±0.8 96.0±0.5 86.9±2.11 103.8±0.78 Detected 
12 months 99.5±0.2 99.0±0.4 102.9±1.0 95.2±2.1 85.9±0.9 103.0±0.9 Detected 
18 months 99.2±0.4 98.91±0.3 102.0±0.3 94.1±3.1 84.1±4.1 102.1±3.1 Detected 
24 months 98.8±0.5 98.2±0.3 101.3±0.3 92.8±0.9 83.9±2.2 101.2±3.8 Detected 
36 months 97.2±1.0 97.0±0.4 100. ±0.5 91.9±3.3 82.3±1.9 99.7±1.5 Detected 
IP requirement:90-110 of amount stated on label(n=3); bn =6; all brands had satisfactory  physical appearance and passed related substances test (IP requirement <1.0%) 
           IP requirement for dissolution test >60% 
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Table No. (16): Results of analysis of the stability study of Artesumine tablets for adult at room 
temperature in Elobied                                           
Time (month) 
aContent%(w/w) 
Drug rel  % 
30 mnb. 
Degradation 
products 
Batch No. 
LS060602 
Batch No. 
LS060301 
Batch No. 
LS060401 
Batch No. 
LS060602 
Batch No. 
LS060301 
Batch No. 
LS060640 
Batch No. 
LS060602 
Batch No. 
LS060301 
Batch No. 
LS060401 
Zero 102.07±0.27 101.9±0.4 104.9±0.50 97.42±1.90 95.60±3.10 98.5±3.3 Not Detected 
3 months 101.00±0.50 100.18±0.40 104.50±1.00 96.70±2.10 95.00±1.30 98.5±1.4 Not Detected 
6 months 100.90±1.00 101.50±0.30 104.8±0.66 95.00±3.30 94.90±0.80 97. 0±2.0 Not Detected 
9 months 100.00±0.40 101.00±1.00 103.00±0.38 95.00±1.80 93.00±0.90 96.4±2.5 Detected 
12 months 100.00±0.20 100.20±0.70 102.60±0.55 94.40±1.60 93.50±1.00 95.5±2.0 Detected 
18 months 99.60±1.00 99.10±0.44 101.30±0.30 93.10±2.30 92.00±1.40 94.9±1.9 Detected 
24 months 98.70±0.60 98.00±0.30 99.80±0.22 91.20±0.80 91.20±3.30 93.8±3.8 Detected 
36 months 97.80±0.5 97.20±0.5 98.00±0.70 90.63±0.90 89.60±1.90 93.0±1.1 Detected 
  IP requirement:90-110 of amount stated on label(n=3); bn =6; all brands had satisfactory  physical appearance and passed related substances test (IP requirement  <1.0%) 
  IP requirement for dissolution test >60% 
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        Table No. (17):  Results of analysis of Artesumin tablets for adults at room temperature in NDQCL 
Time (month) 
aContent%(w/w) Drug rel  % 30 minb. Degradation products 
Batch No. 
040801 
Batch No 
041201 
Batch No. 
040801 
Batch No 
041201 
Batch No. 
040801 
Batch No 
041201 
Zero 105.40±0.66 101.5±0.35 100.80±1.41 96.5±1.77 Not detected 
3 months 104.01±0.40 100.91±0.30 100.00±3.30 96.10±2.30 detected 
6 months 103.92±0.23 100.20±0.23 99.40±2.10 95.64±3.10 detected 
9 months 101.80±0.80 100.00±0.80 99.80±1.10 94.88±1.16 detected 
12 months 100.10±0.45 99.10±0.45 99.00±3.5 95.0±3.20 detected 
18 months 100.80±0.33 99.80±0.33 98.00±2.1 95.9±1.21 detected 
24 months 101.00±0.79 98.30±0.79 97.2±0.90 93.62±0.90 detected 
36 months 100.40±0.55 97.00±0.33 97.00±1.70 92.66±1.87 detected 
           IP requirement:90-110 of amount stated on label(n=3);bn =6; all brands had satisfactory  physical appearance and passed related substances test (IP requirement: <1.0%) 
                            IP requirement for dissolution test >60%  
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      Table No. (18):  Results of analysis of Artesumin tablets for children at room temperature in NDQCL          
Time (month) 
aContent%(w/w) Drug rel  % 30 minb. Degradation products 
Batch No. 
04081 
Batch No. 
04091 
Batch No. 
04081 
Batch No. 
04091 
Batch No. 
04081 
Batch No. 
04091 
Zero 103.80±0.43 101.40±0.3 98.70±1.2 90.70±1.8 Not detected 
3 months 102.70±0.30 100.70±0.60 99.10±0.9 88.10±2.9 detected 
6 months I00. 00±0.40 99. 00±0.50 97.30±1.7 87.30±3.7 detected 
9 months 99.60±0.60 98.60±0.30 97.00±0.88 87.00±0.98 detected 
12 months 98.00±0.52 97.00±0.72 96.00±2.40 86.00±2.70 detected 
18 months 97.80±0.50 96.80±0.40 95.60±1.9 85.60±0.9 detected 
24 months 96.90±0.43 96.00±0.63 93.90±3.1 84.90±2.3 detected 
36 months 95.40±0.76 95.40±0.46 91.90±1.4 84.10±1.6 detected 
          IP requirement:90-110 of amount stated on label(n=3);bn =6; all brands had satisfactory  physical appearance and passed related substances test (IP requirement:<1.0%) 
         IP requirement for dissolution test >60% 
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    Table No. (19):  Results of analysis of Ariplus tablets for adults at room temperatures in NDQCL  
Time (month) 
aContent%(w/w) Drug rel  % 30 minb Degradation products 
Batch No. 
04J06 
Batch No. 
04J11 
Batch No. 
04J06 
Batch No. 
04J11 
Batch No. 
04J06 
Batch No. 
04J11 
Zero 99.73±0.70 101.90±0.90 76.70±1.7 70.70±1.5 Not detected 
3 months 99.00±0.40 100.4±0.33 70.00±2.2 70.00±3.2 detected 
6 months 98.60±0.50 100.0±0.80 69.30±0.91 68.30±1.89 detected 
9 months 98.50±0.33 99.8±0.43 67.10±1.3 66.00±2.63 detected 
12 months 97.30±0.80 97.9±0.77 64.90±2.23 63.10±0.93 detected 
18 months 96.70±0.33 97.00±0.65 62.04±0.88 61.04±1.78 detected 
24 months 95.09±0.41 96.00±0.70 59.30±2.10 57.170±3.10 detected 
        IP requirement:90-110 of amount stated on label(n=3);bn =6; all brands had satisfactory  physical appearance and passed related substances test  (IP requirement:<1.0%) 
         IP requirement for dissolution test >60% 
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     Table No. (20):  Results of analysis of Ariplus tablets for children at room temperature in NDQCL 
Time (month) 
aContent%(w/w) Drug rel  % 30 minb. Degradation products 
Batch No. 
04J22 
Batch No. 
04k04 
Batch No. 
04J22 
Batch No. 
04k04 
Batch No. 
04J22 
Batch No. 
04k04 
Zero 102.00±0.30 101.50±0.50 77.66±1.9 70.32±3.2 Not detected 
3 months 100.10±0.41 100.20±0.66 59.78±3.10 57.00±3.50 detected 
6 months 100.40±0.33 99.40±0.43 50.90±0.99 52.40±1.20 detected 
9 months 99.10±0.77 99.10±0.67 48.30±3.5 49.83±2.5 detected 
12 months 98.30±0,40 98.30±0.70 46.00±3.1 46.90±1.9 detected 
18 months 97.20±0.60 98.20±0.50 45.90±1.60 45.00±1.60 detected 
24 months 9.90±0.55 97.80±0.45 43.68±1.12 42.99±2.62 detected 
          IP requirement:90-110 of amount stated on label(n=3);bn =6; all brands had satisfactory  physical appearance and passed related substances test   (IP requirement <1.0%) 
         IP requirement for dissolution test >60% 
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      Table No. (21):  Results of analysis of Artemal tablets for children at room temperature in NDQCL  
Time (month) 
aContent%(w/w) Drug rel  % 30 minb. Degradation products 
Batch No. 
E1041 
Batch No. 
E1025 
Batch No. 
E1041 
Batch No. 
E1025 
Batch No. 
E1041 
Batch No. 
E1025 
Zero 99.50±0.40 100.99±0.50 90.20±1.2 93± 1.90 Not detected 
3 months 99.00±0.20 100.00±0.60 88.90±1.13 91.60±2.00 detected 
6 months 99.10±0.101 99.77±0.31 88.00±2.2 90.00±1.80 detected 
9 months 98.30±0.30 99.00±0.30 87.40±0.90 88.90±2.30 detected 
12 months 96.90±0.45 98.90±0.75 87.00±2.1 87.90±3.10 detected 
18 months 96.00±0.33 97.00±0.63 86.90±1.67 86.00±1.97 detected 
24 months 95.10±0.78 95.90±0.33 84.30±0.89 85.93±0.99 detected 
36 months 93.99±0.90 95.22±0.49 81.60±2.10 84.60±3.10 detected 
           IP requirement:90-110 of amount stated on label(n=3);bn =6; all brands had satisfactory  physical appearance and passed related substances test (IP requirement<1.0%) 
          IP requirement for dissolution test >60% 
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     Table No. (22):  Results of analysis of Artemal tablets for adults at room temperature in NDQCL  
Time (month) 
aContent%(w/w) Drug rel  % 30 minb. Degradation products 
Batch No. 
F0278 
Batch No. 
F0622 
Batch No. 
F0278 
Batch No. 
F0622 
Batch No. 
F0278 
Batch No. 
F0622 
Zero 101.69±0.34 100.00±0.34 86.95±2.2 95.95±1.92 Not detected 
3 months 100.90±0.30 99.90±0.80 85.00±1.99 94.00±0.98 detected 
6 months 100±0.44 98.0±0.74 82.10±0.88 92.10±0.88 detected 
9 months 99.60±0.35 98.10±0.66 85.20±2.80 90.20±2.80 detected 
12 months 98.13±0.88 96.10±0.48 84.00±1.50 90.00±1.50 detected 
18 months 97.20±0.65 95.20±0.35 80.90±2.60 87.00±3.60 detected 
24 months 95.10±0.42 94.30±0.40 76.10±1.14 85.00±1.44 detected 
36 months 94.22±0.50 92.92±0.60 73.56±1.90 82.00±1.50 detected 
           IP requirement:90-110 of amount stated on label(n=3);bn =6; all brands had satisfactory  physical appearance and passed related substances test  (IP requirement: <1.0%) 
         IP requirement for dissolution test >60% 
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      Table No. (23):  Results of analysis of ASP tablets for children at room temperature in NDQCL 
Time (month) 
aContent%(w/w) Drug rel  % 30 minb. Degradation products 
Batch No. 
060806 
Batch No. 
060610 
Batch No. 
060806 
Batch No. 
060610 
Batch No. 
060806 
Batch No. 
060610 
Zero 99.16±0.32 99.16±0.60 66.63±1.20 70.13±1.9 Not detected 
3 months 98.10±0.34 98.10±0.40 66.10±0.99 68.20±3.13 detected 
6 months 98.06±0.50 98.06±0.55 64.90±2.10 65.50±2.19 detected 
9 months 97.70±0.60 97.70±0.8 63.00±1.40 64.20±2.50 detected 
12 months 97.00±0.80 97.00±0.40 61.46±2.20 62.16±3.10 detected 
18 months 96.18±0.76 96.18±0.36 61.05±0.97 61.95±1.87 detected 
24 months 95.80±0.44 95.80±0.43 60.10±2.00 61.00±4.90 detected 
        IP requirement:90-110 of amount stated on label(n=3);bn =6; all brands had satisfactory  physical appearance and passed related substances test (IP requirement: <1.0%) 
         IP requirement for dissolution test >60% 
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      Table No. (24):  Results of analysis of ASP tablets for adults at room temperature in NDQCL 
Time (month) 
aContent%(w/w) Drug rel  % 30 minb. Degradation products 
Batch No. 
060624 
Batch No. 
0606523 
Batch No. 
060624 
Batch No. 
0606523 
Batch No. 
060624 
Batch No. 
0606523 
Zero 99.60±0.39 100.00±0.70 77.82±1.90 81.82±0..99 Not detected 
3 months 99.10±0.40 99.90±0.33 77.00±2.10 77.00±2.60 detected 
6 months 98.00±0.555 98.80±0.61 76.10±2.30 76.10±3.30 detected 
9 months 97.30±0.64 98.28±0.74 74.80±1.70 73.80±0.99 detected 
12 months 97.10±0.34 97.10±0.34 72.50±0.99 70.50±2.1 detected 
18 months 96.00±0.77 96.00±0.77 68.80±1.10 68.80±1.88 detected 
24 months 94.80±0.63 94.90±0.63 65.92±3.10 63.92±4.10 detected 
        IP requirement:90-110 of amount stated on label(n=3);bn =6; all brands had satisfactory  physical appearance and passed related substances test  (IP requirement:<1.0%) 
        IP requirement for dissolution test >60% 
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      Table No. (25):  Results of analysis of Artecosp tablets for children at room temperature in NDQCL 
Time (month) 
aContent%(w/w) Drug rel  % 30 minb. Degradation products 
Batch No. 
051020 
Batch No. 
051018 
Batch No. 
051020 
Batch No. 
051018 
Batch No. 
051020 
Batch No. 
051018 
Zero 100.30±0.40 102.00±0.99 99.68±2.1 97.58±3.10 Not detected 
3 months 100.00±0.20 101.60±0.33 97.00±1.8 96.00±2.60 detected 
6 months 99.50±0.70 100.50±0.45 96.16±3.2 95.11±4.16 detected 
9 months 98.70±0.40 100.90±0.60 96.40±4.1 94.10±2.19 detected 
12 months 98.00±0.33 100.22±0.86 95.05±3.3 93.95±2.11 detected 
18 months 97.90±0.35 99.70±0.80 95.10±1-7 91.10±1.74 detected 
24 months 97.90±0.71 99.00±0.50 93.00±2.3 90.00±2.30 detected 
           IP requirement:90-110 of amount stated on label(n=3);bn =6; all brands had satisfactory  physical appearance and passed related substances test  (IP requirement:<1.0%) 
         IP requirement for dissolution test >60% 
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      Table No. (26):  Results of analysis of of Artecosp tablets for adults at room temperature in NDQCL 
Time (month) 
aContent%(w/w) Drug rel  % 30 minb Degradation products 
Batch No. 
051106 
Batch No. 
051021 
Batch No. 
051106 
Batch No. 
051021 
Batch No. 
051106 
Batch No. 
051021 
Zero 100.20±0.40 105.20±0.77 97.46±2.3 100.00±3.40 Not detected 
3 months 99.90±0.54 105.00±0.34 97.00±2.20 99..00±3.20 detected 
6 months 100.00.33 103.99±.56 95.70±1.20 99.17±2.40 detected 
9 months 98.50±0.61 102.30±0.50 96.40±0.90 99.00±1.90 detected 
12 months 97.90±0.32 100..90±0.60 96.10±1.70 97.90±4.00 detected 
18 months 97.00±0.53 100.00±0.26 95.00±2.10 96.60±.3.20 detected 
24 months 96.00±0.42 98.80±0.88 93.40±0.99 95.40±0.60 detected 
        IP requirement:90-110 of amount stated on label(n=3);bn =6; all brands had satisfactory  physical appearance and passed related substances test (IP requirement:<1.0%) 
        IP requirement for dissolution test >60%  
   
 135
        
 
Table No. (31): Results of post -marketing surveillance of artesunate tablets (AS+SP) (Khartoum round one) 
 
Drug rel  
% 
30 minb. 
D.T(min.d) 
aContent%
(w/w) AC H.F. Supplier Batch No Product 
98.59 ±1.2 9 min [with disc] 103.97±0.44 Working Other Private Company 040901 
Artesumine for 
Adult 
 
95.45± 0.99 8 min [with disc] 99.62 ±0.43 Not Working Community pharmacy Private Company 041201 
95.96 ±2.1 7 min [with disc] 97.93 ±0.5 Not Working Public pharmacy Private Company 040901 
95.17 ±2.3 More than 15 min [with disc] ,  9 min [without disc] 100.62 ±0.7 Not Working Community pharmacy Private Company 040801 Artesumine          
for Children 
94.71 ±1.1 More than 15 min [with disc],  9 min [without disc] 99.96 ±0.43 Not Working Public pharmacy Private Company 040801 
66.09 ±0.98 3 min [with disc] 96.23 ±0.33 Not Working Other CMS 04J06 
Ariplus for Adult 
 
59.54±3.1 6 min [with disc] 99.71 ±0.67 Not Working Public pharmacy CMS 04J11 
62.39 ±2.3 4 min [with disc] 100.5 ±0.77 Not Working Community pharmacy CMS 04J29 
67.47± 2.2 1:15 min 97.37 ±0.45 Working Hospital Private Company 04106 
47.96 ±±3.5 5 min [with disc] 107.11±0.35 Working Other CMS 04K05 
Ariplus for 
Children 
50.29 ±2.2 5 min [with disc] 100.89 ±0.47 Not Working Public pharmacy CMS 04J22 
50.59± 1.4 6 min [with disc] 100.33 ±0.66 Working Community pharmacy CMS 04J22 
80.87±4.1 3:2 min 97.00±0.34 Working Community pharmacy Private Company 02L16 
IP requirement:90-110 of amount stated on label(n=3); bn =6; all brands had satisfactory physical appearance and passed related substances test (IP requirement<1.0%) 
dn=6(  IP requirement <15min).  IP requirement for dissolution test >60% 
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Table No. (32): Results of post -marketing surveillance of artesunate tablets(AS+SP) ( Elgadarif round one) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                    
IP requirement:90-110 of amount stated on label(n=3); bn =6; all brands had satisfactory physical appearance and passed related substances test (IP requirement: <1.0%) 
dn=6(  IP requirement <15min).  IP requirement for dissolution test >60% 
Drug rel  
% 
30 minb. 
D.T (min.d) 
aContent%
(w/w) AC H.F. Supplier Batch No Product 
95.55±1.5 9 min 103.41±0.33 Not Working Community pharmacy Private Company 040901 Artesumine for Adult 
 98.81±2,3 More than 15min [with disc], 9 min [without disc] 100.77±0.43 Working Public pharmacy Private Company 040901 
96.90± 1.2 More than 15min [with disc], 9 min [without disc] 98.92±0.54 Not Working Community pharmacy Private Company 040801 Artesumine for Children. 
 97.07±0.99 More than 15min [with disc], 9:45 min [without disc] 103.17±0.77 Working Public pharmacy Private Company 040901 
53.18±1.9 3 min 99.98±0.46 Working Hospital CMS 04J06 
Ariplus  for Adult 
 
56.78±3-1 2:35 min 101.12±0.66 Working Other CMS 04J29 
56.09±3.3 3:45 min 98.84±0.44 Not Working Other CMS 04J11 
54.64±2.3 3:40 min 98.02±0.46 Working Public pharmacy CMS 04J27 
57.01±1.5 More than 15min [with disc], 3:30 min [without disc] 98.82±0.71 Working Community pharmacy CMS 04J12 
41.66±0.99 4:45 min 100.02±0.5 Working Hospital CMS 04J22 
Ariplus   for Children. 
 
41.0±0.98 5 min 101.61±0.6 Working Other CMS 04J22 
48.75±3.1 5:40 min 101.3±80.34 Not Working Other CMS 04J22 
42.02±0.89 5 min 99.89±0.4 Working Public pharmacy CMS 04J22 
39.91±2.4 6 min 100.25±0.6 Not Working Community pharmacy CMS 04J22 
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           Table No. (33): Results of post -marketing surveillance of artesunate tablets (AS+SP) (Atbara round one) 
              
Drug rel  
% 
30 minb. 
D.T (min.d) 
aContent%
(w/w) AC H.F. Supplier Batch. No Product 
95.50±1.2 8 min [with disc] 97.51 ±0.3 Working Community pharmacy Private Company 041201 
Artesumine for Adult 
 95.50± 0.90 8 min [with disc] 96.91± 0.6 Working Community pharmacy Private Company 041201 
92.10 ±1.6 8 min [with disc] 93.42± 0.4 Working Public pharmacy Private Company 041201 
98.2±3.1 More than 15min[with disc], 8 min [without disc]99.48 ±0.8 Working Community pharmacy Private Company 040901 
Artesumine for Children 
 
56.47± 2.2 5 min [with disc] 97.23 ±0.44 Working Community pharmacy CMS 04J27 Ariplus for Adult 
 62.08 ±1.8 3 min [with disc] 93.11± 0.36 Not Working Public pharmacy CMS 04J29 
50.11 ±1.9 5 min [with disc] 98.58 ±0.33 Working Community pharmacy CMS 04J22 
Ariplus for Children 
 
45.35± 0.88 4 min [with disc] 91.49 ±0.4 Not Working Other CMS 04J22 
47.76± 0.97 6 min [with disc] 100.09 ±0.7 Not Working Public pharmacy CMS 04J22 
IP requirement:90-110 of amount stated on label(n=3); bn =6; all brands had satisfactory physical appearance and passed related substances test (IP requirement: <1.0%) 
dn=6(  IP requirement <15min).  IP requirement for dissolution test >60% 
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  Table No. (34): Results of post -marketing surveillance of artesunate tablets (AS+SP) ( Elobied round one) 
  
Drug rel  % 
30 minb. D.T (min.
d) 
aContent% 
(w/w) AC H.F. Supplier Batch. No Product 
96.79±3.2 
More than 15min 
[with disc], 10 min 
[without disc] 
100.63±0.44 Not Working Hospital Private Company 040901 Artesumine for Adult  
57.04±1.9 4 min 98.33±0.5 Not Working Hospital CMS 04J11 
Ariplus for Adult 
 
58.21±1.98 5 min 99.17±0.6 Working Community pharmacy CMS 04J13 
46.03±0.99 5 min 97.72±0.35 Not Working Hospital CMS 04J22 
Ariplus for Children 40.03±1.4 4:40 min 100.0±0.77 Not Working Community pharmacy CMS 04J22 
49.29±4.1 5 min 100.50±0.67 Working Public pharmacy CMS 04K04 
              IP requirement:90-110 of amount stated on label(n=3); bn =6; all brands had satisfactory physical appearance and passed related substances test (IP requirement<1.0%) 
                         dn=6(  IP requirement <15min).  IP requirement for dissolution test >60% 
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Table No. (35): Results of post -marketing surveillance of artesunate tablets (AS+SP) ( Khartoum round two) 
 
Drug rel  
% 
30 minb. 
D.T (min.d) 
aContent%
(w/w) AC H.F. Supplier Batch  No. Product 
96.00±1.1 After 15 min 4 tabs remained [with disc]  Dis after 9:4 min [without disc]99.68±0.33 Working Hospital Private Company 041201 
Artesumine for Adult 
96.51±1.2 After 15 min one tab remained [with disc]  Dis after 9:45 min [without disc]98.42±0.4 Working Community  pharmacy Private Company 041201 
97.75±2.3 After 15 min one tab remained [with disc]  Dis after 8:50 min [without disc]101.00±0.6 Working Community  pharmacy Private Company 040901 
98.32±0.9 After 15 min one tab remained [with disc]  Dis after 9:50 min [without disc]100.3±0.5 Working Public pharmacy Private Company 041201 
61.49±2.4 3 min [with disc] 98.43±0.3 Working Community  pharmacy CMS 05C29 
Ariplus for Adult  
64.89±1.1 2 min [with disc] 100.95±0.9 Working Public pharmacy Private Company 04J29 
69.92±1.1 3:17 min [with disc] 96.82±0.66 Working Community  pharmacy CMS 05C23 
60.88±2.5 3:19 min [with disc] 98.44±0.4 Working Public pharmacy CMS 05C23 
52.84±1.3 3:8  min [with disc] 97.2±0.8 Working Community  pharmacy CMS 05001 
55.71±4.1 4   min [with disc] 98.5±0.4 Working Hospital CMS 05005 
45.68±2.5 4:30 min [with disc] 98.2±0.43 Working Community  pharmacy Private Company 04K04 
Ariplus for Children 
43.79±2.3 4:20 min [with disc] 100.09±0.4 Working Community  pharmacy CMS 04J22 
81.02±1.4 2:35 min [with disc] 93.16±.06 Working Community  pharmacy Private Company 04106 
45.08±0.9 3:35  min [with disc] 98.17±0.5 Working Public pharmacy Private Company 04J22 
80.38±3.1 32 Sec [with disc] 98.89±0.7 Working Hospital Private Company E1033 
Artemal for Adult 84.41±2.1 35 Sec [with disc] 96.18±0.5 Not Working Public pharmacy Private Company F0278 
86.21±3.1 40 Sec [with disc] 95.7±0.44 Working Community  pharmacy Private Company E1027 
89..90±1.5 32 Sec [with disc] 95.01±0.50 Working Hospital Private Company E1043 
Artemal for Child 
 89.97±2.2 50 Sec [with disc] 96.00±0.6 Working Community  pharmacy Private Company E1043 
90.83±1.9 45 Sec [with disc] 94.64±0.44 Working Public pharmacy Private Company E1041 
              IP requirement:90-110 of amount stated on label(n=3); bn =6; all brands had satisfactory physical appearance and passed related substances test (IP requirement: <1.0%) 
                     dn=6(  IP requirement <15min).  IP requirement for dissolution test >60% 
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          Table No. (36): Results of post -marketing surveillance of artesunate tablets(AS+SP)( Elgadarif round two) 
          
           IP requirement:90-110 of amount stated on label(n=3); bn =6; all brands had satisfactory physical appearance and passed related substances test (IP requirement: <1.0%) 
                dn=6(  IP requirement <15min).  IP requirement for dissolution test >60% 
Drug rel  
% 
30 minb. 
D.T (min.d) 
aContent% 
(w/w) AC H.F. Supplier Batch No. Product 
96.66±2.1 7:30 min [with disc] 98.54±0.33 Working Community  pharmacy Private Company 050610 Artesumine for Adult 
 94.18±1.3 7:43 min [with disc] 100.74±0.5 Working Community  pharmacy Private Company 050610 
96.65±2.1 10 min [with disc] 107.32±0.6 Not Working Community  pharmacy Private Company 050608 
Artesumine for 
Children 
 
 
95.40±3.1 After 15 min 2 tabs remained [with disc]  Dis after 9 min [without disc] 99.60±0.43 Not Working Hospital Private Company 050608 
101.5±3.2 After 15 min one tab remained [with disc] Dis after 9:10 min [without disc] 103.74±0.8 Not Working Other Private Company 050608 
95.63±1.1 14 min [with disc] 103.13±0.4 Not Working Other Private Company 041101 
94.15±1.4 After 15 min 2 tab remained [with disc]  Dis after 10:30 min [without disc] 100.96±0.4 Working Public pharmacy Private Company 041101 
95.40±0.9 one tab remained [with disc]  Dis after 9min [without disc] 104.43±0.8 Working Community  pharmacy Private Company 050608 
99.98±0.8 2 tabs  remained After 15 min [with disc]  Dis after 8:45 min [without disc] 103.57±0.6 Working Drug store Private Company 050608 
71.14±1.1 1:45 min [with disc] 95.81±.0.45 Working Community  pharmacy Private Company 04J29 
Ariplus for  Adult 
 
59.69±±1.4 2:19 min [with disc] 99.74±0.6 Not Working Hospital CMS 04J12 
62.56±2.1 2:55 min [with disc] 95.49±0.4 Not Working Other CMS 05C23 
53.71±0.8 3:15 min [with disc] 91.49±0.6 Working Public pharmacy CMS F0618 
45.53±1.5 2:00 min [with disc] 93.04±0.8 Working Community  pharmacy Private Company 04J22 Ariplus  for Children  
94.25±1.7 52 Sec [with disc] 96.48±0.4 Working Community  pharmacy Private Company F0622 
Artemal  for Adult 
 
89.27±0.8 49 Sec [with disc] 101.78±0.5 Working Public pharmacy CMS F0618 
95.47±2.1 After 15 min one tab remained [with disc]Dis after 9:48 min [without disc] 98.25±0.7 Working Community  pharmacy Private Company 050610 
93.06±1.1 37 Sec [with disc] 101.53±0.3 Working Community  pharmacy Private Company E1045 Artemal for  Children 
 
 93.81±0.7 33 Sec  [with disc] 100.67±0.7 Working Public pharmacy Private Company E1039 
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            Table No. (37): Results of post- marketing- surveillance of artesunate tablets (AS+SP) ( Atbara round two)  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                IP requirement:90-110 of amount stated on label(n=3); bn =6; all brands had satisfactory physical appearance and passed related substances test (IP requirement: <1.0%) 
                          dn=6(  IP requirement <15min).  IP requirement for dissolution test >60% 
 
Drug rel  
% 
30 minb. 
D.T (min.d) 
aContent% 
(w/w) AC H.F. Supplier Batch No. Product 
75.56±1.1 After 15 min 5 tab remained [with disc]  
Dis after8:40  min [without disc] 
99.20 ±0.6 Working Community pharmacy Private Company 041201 Artesumine for Adult 
100±1.4 
After 15 min 3 tab remained [with disc] 
Dis after 8:20 min [without disc] 
102.32±0.4 Working Community pharmacy Private Company 040901 
Artesumine for 
Children 
42.33±2.4 4 min [with disc] 97.80±0.33 Working Hospital CMS 05011 
Ariplus for  Adult 
 
48.06±3.1 4:20 min [with disc] 96.81±0.8 Working Community pharmacy CMS 05C29 
47.13±4.1 4 min [with disc] 102.27±0.6 Not Working Community pharmacy CMS 
05001 
52.33±2.2 3:45 min [with disc] 98.21±0.5 Working Public pharmacy CMS 05005 
54.73±0.9 3:30 min [with disc] 99.72±0.4 Working Drug Store CMS 05C23 
94.59±0.8 
After 15 min 2 tab remained [with disc]  
Dis. after 9 min [without disc] 
100.79±0.23 Working Hospital Private Company 040901 
Ariplus for Children 
 
44.82±1.3 4 min [with disc] 97.27±0.6 Working Other CMS 04K04 
41.72±2.1 4:25 min [with disc] 97.76±0.6 Working Community pharmacy Private Company 04K05 
45.73±1.5 4:45 min [with disc] 101.19±0.7 Working Public pharmacy CMS 04K04 
77.57±2.5 30 Sec [with disc] 98.58±0.5 Working Community pharmacy Private Company E1029 
Artemal for Adult 
 96.50±2.3 30 Sec [with disc] 98.23±0.4 Not Working Public pharmacy Private Company E1031 
93.00±1.9 1:15 min [with disc] 96.75±0.33 Working Drug Store Private Company E1041 Artemal  for  Children  
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Table No. (38): Results of post -marketing surveillance of artesunate tablets (AS+SP) ( Elobied round two) 
 D
rug rel  
% 
30 minb. 
D.T (min.d) 
aContent%
(w/w) AC H.F. Supplier Batch No. Product 
96.07±1.3 
1 tab remain After 15 min  
[with disc]  Dis after 10:15 
min [without disc] 
96.42±0.5 Not Working Community  pharmacy Private Company 041201 
Artesumine for Adult 96.58±2.2 
1 tab remain After 15 min  
[with disc]  Dis after 9:35 
min [without disc] 
97.95±0.7 Not Working Other Private Company 041201 
98.71±2.3 
1 tab remain After 15 min  
[with disc]  Dis after 9:45 min 
[without disc] 
99.33±0.8 Working Hospital Private Company 041201 
93.55±1.4 
1 tab remain After 15 min  
[with disc]  Dis after 8:45 min 
[without disc] 
95..55±0.33 Not Working Community  pharmacy Private Company 050608 
Artesumine for 
Children 
 
96.51±1.5 
1 tab remain After 15 min  
[with disc]  Dis after 8:45 min 
[without disc] 
98.53±0.5 Not Working Hospital Private Company 040801 
98.31±3.1 
1 tab remain After 15 min  
[with disc]  Dis after 8:30 
min [without disc] 
98.35±0.7 Not Working Hospital Private Company 050608 
96.72±2.1 
1 tab remain After 15 min  
[with disc]  Dis after 10 min 
[without disc] 
97.73±0.4 Not Working Public pharmacy Private Company 041101 
92.77±0.9 11 min  [with disc] 95.62±0.6 Not Working Hospital Private Company 041201 
Artemal for Adult 
 83.61±2.2 32 Sec [with disc] 93.82±0.3 Not Working Hospital Private Company E1033 
84.29±3.2 33 Sec [with disc] 90.68±0.7 Not Working Community  pharmacy Private Company E1033 
89.1±1.7 50 Sec [with disc] 94.98±0.8 Not Working Public pharmacy Private Company E1039 Artemal for Children 
 88.39±1`.9 44 Sec [with disc] 94.71±0.6 Not Working Community  pharmacy Private Company E1039 
46.32±3.1 3:30 min [with disc] 95.72±0.4 Not Working Other Private Company 04J22 Ariplus for Children  
52.79±1.1 2:25  min [with disc] 96.16±0.8 Working Public pharmacy CMS 05005 Ariplus for Adult 
                    IP requirement:90-110 of amount stated on label(n=3); bn =6; all brands had satisfactory physical appearance and passed related substances test (IP requirement: <1.0%) 
                              dn=6(  IP requirement <15min).  IP requirement for dissolution test >60% 
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    Table No. (39): Results of post- marketing surveillance of artesunate tablets (AS+SP) (Khartoum round three)  
 
Drug rel  
% 
30 minb. 
D.T (min.d) 
 
aContent% 
(w/w) 
 
AC H.F. Supplier Batch No. Product 
59.32±1.2 18 Sec  [with disc] 94.27±0.5 Working Community  pharmacy CMS P0555C 
Combisunate for Adult 
 54.71±2.3 12 Sec min  [with disc] 89.40±0.6 
Working Hospital CMS P0595C 
52.90±2.5 10 Sec  [with disc] 87.46±0.7 Working Public pharmacy 
CMS P0585C 
90.91±1.9 48 Sec [with disc] 97..33±0.5 Working Public pharmacy 
Private 
Company E1039 
Artemal for Children 
 
90.435±2.7 3 min  [with disc] 96.68±0.4 Not Working Community  pharmacy 
Private 
Company E1043 
92.91±0.9 1:50 Sec [with disc] 98.73±0.33 Working Public pharmacy 
CMS F1025 
91.03±3.1 2 min  [with disc] 94..92±0.4 Working Public pharmacy 
Private 
Company F1025 
91.43±2.4 55 Sec  [with disc] 96..30±0.5 Working Community  pharmacy 
Private 
Company F1017 Artemal for Adult 
 83..84±1.7 1:52 min  [with disc] 97..97±0.6 Working Public pharmacy 
CMS F1021 
94.025±2.1 7 min  [with disc] 102.19±0.4 Working Community  pharmacy 
Private 
Company 051115 Artesumine for Adult 
 82.51±4.1 6:9 min [with disc] 99..36±0.34 Working Public pharmacy 
Private 
Company 050610 
95.13±2.3 9 min  [with disc] 105.63±0.6 Working Public pharmacy 
Private 
Company 051114 Artesumine for Children 
 96.18±0.9 7:33 min  [with disc] 98..85±0.8 Working Community  pharmacy 
Private 
Company 051114 
                   IP requirement:90-110 of amount stated on label(n=3); bn =6; all brands had satisfactory physical appearance and passed related substances test (IP requirement<1.0%) 
                          dn=6(  IP requirement <15min).  IP requirement for dissolution test >60% 
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             Table No. (40): Results of post- marketing surveillance of artesunate tablets (AS+SP) (Elgadarif round three) 
Drug rel  % 
30 minb. D.T (min.
d) 
 
aContent% 
(w/w) 
 
AC H.F. Supplier Batch No. Product 
91.46±1.1 13 min  [with disc] 104.21±0.4 Working Public pharmacy Private Company 050909 
Artesumine  for Children 
 100.63±3.1 10:12 min  [with disc]98.41±0.7 Not Working Other Private Company 050608 
90.48±1.5 9:39 min  [with disc]102.62±0.4 Working Community  pharmacy Private Company 050909 
94.27±1.8 11 min  [with disc] 108.06±0.7 Working Community  pharmacy Private Company 051115 Artesumine  for Adult 
 96.23±1.7 10 min  [with disc] 101.47±0.4 Working Public pharmacy Private Company 050610 
85.16±2.1 2:10 min  [with disc]101.18±0.3 Not Working Community  pharmacy Private Company F1025 Artemal  for Children 
 94.57±2.2 2 min  [with disc] 104.66±0.4 Working Public pharmacy CMS F1025 
49.48±1.5 30 Sec  [with disc] 94.11±0.9 Working Public pharmacy CMS P0555C 
Combisunate for Adult 
 
53.70±1.4 48 Sec  [with disc] 90.55±0.8 Not Working Other CMS P0575C 
53.53±2.1 23 Sec  [with disc] 89.92±0.4 Not Working Community  pharmacy CMS P0575C 
55.23±1.1 20 Sec  [with disc] 91.40±0.6 Not Working Community  pharmacy CMS P0585C 
92.19±0.9 7:27 min  [with disc]100.87±0.4 Not Working Other Other 051111 
Artescope for Adult 
 
90.27±0.9 15 min  [with disc] 105.21±0.8 Not Working Drug Store Other 051111 
90.84±2.2 8:11 min  [with disc]99.69±0.4 Not Working OtherOther 051106 
89.78±3.2 7:23 min  [with disc]100.04±0.3 Working Hospital Other 051106 
100.03±1.4 8 min  [with disc] 103.12±0.6 Not Working Other Other 051018 
Artescope for Children 
 
94.90±1.3 13 min  [with disc] 99.67±0.4 Not Working Other Other 051013 
99.00±2.3 14 min  [with disc] 100.00±0.7 Working Hospital Other 051020 
97.25±2.1 14:2 min  [with disc]105.20±0.8 Not Working Drug Store Other 051018 
                      IP requirement:90-110 of amount stated on label(n=3); bn =6; all brands had satisfactory physical appearance and passed related substances test (IP requirement: <1.0%) 
                                dn=6(  IP requirement <15min).  IP requirement for dissolution test >60% 
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   Table No. (41):  Results of post- marketing surveillance of artesunate tablets (AS+SP) (Atbara round three) 
 
Drug rel  
% 
30 minb. 
D.T (min.d) 
 
aContent%
(w/w) 
 
AC H.F. Supplier Batch No. Product 
94.38±1.1 4 Sec  [with disc] 101.6±0.5 Not Working Other CMS F1019 Artemal  for Adult 
 93.61±3.2 1.5 min  [with disc] 98.98±0,3 Not Working Public pharmacy Private Company F1019 
100.18±2.2 52 Sec  [with disc] 107.04±0.7 Not Working Other CMS F1023 
Artemal  for Children 
 96.19±3.1 1.5 min  [with disc] 102.59±0.6 Working 
Community  
pharmacy Private Company F1023 
91.01±1.4 50 Sec  [with disc] 103.08±0.5 Not Working Public pharmacy Private Company F1025 
53.14±0.9 36 Sec  [with disc] 86.19±0.3 Not Working Public pharmacy CMS P0595C 
Combisunate for Adult 
 
47.82±1.8 40 Sec [with disc] 92.21±0.6 Not Working Other CMS *P0595C 
49.52±0.9 42 Sec  [with disc] 93.21±0.7 Working Community  pharmacy CMS P0585C 
51.29±2.2 40 Sec [with disc] 93.21±0.4 Working Hospital CMS P0585C 
94.61±4.1 13  min  [with disc] 94.84±0.6 Working Public pharmacy Private Company 050909 
Artesumine for Children 
 
95.75±2.4 12 min  [with disc] 100.89±0.8 Not Working Public pharmacy Private Company 050704 
103.61±3.3 7 min  [with disc] 104.24±0.3 Not Working Community  pharmacy 
Private Company 051114 
89.59±2.3 12 min  [with disc] 101.89±0.6 Not Working Community  pharmacy 
Private Company 051209 Artesumine  for Adult 
 98.38±3.2 11 min  [with disc] 102.38±0.4 Working Public pharmacy Private Company 051115 
                     IP requirement:90-110 of amount stated on label(n=3); bn =6; all brands had satisfactory physical appearance and passed related substances test (IP requirement: <1.0%) 
                               dn=6(  IP requirement <15min).  IP requirement for dissolution test >60%.      *=not comply physical appearance 
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Table No. (42):  Results of post- marketing surveillance of artesunate tablets (AS+SP) ( Elobied round three) 
 
  
Drug rel  
% 
30 minb. 
D.T (min.d) 
aContent%
(w/w) AC H.F. Supplier Batch No. Product 
90.74±1.0 9 min  [with disc] 99.60±0.3 Not Working Drug Store Other 051106 
Artescope for Adult 
 
92.04±2.1 11:20 min  [with disc] 102.14±0.4 Working Drug Store Other 051110 
94.11±2.2 10 min  [with disc] 100.50±0.6 Not Working Hospital Other 051021 
101.33±1.3 After 15 min  [with disc]  Dis after 9:40 min [without disc] 107.80±0.7 Not Working Other Other 051021 
93.77±1.4 9 min  [with disc] 100.50±0.7 Not Working Other Other 051111 
100.8±`0.3 After 15 min  [with disc]  9:52 min [without disc] 101.70±0.3 Not Working Hospital Other 051018 
Artescope for 
Children 
 
95.42± 2.3 9:13 min  [with disc] 102.20±0.4 Not Working Drug Store Other 051018 
96.80±1.6 After 15 min  [with disc]  Dis after 10:20 min [without disc] 105.23±0.9 Working Drug Store Other 051009 
94.54±3.1 10 min  [with disc] 104.1±0.5 Not Working Other Other 051018 
101.51±1.1 After 15 min  [with disc]  Dis after 11 min [without disc] 105.21±0.6 Not Working Other Other 051013 
96.45±0.9 2 min  [with disc] 101.32±0.4 Working Community  pharmacy Private Company F1021 
Artemal for Adult 
 
91.68±2.2 1:52 min  [with disc] 97.03±0.3 Working Community  pharmacy Private Company G0228 
Artemal  for Children 
 
82.43±3.1 10 min  [with disc] 98.00±0.7 Not Working Community  pharmacy Private Company 051209 Artesumine for Adult 
 89.97±4.1 10:35 min  [with disc] 102.14±0.3 Working Community  pharmacy Private Company 051209 
87.61±1.1 13:55 min  [with disc] 101.10±0.8 Not Working Community  pharmacy Private Company 051114 Artesumine for Children 
 97.11±2.2 7 min  [with disc] 104.18±0.6 Working Community  pharmacy Private Company 051114 
                       IP requirement:90-110 of amount stated on label(n=3); bn =6; all brands had satisfactory physical appearance and passed related substances test (IP requirement: <1.0%) 
                                    dn=6(  IP requirement <15min).  IP requirement for dissolution test >60% 
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 Table No. (43):  Results of post -marketing surveillance of artesunate tablets(AS+SP) (Khartoum round four) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                   IP requirement:90-110 of amount stated on label(n=3); bn =6; all brands had satisfactory physical appearance and passed related substances test (IP requirement<1.0%) 
                            dn=6(  IP requirement <15min).  IP requirement for dissolution test >60% 
Drug rel  % 
30 minb. D.T (min.
d) 
aContent% 
(w/w) AC H.F. Supplier Batch  No. Product 
85.68±1.1 9 min with disc 103.47±0.3 Working Public pharmacyPrivate companyLS 060602 
Artesumine  for 
Adult 
 
90.84±2.1 8:20   min with disc 109.68±0.4 Working Hospital Private companyLS 060602 
83..93±3.1 12 Min  with disc 101.14±0.8 Not working Community pharmacy Private companyLS 060301 
91.77±2.3 51 sec with disc 104.61±0.4 Working Public pharmacyPrivate companyG 0228 
Artesumine for 
Children 
 
91.76±3.3 14min with disc 101.69±0.6 Not working Hospital Private company051208 
92.02±1.8 After 15 min one tab remained with disc ,disc after 9:1 min without disc 105.26±0.4 Not working
Community 
pharmacy Private company051114 
91.03±3.2 4 sec with disc 101.12±0.33 Not workingCommunity pharmacy Private companyF 1017 Artemal   for Adult 
 79.40±2.1 10 sec with disc 95.65±o.5 Not working Other Private companyF 1017 
94.61±1.1 40 sec with disc 109.5±0.8 Working Community pharmacy Private companyF 1025 
Artemal   for 
Children 
 
79.74±4.1 7 min with disc 96.22±0.5 Not workingCommunity pharmacy Private company060624 
ASP  for Adult 
 
80.00±1.9 8 min with disc 98.99±0.3 Not workingDrug store Private company060624 
65.45±2.5 10 min with disc 98.08±0.5 Not workingOther Private company060523 
61.64±2.2 8 min with disc 94.00±0.7 Not working Other Private company060528 
66.82±2.3 13 min with disc 97.65±0.3 Not workingDrug store Private company060806 ASP for Children 
 79.08±1.5 15 min with disc , 99.46±9.5 Not working Community pharmacy Private company060610 
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                  Table No. (44): Results of post- marketing surveillance of artesunate tablets (AS+SP) (Atbara round four) 
 
Drug rel  
% 
30 minb. 
D.T (min.d) 
aContent% 
(w/w) AC H.F. Supplier Batch  No. Product 
70.87±1.1 12  min with disc 99.83±0.6 Not working Other CMS 060806 
ASP for Children 
 
77.98±1.3 13 min with disc 96.69±0.4 working Drug store CMS 060610 
62.81±2.1 14 min with disc 99.96±0.5 Not working Drug store CMS 060517 
73.04±0.9 15 min with disc 96..36±0.8 Not working Other CMS 061005 
75.99±2.2 7 min with disc 97.18±0.3 Not working Other CMS 060619 
ASP for Adult 
 
70.49±4.1 11 min with disc 101.64±0.4 Not working Drug store CMS 060101 
68.27±3.3 8 min with disc 95..27±0.3 Not working Community pharmacy CMS 060615 
68.11±1.3 8 min with disc 96.74±0.5 Working Drug store CMS 060629 
82.83±2.3 4 sec with disc 95.6o±0.6  Not working Other CMS F 1021 Artemal  for Adult 
 81.17±2.2 6sec with disc 98..36±0.3 Not working Public pharmacy CMS F 1019 
77.88±1.5 5 sec with disc 101.40±0.6 Not working Community pharmacy CMS F 1169 
90.85±1.9 50 sec with disc 95.06±0.5 Not working Other CMS F 1023 
Artemal  for Children 
 93.93±4.2 45 sec with disc 100.34±0.7 Not working Hospital CMS F 1023 
90.95±2.2 50 sec with disc 95.16±0.4 Not working Community pharmacy CMS G 0226 
80.43±3.4 
After 15 min one 
tab remained with 
disc ,after 7 min 
without disc 
97.77±0.8 Not working Community pharmacy Private company 051114 
Artesumine for 
Children 
 
73.65±4.1 8 min with disc 96.19±0.3 Not working Other Private company 051115 Artesumine  for Adult 
 90.0 ±2.3 9 min with disc 99.01±0.4 Not working Community pharmacy Private company 051209 
                        IP requirement:90-110 of amount stated on label(n=3); bn =6; all brands had satisfactory physical appearance and passed related substances test (IP requirement<1.0%) 
                                    dn=6(  IP requirement <15min).  IP requirement for dissolution test >60% 
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  Table No. (45):  Results of post -marketing surveillance of artesunate tablets(AS+SP) ( Elobied round four) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                    IP requirement:90-110 of amount stated on label(n=3); bn =6; all brands had satisfactory physical appearance and passed related substances test (IP requirement: <1.0%) 
                              dn=6(  IP requirement <15min).  IP requirement for dissolution test >60% 
 
Drug rel  
% 
30 minb. 
D.T (min.d) 
aContent% 
(w/w) AC H.F. Supplier Batch No. Product 
86.56±2.2 8:20 min with disc 100.27±0.3 Not working Public pharmacy Private company 051208 
Artesumine 
for children 
95.45±2.1 After 15 min one tab remained with disc ,after 7min without disc 100.58±0.4 working 
Community 
pharmacy Private company 051114 
90.87±2.2 After 15 min one tab remained with disc ,after 10 min without disc 100.3±0.6 Not working Hospital Private company 051114 
59.77±3.2 8 min with disc 96.34±0.7 Not working Public pharmacy Private company 060528 ASP  for Adult 
 59.61±4.1 9 min with disc 94.13±0.4 Not working Community pharmacy Private company 060528 
84.75±1.1 12 min with disc 102.0±0.7 Not working Hospital Private company 050610 
Artesumine Adult 
94.99±2.1 11 min with disc 98.61±0.3 working Community pharmacy Private company LS 060301 
96.91±3.1 51 sec with disc 98.20±0.4 Not working Community pharmacy Private company G 0228 
Artemal  for  Children 86.1±3.3 40 sec with disc 96.49±0.5 Not working Public pharmacy Private company 00226 
88.6±3.4 44 sec with disc 97.03±0.7 Not working Community pharmacy CMS F1023 
86.66±1.4 7 min with disc 100.13±0.3 Not working Hospital Other 051106 
Artecospe for Adult 
 
90.3±1.2 10 min with disc 97.83±0.6 Not working Other Other 051021 
99.05±1.1 8 min with disc 100.33±0.4 Working Drug store Other 051021 
90.0±70.9 9 min with disc 97.78±0.7 Not working Drug store Other 051106 
95.05±2.4 8min with disc 97.42±0.4 Not working Hospital Other 051013 
Artecospe for Children 
 
98.7±2.2 After 15 min one tab remained with disc ,after 7 min without disc 99.62±0.3 Working Drug store Other 051013 
94.72±1.7 After 15 min one tab remained with disc ,after 10 min without disc 98.69±0.5 Not working Other Other 051013 
98.71±1.9 After 15 min one tab remain with disc ,after 9 min without disc 99.89±0.3 Not working Drug store Other 05009 
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         Table No. (46):  Results of post -marketing surveillance of artesunate tablets (AS+SP) ( Khartoum round five) 
 
Drug rel  % 
30 minb. D.T (min.
d) 
aContent%
(w/w) AC H.F. Supplier Batch No. Product 
82.08± 2.7 10  min with disc 97.22±0.4 working Public pharmacy CMS 060625 
ASP for Adult 
 74.1 ±3.2 12 min with disc 94.44±0.7 working Community pharmacy Private company 060621 
73.41±  1.3 12 min with disc 95.09±0.5 working Drug store CMS 060624 
68.25 ±2.2 12:45 min with disc 93.69±0.3 working Public pharmacy CMS 061006 
ASP for Children 
 
87.32 ±1.9 13 min with disc 98.3±0.5 working Community pharmacy CMS 060901 
84.07 ±1.7 13 min with disc 96.26±0.3 working Hospital Private company 060610 
67.58 ±1.5 13 min with disc 93.78±0.6 working Drug store Private company 060806 
89.82 ± 3.3 9 min with disc 100.81±0.4 working Public pharmacy Private company LS061201 Artesumine for Adult 
 93.29± 3.2 8:45 min with disc 99.13±0.8 working Community pharmacy Private company LS061201 
88.70 ± 0.9 10 min with disc 102.21±0.5 Not working Public pharmacy Private company 051208 
Artesumine for Children 
 93.45 ± 1.1 11 min with disc 96.98±0.4 Not working Community pharmacy Private company 051208 
94.22 ±4.1 9:30 min with disc 101.57±0.3 working Drug store Private company 041101 
76.68 ±2.1 2:20 min with disc 95.1±0.4 working Community pharmacy CMS G0220 Artemal  for Adult  
82.08±2.1 2:00 min with disc 97.44±0.6 working Community pharmacy Private company G0226 Artemal for Children  
                         IP requirement:90-110 of amount stated on label(n=3); bn =6; all brands had satisfactory physical appearance and passed related substances test (IP requirement: <1.0%) 
                                    dn=6(  IP requirement <15min).  IP requirement for dissolution test >60% 
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                   Table No. (47):  Results of post- marketing surveillance of artesunate tablets (AS+SP) ( Elgadarif round five) 
 
Drug rel  
% 
30 minb. 
D.T (min.d) 
aContent%(w
/w) 
 
AC H.F. Supplier Batch No. Product 
88.70±2.1 13.00 min with disc 99.64±0.4 Not working Hospital Other 051021 
Artescope for 
Adult 
 
85.52±1.3 14.2 min with disc 97.84±0.3 Not working Other Other 051021 
83.68±2.5 9.23 min with disc 98.00±0.6 working Hospital Other 05102 
84.60±2.2 14.35 min with disc 98.68±0.4 Not working Drug store Other 051021 
97.61± 3.2 14:00 min with disc 99.5±0.7 Not working Other Other 051018 
Artescope for 
Children 
 
94.71±3.1 9:00 min with disc 101.56±0.3 working Hospital Other 051009 
94.25± 4.1 8 min with disc 98.56±0.4 Not working Drug store Other 051013 
93.44 ±3.5 7:45 min with disc 101.18±0.3 Not working Other Other 051013 
99.35± 1.1 9:55 min with disc 100.5±0.6 Not working Hospital Other 051018 
81.63 ±2.1 11 min with disc 98.64±0.9 working Community pharmacy Private company LS061201 
Artesumine 
for Adult  86.67± 0.9 11:20 min with disc 99.96±0.3 working Community pharmacy Private company LS061201 
87.08 ±0.8 9 min with disc 99.06±0.30. working Public pharmacy Private company 050908 
95.5± 1.1 10 min with disc 97.0±0.5 working Community pharmacy Private company LS060401 
Artesumine 
for Children 100.66± 0.7 10:1 min with disc 101.40.±0.6 working Community pharmacy Private company LS060401 
99.7± 0.6 8:33 min with disc 100.8±0.3 working Public pharmacy Private company 051208 
69.6± 0.9 2 min with disc 97.3±60.5 working Community pharmacy Private company F1169 Artemal for 
Adult 69.01± 4.2 3 min with disc 98.5±0.8 working Community pharmacy Private company G0220 
75.32 ±1.1 2:5 min with disc 93.99±-0.3 working Community pharmacy Private company G0228 Artemal for Children 
69.35± 1.2 13 min with disc 98.05±0.6 Not working Drug store CMS 060529 ASP for 
Adult 68.62 ±2.2 11:81 min with disc 96.27±0.7 Not working Hospital CMS 060529 
              IP requirement:90-110 of amount stated on label(n=3); bn =6; all brands had satisfactory physical appearance and passed related substances test (IP requirement: <1.0%) 
                                    dn=6(  IP requirement <15min).  IP requirement for dissolution test >60% 
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Table No. (48): Results of post -marketing surveillance of artesunate tablets (AS+SP) (Atbara round five) 
 
Drug rel  
% 
30 minb. 
D.T (min.d) 
aContent%(w
/w) AC H.F. Supplier Batch No. Product 
92.40 ±2.1 14:00  min with disc 100.10±0.7 Not working Drug store Other LS060903 
Artescope for Adult 
 94.82± 2.2 9:30 min with disc 99.78±0.5 working Hospital Other LS060903 
91.27 ±1.6 11:2 min with disc 101.61±0.4 working Other Other LS060903 
80.08 ±1.8 10:00 min with disc 91.50±0.8 Not working Drug store Other LS060902 
Artescope for Children 
 101.45±3.2 8:00 min with disc 102.57±0.3 working Hospital Other LS060902 
93.24 ±3.1 8:15 min with disc 104.02±0.5 working Other Other LS060902 
70.33 ±4.1 7:45 min with disc 98.39±0.6 working Drug store CMS 060614 
ASP for Adult 
 74.62 ±1.1 13  min with disc 97.74±0.4 Not working Community pharmacy CMS 060615 
73.87 ±3.1 9 min with disc 97.19±0.4 working Public pharmacy CMS 060621 
82.87 ±2.2 11 min with disc 96.63±0.5 working Public pharmacy CMS 060901 
ASP for Children 
 82.89± 2.3 11 min with disc 94.01±0.3 Not working Community pharmacy CMS 060901 
75.83± 2.2 10 min with disc 94.83±0.3 working Drug store CMS 061005 
91.34 ±0.9 11 min with disc 102.62±0.7 working Public pharmacy Private company LS060902 Artesumine for Adult  
96.27 ±1.9 9 min with disc 99.59±0.5 working Public pharmacy Private company 051208 Artesumine Children  
91.08 ±2.8 2  min with disc 98.38±0.5 working Other Private company F023 Artemal  for Children  
                        IP requirement:90-110 of amount stated on label(n=3); bn =6; all brands had satisfactory physical appearance and passed related substances test (IP requirement: <1.0%) 
                                    dn=6(  IP requirement <15min).  IP requirement for dissolution test >60% 
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Table No. (49):  Results of post- marketing surveillance of artesunate tablets (AS+SP) ( Elobied round five) 
 
Drug rel  
% 
30 minb. 
D.T (min.d) 
aContent%
(w/w) 
 
AC H.F. Supplier Batch No. Product 
94.82±0.3 12:00  min with disc 100.29±2.1 Not working Hospital Other 051106 
Artescope for Adult 
 
91.24±2.1 10 min with disc 97.59±0.9 Not working Other Other LS070205 
95.09±1.5 12:22 min with disc 96.65±0.5 Not working Other Other LS070203 
91.59±1.6 13 min with disc 96.29±0.6 Not working Drug store Other LS070203 
90.13±2.3 11 min with disc 97.06±0.3 Not working Hospital Other 051013 
Artescope for 
Children 
 
96.11±1.5 10:30 min with disc 95.96±0.6 Not working Other Other 051020 
95.79±2.2 13 min with disc 96.72±0.2 Not working Other Other 051018 
91.66±3.3 10 min with disc 98.62±0.2 Not working Drug store Other LS070301 
93.31±1.8 11 min with disc 98.16±0.3 working Community pharmacy Private company LS061201 Artesumine for Adult 
 88.58±2.2 11min with disc 98.40±0.8 working Other Private company LS060301 
100.15±4.1 9 min with disc 105.81±0..9 working Other Private company 051114 Artesumine for 
Children 
 
96.79±1.1 10 min with disc98.16±0.2 workingHospital CMS051114 
96.13±2.2 11  min with disc 99.08±0.4 working Community pharmacy Private company LS060401 
81.78±4.1 2:30  min with disc 99.43±0.2 working Community pharmacy Private company F1021 Artemal for Adult  
86.92±3.1 3 min with disc 92.9±0.3 Not working Community pharmacy Private company G0228 Artemal for Children 
 81.14±1.1 2 min with disc 101.92±0.4 working Hospital CMS G0228 
79.56±1.2 13:50 min with disc 96.53±0.6 Not workingHospital CMS 060624 ASP Adult 
 75.47±1.7 13 min with disc 93.23±0.7 working Community pharmacy CMS 060615 
75.01±2.8 14 min with disc 97.9±0.8 Not working Hospital CMS 061005 ASP for Children 
 86.25±1.1 12  min with disc 93.23±0.3 working Community pharmacy CMS 060901 
                        IP requirement:90-110 of amount stated on label(n=3); bn =6; all brands had satisfactory physical appearance and passed related substances test (IP requirement: <1.0%) 
                                    dn=6(  IP requirement <15min).  IP requirement for dissolution test >60% 
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 Table No. (50):  Results of post -marketing surveillance of artesunate tablets (AS+SP) ( Khartoum round six) 
 
Drug rel  % 
30 minb. D.T (min.
d) 
aContent%
(w/w) AC H.F. Supplier Batch No. Product 
92.12±1.0 11 min with disc 101.23±0.5 Not working Other Other LS060902 
ASP for Children 
 
83.91±1.1 11 min with disc 100.55±0.3 working Public Pharmacy CMS 061004 
84.41±2.4 10 min with disc 94.81±0.4 working Hospital CMS 061010 
82.86±2.4 13 min with disc 97.46±0.7 working Public Pharmacy Private company 061009 
69.87±4.1 11 min with disc 94.29±0.6 working Community Pharmacy CMS 061006 
67.75±2.3 14 min with disc 96.96±0.4 Not working Drug Store Private company 060805 
80.87±3.1 11 min with disc 98.93±0.3 working Other Private company 060614 
ASP for Adult 
 
81.70±0.9 7 min with disc 100.35±0.8 working Public Pharmacy CMS 061123 
81.29±3.8 9 min with disc 95.00±0.5 working Hospital Private company 061122 
80.87±1.9 7 min with disc 96.60±0.3 working Community Pharmacy CMS 061130 
84.05±0.8 33 sec with disc 96.08±0.5 working Hospital Private company F1169 
Artemal for Adult 
80.44±0.7 30 sec with disc 96.83±0.7 working Public Pharmacy Private company G0220 
84.13±2.1 50 sec with disc 100.12±0.6 working Public Pharmacy Private company H0237 Artemal for Children  
92.37±2.2 8 min with disc 98.10±0.3 working Public Pharmacy Private company L5060601 Artesumine for children 
 92.57±1.4 9 min with disc 94.69±0.5 working Community Pharmacy Private company 051114 
91.66±1.3 9 min with disc 101.50±0.4 working Public Pharmacy Private company L5070401 Artesumine for Adult  
                         IP requirement:90-110 of amount stated on label(n=3); bn =6; all brands had satisfactory physical appearance and passed related substances test (IP requirement: <1.0%) 
                                    dn=6(  IP requirement <15min).  IP requirement for dissolution test >60% 
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Table No. (51):  Results of post -marketing surveillance of artesunate tablets (AS+SP)  ( Elgadarif round six) 
 
Drug rel  %
30 minb. D.T (min.
d) 
aContent% 
(w/w) AC H.F. Supplier Batch No. Product 
97.92±1.6 10 min without dsc 100.21±0.4 Not working Drug store Other LS070202 
Artecosp for Children 
  95.25±1.2 10 min without dsc 101.34±0.5 Not working Hospital Other 051009 
94.5±1.3 11 min without dsc 98.87±0.3 Not working Drug store Other L5070202 
81.54±3.2 9 min with dsc 99.72±0.6
 
Not working Public pharmacy CMS 061004 ASP for Children   
101.24±2.0 13 min without dsc 103.56±0.4 Not working Hospital Other LS070205 Artecosp for Adult 
  92.03±3.7 14 min without dsc 99.32±0.3 Not working Drug store Other L5070203  
67.27±0.9 7 min with dsc 60.3±0.59 working Community pharmacy CMS 060614 ASP Adult 
  76.00±1.1 7 min withdsc 94.56±0.49 working Public pharmacy CMS 060626 
83.59±2.1 44 sec with dsc 97.42±0.3 working Community pharmacy Private company F1023 
Artemal  for Children 
  
65.98±1.1 50see with dsc 93.60±0.6 Not working Public pharmacy Private company G0383 
Artemal for Adult 
 
90.83±0.9 11 min without dsc 100.60±0.4 Not working Public pharmacy Private company L5061201 Artesumine for Adult 
 93.15±3.2 9 min without dsc 99.44±0.8 working Community pharmacy  050610 
100.1±3.3 40sec with dsc 102.46±0.9 working Public pharmacy Private company 051208 
Artesumine for 
Children 
                        IP requirement:90-110 of amount stated on label(n=3); bn =6; all brands had satisfactory physical appearance and passed related substances test (IP requirement<1.0%) 
                                    dn=6(  IP requirement <15min).  IP requirement for dissolution test >60% 
94.56±0.59
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Table No. (52):  Results of post -marketing surveillance of artesunate tablets (AS+SP) (Atbara round six) 
 
Drug rel  
% 
30 minb. 
D.T (min.d) 
aContent% 
(w/w) AC H.F. Supplier Batch No. Product 
95.56±0.9 10 min without disc 100.74±0.7 Not working Drug store Other LS060902 
Artecosp for 
Children 
 
 
99.0±2.2 8 min without disc 99.29±0.3 working Other Other LS070510 
98.48±3.0 9 min without disc 100.96±0.3 Not working Hospital Other LS070510 
103.06±2.2 9 min without disc 104.19±0.4 Not working Other Other 051018 
76.60±3.1 10 min with disc 96.70±0.5 working Community pharmacy CMS 061006 
ASP for Children 
 78.92±4.1 9 min with disc 95.40±0.3 working Public pharmacy 
CMS 061006 
85.20±3.5 9 min with disc 97.31±0.9 working Drug store CMS 061009 
91.9±30.9 14 min without disc 97.07±0.4 Not working Drug store Other LS060903 
Artecosp for Adult 
94.92±0.8 10 min without disc 103.02±0.6 working Other Other LS070511 
89.62±3.2 13 min without disc 98.34±0.4 Not working Hospital Other LS070511 
91.72±4.1 13 min without disc 103.22±0.5 Not working Other Other LS060903 
67.12±3.3 10 min with disc 103.06±0.3 working Community pharmacy CMS 060620 
ASP for Adult 
 69.60±2.2 11 min with disc 99.33±0.7 Not working Public pharmacy CMS 060618 
78.65±2.3 9 min with disc 95.33±0.6 working Drug store CMS 070501 
81.58±2.7 35 sec with disc 93.96±0.3 working Other Private company G0226 Artemal for 
Children 
 92.80±1.8 33 sec with disc 94.34±0.6 working Public pharmacy Private company G 0226 
99.38±1.9 6 min without disc 101.43±0.5 working Public pharmacy Private company LS060401 
Artesumine for 
Children 
 
93.61±2.0 8 min without disc 101.55±0.4 working Public pharmacy Private company LS070401 Artesumine for Adult 
                         IP requirement:90-110 of amount stated on label(n=3); bn =6; all brands had satisfactory physical appearance and passed related substances test (IP requirement: <1.0%) 
                                    dn=6(  IP requirement <15min).  IP requirement for dissolution test >60% 
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Table No. (53):  Results of post-marketing surveillance of artesunate tablets (AS+SP) (Elobied round six) 
 
Drug rel  % 
30 minb. D.T (min.
d) 
aContent%
(w/w) AC H.F. Supplier Batch No. Product 
84.73±3.3 10  min with disc 93.63±0.6 working Public pharmacy Private company 070602 ASP for Children 
 75.75±2.2 10 min with disc 95.01±0.9 working Community pharmacy Private company 061020 
73.73±2.1 10 min with disc 97.97±0.8 working Public pharmacy Private company 060814 ASP for Adult 
 76.64±3.2 10 min with disc 98.70±0.3 working Community pharmacy Private company 070505 
82.59±1.1 40sec with disc 98.27±0.5 working Hospital Private company G0228 
Artemal  for 
Children 
 
91.37±4.0 7 min without disc 100.20±0.4 working Public pharmacy Private company LS060601 
Artesumine for 
Children 
 
91.34±3.0 9 min without disc 98.5±0.9 working Community pharmacy Private company LS060401 
95.59±3.2 8 min without disc 102.22±0.7 working Hospital Private company 051114 
92.0±2.2 9 min without disc 96.94±0.6 Not working Hospital Other LS060902 
Artecosp for 
Children 
 
93.73±±3.7 8 min without disc 95.35±0.5 Not working Drug Store Other LS060902 
96.68±0.9 8 min without disc 98.27±0.8 Not working Other Other LS060902 
87.49±1.5 13 min with disc 100.22±0.4 Not working Public pharmacy Private company LS070401 Artesumine for 
Adult 
 95.22±4.2 11 min with disc 98.02±0.3 working Hospital Private company LS061201 
98.8±2.2 14 min without disc 99.97±0.4 Not working Drug Store Other LS060903 Artecosp for Adult 
 96.72±1.9 13 min without disc 99.97±0.6 Not working Other Other LS070302 
                           IP requirement:90-110 of amount stated on label(n=3); bn =6; all brands had satisfactory physical appearance and passed related substances test (IP requirement: <1.0%) 
                                    dn=6(  IP requirement <15min).  IP requirement for dissolution test >60% 
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Table: (54)Mean temperature and humidity (2005-2006-2007- 2008) 
Station : Elobied 
Month 
Mean 
Temperature °C 
Mean Relative 
Humidity% 
Max Min 
January 29.8 14.8 25 
February 35.5 16.1 18 
March 36.8 20.5 13 
April 35.6 23.0 26 
May 37.0 25.2 40 
June 37.8 24.1 52 
July 34.0 23.2 64 
August 32.2 22.0 74 
September 33.3 21.7 73 
October 36.0 22.6 42 
November 32.9 18.6 25 
December 31.2 15.5 27 
 
   
159 
 
Table No.(55)Mean temperature and humidity (2005-2006-2007-
2008) Station : Khartoum 
Month 
Mean 
Temperature °C 
Mean Relative 
Humidity% 
Max Min 
January 34.1 16.4 32.3 
February 35.8 17.6 24.3 
March 39.6 21.4 16.6 
April 40.8 24.73 21.6 
May 42.5 27.9 29.3 
June 41.8 26.7 42.3 
July 39.9 25.2 61.3 
August 38.3 23.4 57.6 
September 39.8 24.5 52.6 
October 41.0 24.2 33.3 
November 36.96 22.2 29.3 
December 37.16 19.2 37.3 
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Table No.(56) Mean temperature and humidity (2005-2006-2007-
2008) Station: Atbara 
Month 
Mean 
Temperature °C 
Mean Relative 
Humidity% 
Max Min 
January 30.8 13.9 18.9 
February 33.8 14.7 14.7 
March 38 18.0 18.0 
April 40.8 22.7 16.0 
May 43.5 26.3 26.3 
June 44.2 31.6 31.6 
July 41.6 27.3 27.3 
August 41.3 27.63 27.6 
September 41.7 27.3 27.3 
October 40.43 24.8 24.8 
November 36.0 19.9 19.9 
December 32.4 15.8 15.8 
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Table No.(57) Mean temperature and humidity (2005-2006-2007-
2008) Station: Port Sudan 
Month 
Mean 
Temperature °C 
Mean Relative 
Humidity% 
Max Min 
January 27.6 21.0 60 
February 28.2 20.9 63 
March 30.7 21.4 60 
April 33.4 24.4 58 
May 37.6 27.2 40 
June 40.3 30.5 31 
July 41.4 31.4 35 
August 42.03 29.5 35 
September 41.16 31.5 44 
October 36.5 28.1 65 
November 31.3 24.8 65 
December 28.5 22.2 61 
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Table No.(58) Mean temperature and humidity (2005-2006-2007-
2008) Station: Elgadarif 
Month Mean 
Temperature °C 
Mean Relative 
Humidity% 
Max Min 
January 34.8 18.1 35 
February 36.6 19.4 30 
March 40.1 22.4 23 
April 41.2 25.3 28 
May 41.0 26.0 34 
June 38.1 25.1 50 
July 34.4 22.2 68 
August 33.2 21.6 73 
September 34.6 21.9 69 
October 37.0 22.8 52 
November 37.7 21.9 35 
December 36.0 19.2 37 
 
 
